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Abstract 
 
Metallo-drugs have been highly significant in the development of novel anticancer agents. 
Supramolecular drug agents allow the design and synthesis of a range of molecular 
architectures. The work in this thesis has built upon previous knowledge on this subject by 
undertaking novel biological studies on known metal supramolecular helicates as well as 
the design of a new helicate in order to improve upon existing drugs.  
 
In chapter three, the DNA three-way junction binding of a number of supramolecular 
cylinders is described. Three-way junction binding is a new mode of DNA recognition and 
relevant to the DNA replication fork, present in dividing cells.  
 
Chapter four outlines a number of novel in vitro studies on an iron supramolecular cylinder 
which indicate new, unsuspected and unprecedented biological actions. 
 
In chapter five biological studies of unsaturated ruthenium(II) helicates are discussed. 
These complexes combine a cisplatin like coordinative binding mode with a helical 
supramolecular design. 
 
Chapter six discusses the design of a synthetic route from an unsaturated ruthenium(II) 
complex to create a novel supramolecular compound with a tuneable ligand surface. 
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Chapter 1 
 
 
Introduction 
 
 2 
1.1  Supramolecular Chemistry 
Supramolecular chemistry, first defined by Jean-Marie Lehn in 1978 as ‘the chemistry of 
molecular assemblies and of the intermolecular bond’1 is one of the fastest growing fields 
of chemistry. The Nobel Prize was won in 1987 by Donald J. Cram, Jean-Marie Lehn and 
Charles. J. Pedersen for their pioneering work in this area and subsequent advances in this 
field, notably by Hannon and co-workers (see section 1.7), have shown how the 
supramolecular approach can be a valuable tool for the design of new DNA recognition 
agents.
2
 Supramolecular chemistry is able to bridge the size gap between synthetic 
chemistry and biology.  
 
In this introduction, the principles of supramolecular chemistry and DNA recognition will 
be discussed and some examples of DNA binding metal complexes will be presented.  
 
1.1.1  Supramolecular Helicate Classification and Design 
Research into helicates was pioneered by Jean-Marie Lehn, in 1987.
3
 The term helicate is 
used when one or more organic, covalent ligand strands are wrapped around metal ions, 
thus defining the helical axis.
4
 These compounds are usually formed through self-
assembly, a process by which specific components spontaneously assemble with high 
selectivity into a well-defined, discrete supramolecular architecture. This self assembly 
may be driven to completion by, for example, positive cooperativity or energy flow.
5
 
 
Helicates may be classified as either homotopic or heterotopic, represented 
diagrammatically in Figure 1. 1. Helicates may also exist as two optical isomers. When a 
 3 
molecule and its mirror image are not structurally identical it is termed to be chiral. In this 
case homotopic helicates can exist in two isomeric forms, heterotopic helicates in four.
4
  
 
Figure 1. 1 Representation of homotopic and heterotopic helicates.
4
 
 
When designing helical agents there are a number of factors that need to be taken into 
consideration. The ligand must be designed to have at least two binding sites which will be 
able to recognise and coordinate to the chosen metal ion. Furthermore, the ligand should be 
flexible enough between binding sites to allow it to wrap around the helical axis, but not 
too flexible so one ligand coordinates multiple times to the same metal ion. 
 
1.2  Deoxyribonucleic Acid (DNA) 
A well defined helix, formed through self assembly, is the DNA double helix. The focus 
herein will be on the B-form of the DNA helix which consists of two polynucleotide 
strands, comprising four different nucleotides, twisted together to form a right handed helix 
with a sugar phosphate backbone. The helix is held together via hydrogen bond 
interactions of the DNA bases, Figure 1. 2. 
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(1)
(2)
sugar
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sugar
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C G T A
 
Figure 1. 2 (1) DNA bases and their hydrogen bond pairs. (2) The sugar phosphate 
backbone. 
 
There are two distinct grooves in this double stranded structure, labelled the major and 
minor groove, Figure 1. 3. B-DNA has a wide, deep major groove, and a narrow, deep 
minor groove. 
 
Figure 1. 3 The DNA helix, illustrating a major and minor groove.
6
 
 
The DNA molecule may exist in various other forms, for example A- and Z-DNA, Figure 
1. 4, however B-DNA is the most prevalent in biological systems. 
 5 
(1) (2)
 
Figure 1. 4 A-DNA (1) and Z-DNA (2) structures.
6
 
 
1. 2. 1  Other DNA Structures 
Although the double stranded structure of DNA is the predominant form in biological 
systems, DNA can adopt other structures and levels of ordering which may then be 
recognised by a drug molecule. Triplex, quadruplex and junction structures are examples 
of higher order DNA structures. Triplex DNA, Figure 1. 5, is formed when duplex DNA 
associates with an additional polynucleotide strand. This lies in the major groove of the 
DNA and is held in place by hydrogen bonding interactions between base pairs.  
 
Figure 1. 5 Schematic representation of triplex DNA.
6 
 6 
G-quadruplex DNA is a four-stranded DNA structure formed by non-Watson-Crick base 
pairing between stacked sets of guanine tetramers, Figure 1. 6. 
 
 
Figure 1. 6 Guanine tetramers (the basis for quadruplex formation) and possible DNA 
strand orientations for the formation of a G-quadruplex structure.
7
 
 
DNA junction structures arise when two or more polynucleotide chains come together, 
illustrated in Figure 1. 7. 
(1) (2)
 
Figure 1. 7 Examples of three-way (1)
8
 and four-way (2)
9
 junction structures. 
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DNA junctions such as these have been defined by David Lilley as ‘branch points where 
double-helical segments intersect with axial discontinuities, such that strands are 
exchanged between the different helical sections.
9
 Junction structures are present as 
intermediates in a number of genetic processes and are therefore of interest biologically. 
For example, an intermediate related to the DNA three-way junction structure is present 
during DNA replication and transcription, processes occurring in all living cells. Junction 
structures have also been implicated in the advancement of a number of diseases, for 
example Huntington’s disease, which is characterised by a triplet repeat expansion in the 
DNA.
10 
 
1. 2. 2  DNA Recognition 
Nature has a very accurate recognition system, beginning with the replication of DNA. 
Segments of the original DNA sequence are copied into RNA molecules, which in turn 
code for specific protein sequences. Each of these segments of DNA, corresponding to a 
final protein product is called a gene. Genes dictate the exact nature of the final protein, 
including the structure as well as under which conditions it will be produced. It is clear 
how much influence these genes have and hence why they are so important in disease 
states. Cancers for example, may occur when mutations in a subset of genes give a growth 
advantage to a group of cells. With the advent of genomic sequencing, medical research 
has turned to the ambitious idea of using the control of genes for the fight against disease. 
Theoretically, this may be achieved by creating synthetic agents (or utilising natural ones) 
that can bind selectively to genes in order to control their action.
2
 Novel therapeutics may 
also be able to overcome drawbacks of current drugs such as toxic side effects or acquired 
resistance. 
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A number of DNA recognition modes have been investigated for their potential as key 
drug targets: major/minor groove binding, intercalation, backbone recognition, covalent 
binding to DNA bases and binding to DNA junctions or other DNA structures. 
 
1.3  Metal Coordination Complexes as Anticancer Agents 
Metal ions are a clear target for medicinal chemists attempting to make novel drug agents, 
especially ones that bind to DNA. The idea of using metal ions in drugs stems from the 
ubiquitous presence of metal ions in nature. Fe, Zn, Cu, Na, K and many others are present 
in the human body in trace amounts, however without them our bodies would not function. 
These ions are essential for many metabolic and catalytic processes. A particularly 
important example in this context is the zinc finger protein. The metal ion is used 
specifically for the structural configuration it confers to the protein.
11
 This has parallels in 
the use of metals for drug design and gives an advantage over purely organic compounds.  
 
Complexes of transition metal cations have become attractive targets in drug design due to 
their many possible structures, flexibility in ligand choice and the variety of DNA 
interactions and binding modes available. Currently, however, the only metal containing 
anticancer agents which have reached the clinic are the well known range of platinum 
compounds including cisplatin, carboplatin and oxaliplatin
12
 (discussed in more detail in 
section 1.4). There are also a number of metal containing drugs undergoing clinical trials, 
for example the ruthenium compounds KP1019
13
 and NAMI-A
14
 (discussed in more detail 
in section 1.5.2.1) and many more in early stage research. 
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1.4  Platinum Anticancer Agents 
1.4.1  Cisplatin and its Analogues 
Cisplatin, Figure 1. 8, was first discovered by M. Peyrone in 1845
15
, although it was not 
until the 1960s that its potential as an anticancer agent became apparent. 
 
Figure 1. 8  The structure of cisplatin. 
 
Cisplatin is now the most widely used anticancer agent worldwide
16
 and therefore remains 
the benchmark for many researchers investigating novel anticancer agents, regardless of 
the compounds mode of action. Cisplatin acts through the loss of two cis-chloride groups 
on the platinum metal centre, either through aquation or binding to sulphur containing 
ligands. The labile nature of these ligands then allows the coordination to two 
neighbouring guanine molecules (usually through N-7) of the DNA chain, Figure 1. 9. 
 
Figure 1. 9 Cisplatin bound to two guanine molecules. 
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This is a fast reaction and the DNA-Pt bond is kinetically inert. This causes a kink in the 
DNA, Figure 1. 10, and the subsequent inability of this DNA to be processed, leading to 
cell death through arrest of the cell cycle at G2 and apoptosis.
17
 
 
Figure 1. 10  DNA with cisplatin bound illustrating the kink caused in the DNA 
structure.
18
 
 
The details of the cellular uptake of cisplatin have yet to be fully elucidated. Early studies 
indicated passive diffusion to be an entry mechanism, with more recent work indicating 
that active copper transport proteins (influx CTR1 and efflux ATP7A and ATP7B) may 
play a role,
19
 Figure 1. 11. 
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Figure 1. 11 Overview of the proposed pathway of cisplatin in the cell. 
20
 
 
Despite the obvious success of cisplatin, there are a number of drawbacks. The dose that 
can be administered is limited by kidney toxicity and although this may be ameliorated by 
hydrating the patient during treatment, this is not an ideal situation. Resistance to cisplatin 
caused by repair of the DNA-platinum lesion, reduced intracellular accumulation, or 
interaction with thiol containing molecules (such as glutathione) is also a problem. 
Furthermore, cisplatin is only active against a narrow spectrum of cancers, mostly notably 
testicular and ovarian.
21
 
 
Second generation platinum drugs were initially designed to try and overcome some of the 
inherent toxicity of cisplatin. Carboplatin, Figure 1. 12, contains a cyclobutane 
dicarboxylic acid ligand. This ligand exhibits slower aquation, meaning less interaction 
with biological ligands en-route to DNA. This was found to reduce nephrotoxicity, 
however carboplatin has a similar clinical profile to cisplatin, therefore displaying cross 
resistance.
21
 Oxaliplatin, Figure 1. 12, has the NH3 moieties of cisplatin replaced with more 
inert nitrogen donor ligands. This increases water solubility and makes ligand exchange 
 12 
reaction rates more favourable. First and second generation platinum drugs, however, are 
not orally bioavailable. In order to overcome this problem, the third generation drug, 
satraplatin, Figure 1. 12, was developed comprising a Pt(IV) octahedral centre. This drug is 
stable for days in biological media and remains unchanged until it reaches its biological 
target. Here it is converted to the more labile Pt(II) species by biological reductants 
(ascorbate, glutathione or NADPH), assisted by the hypoxic environment of solid 
tumours.
22
 Satraplatin was indeed found to increase the oral bioavailability of the drug as 
well as showing some activity in cisplatin resistant tumour cell lines.
21
 However, 
satraplatin has been unsuccessful in clinical trials. A further platinum drug designed to 
overcome cross resistance with cisplatin is picoplatin, Figure 1. 12, where the steric bulk of 
the methyl substituted pyridine slows reaction and substitution rates with thiol containing 
ligands, thus allowing more time for the drug to reach its target of DNA.
21
 
(1) (2)
(3) (4)
 
Figure 1. 12 Platinum second and third generation anticancer drugs: (1) carboplatin, (2) 
oxaliplatin, (3) satraplatin, (4) picoplatin. 
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1.4.2  Other Platinum Anticancer Agents 
Extended analogues of cisplatin have also been investigated in order to improve upon 
existing agents further. The complex BBR3464 (triplatin) is a triplatinum tetracationic 
complex in which the metal centres are linked by flexible diamine chains,
23
 Figure 1. 13. 
Interestingly, even though this complex does not contain platinum centres with cis leaving 
groups, it is more cytotoxic than cisplatin as well as displaying activity against cisplatin 
resistant cell lines.
24
  
 
Figure 1. 13 Triplatin, a multinuclear cationic trans Pt(II) complex. 
 
This complex binds to DNA forming inter- and intra-stand crosslinks as well as causing the 
reversible switching from a right handed B-DNA helix to a left handed Z-DNA structure.
25
 
This complex has undergone phase (II) clinical trials,
26
 but is not proceeding further at this 
time. 
 
An analogue of BBR3464, Figure 1. 14, is an octacationic trinuclear complex, where the 
reactive Pt-Cl moieties of BBR3464 have been replaced with amines. This changes the 
DNA binding of this complex dramatically, meaning only non-covalent, electrostatic 
binding is possible.  
 
 14 
 
Figure 1. 14 Octacationic trinuclear platinum DNA backbone binder. 
 
This complex binds to the DNA backbone through the formation of hydrogen bonds from 
two cis amine groups to one oxygen phosphate. This allows the complex to either track 
along the backbone or to bind spanning across the minor groove, making contacts with 
either side of the DNA backbone. This binding has been termed a phosphate clamp,
27
 
Figure 1. 15. Most importantly, this complex also shows good activity against cancer cell 
lines.
28
 
 
Figure 1. 15 DNA backbone tracking by a platinum phosphate clamp.
29
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1.5   Ruthenium Anticancer Agents 
1.5.1  Ruthenium as a Metal Centre 
Despite the continuing success of platinum anticancer agents, the fact remains that many of 
these complexes are toxic, mutagenic and act against a limited number of cancers. It has 
become apparent in recent years that new metal centres, with new structures and modes of 
action are needed. Desirable properties in a new metal centre include: additional 
coordination sites, the ability to change oxidation states and differing ligand affinities and 
substitution kinetics.
30
 A ruthenium centre possesses all of these properties making this an 
interesting metal to investigate. Ruthenium drugs have historically been used for many 
medical applications including immunosuppressant, antibiotics and NO scavengers. 
 
Few metallo-drugs remain unchanged, without interaction with biomolecules such as 
proteins or water, before they reach their biological target; therefore ligand lability is an 
important factor in determining biological activity. Ru(II) and Ru(III) have similar ligand 
exchange kinetics to Pt(II) complexes.
31
 The coordination number of the metal centre is 
also important. For example Ru(II), (III) and (IV) complexes have a hexacoordinate metal 
centre, with octahedral geometry. This is markedly different to the well known platinum 
drugs where the metal usually has a square planar geometry. For this reason it was thought 
that the action of ruthenium drugs would be substantially different to those of cisplatin and 
its analogues. 
 
Ruthenium (II), (III) and (IV) are all accessible under physiological conditions. Ru(II) 
complexes are generally the active species, with Ru(III) complexes being relatively 
biologically inert.
31
 It is hypothesised that one way the inactive Ru(III) compounds may 
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enter cells is by mimicking iron and binding to biomolecules such as albumin and serum 
transferrin.
31
 Rapidly dividing cells have a higher requirement for iron and have an 
increased number of transferrin receptors on their cell surfaces, hence facilitating selective 
toxicity and increased uptake within cancer cells,
32
 Figure 1. 16. 
 
Drug molecules administered as inert Ru(III) complexes may be activated, once inside the 
cell, by a process called activation by reduction.
33
 Angiogenesis, the creation of new blood 
vessels around tumour sites, uses up oxygen and other nutrients. This hypoxia (low O2 
content) means cancer cells depend more heavily on glycolysis for their energy, creating an 
excess of lactic acid in the surrounding tumour tissues. This in turn lowers the pH of the 
local environment, favouring the production of Ru(II) with respect to Ru(III) within the 
cancer cells,
33
 Figure 1. 16. 
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Figure 1. 16 Oxidation states of ruthenium in cancer cells and healthy tissues.
31
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Photoactivity, the ability to bind to and cause DNA damage in the presence of light, is a 
further desirable characteristic of many ruthenium complexes and may allow selectivity in 
DNA binding. In order for a compound to be suitable for this purpose it should conform to 
the following rules:
32
 be stable towards aquation and relatively non toxic, accumulate 
preferentially in cancer versus normal cells, absorb strongly at relatively long wavelengths 
(640-850 nm) that are not significantly absorbed by biological tissues and produce high 
quantum yields of free radical intermediates or singlet O2 upon irradiation. 
 
1.5.2  Ruthenium Mononuclear Complexes 
1.5.2.1  Ru (II)/(III) Chloride Complexes 
Inspired by cisplatin, ruthenium drugs with chloride leaving groups have been extensively 
studied. The first example of a ruthenium anticancer complex was a Ru(II) ammine 
compound, [RuCl2(NH3)4], synthesised in the 80s.
33
 Unfortunately, being uncharged, this 
complex was too insoluble for the clinic, however its activity sparked interest into the 
search for other ruthenium complexes for use as anticancer agents. The related analogue, 
cis-[Ru(bpy)2(NH3)2]
2+
 was shown to bind coordinatively to 9-methyl and 9-ethyl guanine 
through the formation of an aqua complex, under irradiation (λirr > 345 nm). Both single 
and double stranded DNA binding was observed.
34
  
 
In order to overcome solubility issues of [RuCl2(NH3)4] the Ru (II) complex 
[Ru(DMSO)4Cl2] (where DMSO is S bound) was explored. This complex is highly soluble. 
Isomers were investigated for anticancer activity as early as 1988, with the trans isomer 
being 20-fold more active than the cis isomer.
35
 This compound was also found to localise 
in tumour cells more than normal tissue and has lower toxicity than cisplatin in normal 
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proliferating tissue.
36
 Both isomers of [Ru(DMSO)4Cl2] also exhibit photo-dependant 
cytotoxicity under UV illumination with the less anticancer active cis isomer thought to 
isomerise to the more active trans isomer upon irradiation.
37
 This pro-drug approach is 
attractive as a method to reduce side effects. 
 
Ruthenium drugs investigated for their antimetastatic properties include the range of 
chloride, indazole complexes; KP1019, KP1339 and NAMI-A, Figure 1. 17. NAMI-A and 
KP1019 have both progressed to clinical trials, with NAMI-A being the first ruthenium 
anticancer drug to progress this far.
13 
(1) (2) (3)
 
Figure 1. 17 The structures of (1) KP1019, (2) KP1339, (3) NAMI-A. 
 
KP1019, indazolium trans[tetrachlorobis(1H-indazole)ruthenate(III)] is only moderately 
soluble in aqueous solutions and is therefore administered as the sodium salt, KP1339 
which is used for in-situ preparation of KP1019.
38
 The mechanism of uptake is thought to 
be through binding to the serum protein transferrin, with two ruthenium moieties residing 
in each iron binding site.
39
 Apoptosis is induced via a mitochondrial pathway, which may 
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be produced via DNA binding, or through direct interaction with mitochondria.
39
 
Preclinical studies showed moderate activity with a high level of selectivity towards 
colorectal tumours. Clinical studies confirmed this.
40
  
 
Despite being structurally similar to KP1019, NAMI–A, (H2im)[trans-
RuCl4(Him)(DMSO)] exhibits a very different spectrum of activity. This complex displays 
limited activity against primary tumours but acts against the development and growth of 
metastases. This is associated with a number of biological processes including an increase 
of actin dependant cell adhesion, inhibition of matrix degradation by matrix 
metalloproteinases and reduction of cell invasiveness and migration.
41
 The low in vitro 
cytotoxicity of this complex is attributed to the small number of metastatic cells present in 
the primary tumour.
40  
With metastases of solid tumours representing the main reason for 
failure in cancer chemotherapy, compounds which possess this ability are very desirable. 
 
Further ruthenium chlorido complexes include the pseudo-octahedral ruthenium 
‘pianostool’ complexes, of general formula [(η6-arene)Ru(X)(Y)(Z)], Figure 1. 18. 
Structure activity relationships have determined that a chelating ligand can help to control 
the stability and ligand-exchange kinetics of the complexes; the nature of the arene can 
influence cell uptake and interaction with biological targets; and the chloride or leaving 
group can help to control the timing of activation of the complexes.
42
  
 
 20 
(1) (2) (3)
L=
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Figure 1. 18 Ruthenium ‘pianostool’ half sandwich complexes and examples of chelating 
ligands: (1) en, (2) acac, (3) dppz. 
 
It appears that a more hydrophobic arene ligand and a single ligand exchange site, with the 
two other sites occupied by a bidentate chelating ligand, Figure 1. 19, increases 
cytotoxicity.
42
 A mechanistic study showed initial aquation of the complex was followed 
by rapid binding to the 5’-phosphate group. A rearrangement then gives rise to nitrogen-
bound adducts.
43
 
(1) (2) (3)
(4) (5)
 
Figure 1. 19 Modified ruthenium ‘pianostool’ half sandwich complexes, with examples of 
R groups: (1) benzene, (2) p-cymene, (3) biphenyl, (4) dihydroanthracene, (5) 
tetrahydroanthracene. 
 
These complexes do not show any cross resistance with cisplatin, so may have a distinct 
mode of action. Coordinative DNA binding is with a strong preference for guanine bases 
which may allow targeting of guanine rich portions of DNA such as G-quadruplexes, 
present in DNA telomeres. 
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A number of related Ru(II) complexes have also been investigated for their antimetastatic 
properties. A series of drugs of formula [Ru(II)(arene)Cl2PTA], (RAPTA) where (PTA = 
1,3,5-triaza-7- phospaadamantane) have been developed. A p-cymene derivative, RAPTA-
C (1) and a toluene derivative, RAPTA-T (2), Figure 1. 20, show pH dependant DNA 
damage, meaning selectivity towards hypoxic tumour cells.
44
  
(1) (2) (3)
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(1) (2)(1) (2) (3)
(4) (5)
 
Figure 1. 20 The structures of RAPTA-C (1) and RAPTA-T (2) 
 
These complexes showed relatively low activity in vitro, however in vivo RAPTA-T 
selectively reduced the growth of lung metastases.
44
 The mechanism of action is thought to 
be through the inhibition of some steps of the metastatic process, such as detachment from 
the primary tumour, migration/invasion and re-adhesion to a new growth substrate.  
Unfortunately however, these complexes are prone to fast hydrolysis and in order to 
suppress this would have to be administered in saline. Second generation RAPTA 
complexes have therefore been developed employing bidentate carboxylate ligands, based 
on second generation Platinum drugs, Figure 1. 21. These drugs are resistant to hydrolysis 
and show similar DNA binding and antimetastatic activities to the original RAPTA 
complexes.
45
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Figure 1. 21 Examples of second generation RAPTA complexes. 
 
A further class of Ru(II) complexes have been developed, combining structural features of 
NAMI-A (imidazole ligands; imidazole, benzimidazole, N-methylimidazole, N-
butylimidazole, N-vinylimidazole or N-benzoylimidazole) with the ‘piano-stool’ arene 
moiety, Figure 1. 22.
46
 
(1) (2) (3)
L=
2+
 
Figure 1. 22 Example of a RAPTA-NAMI complex. 
 
These complexes displayed in vitro activities similar to those of the RAPTA complexes 
and several compounds were shown to be selective towards cancer cells as opposed to 
nontumorigenic cells. Two of these complexes, [Ru(η6-p-cymene)Cl(vinylimid)2][Cl], 
(vinylimid=N-vinylimidazole) and [Ru(η6-benzene)(mimid)3][BF4]2, (mimid=N-
methylimidazole) have been selected for more detailed in vivo evaluation.
47
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1.5.2.2  Ru(II) Polypyridyl Complexes 
Ruthenium polypyridyl complexes have been extensively studied for their photophysical 
and DNA binding properties.
18
 The simplest of these complexes, [Ru(bpy)3]
2+
 and 
[Ru(phen)3]
2+
 show stereospecific DNA binding.
48
 For [Ru(phen)3]
2+
 there are two distinct 
binding modes; the D-enantiomer adopts an intercalative binding mode and prefers GC 
rich DNA, while the L-enantiomer binds in the minor groove and prefers AT rich DNA.
 49
 
In contrast, the binding of [Ru(bpy)3]
2+
 is simply electrostatic as this complex does not 
have a ligand surface great enough for pi-stacking to DNA bases. DNA cleavage upon 
visible irradiation is, however, present for both complexes.
50
  
 
Changing the ligand surface of these parent complexes has resulted in a range of 
compounds, Figure 1. 23. An increase in size of intercalator increases DNA binding, 
unwinding, luminescence and photocleavage.
51
 
(1) (2) (3)
(4) (5)
 
Figure 1. 23  Ruthenium polypyridyl complexes with examples of ligands: (1) bpy, 
(2) phen, (3) dpq, (4) dppz, (5) dppn. 
 
The anticancer activities of this range of complexes have been investigated. The activity of 
complex 5 is the highest in the cell lines tested, with comparable activity to cisplatin.
52
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Unlike the chlorido complexes discussed previously, this range of compounds possess no 
leaving groups, so the mode of action is likely to be DNA intercalation.  
 
The structurally similar dipyridophenazine complexes, [RuL2(dppz)]
2+
, Figure 1. 24, show 
a luminescence enhancement of several orders of magnitude upon DNA binding.
53
 They 
have also been shown to be taken up into HeLa cells through flow cytometry. No loss of 
luminescence was observed, confirming the stability of these complexes in the intracellular 
environment.
 54
 This is critical for a drugs application as a therapeutic or diagnostic agent. 
2+
=
(1)
(2) (3)
(4) (5)
 
Figure 1. 24 Dipyridophenazine complexes with examples of ligands: (1) DIP, (2) bpy, 
(3) CO2Et-bpy, (4) phen, (5) mcbpy. 
 
There are a number of other similar complexes with extended aromatic surfaces which 
have shown specific interactions with DNA. [Ru(bpy)2L]Cl2 where L = tpqp or tactp, 
Figure 1. 25, bind selectively to DNA base mismatches. The bulky intercalating ligand is 
not able to bind to the normal form of B-DNA, but slots easily into the thermodynamically 
destabilised regions of DNA around base mismatches.
 55
  Base mismatches occur in the 
genome as a result of various cellular errors such as a polymerase error, as well as external 
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factors including UV/ionising radiation or genotoxic chemicals. Cellular failure to correct 
these errors is present in colon and some breast cancers.  
(1) (2)
 
Figure 1. 25 Structures of [Ru(bpy)2(tpqp)]
2+
 (1) and [Ru(bpy)2(tactp)]
2+
 (2) 
55
 
 
A range of mononuclear azopyridyl complexes of the form [Ru(azpy)2Cl2], an isomer of 
which is illustrated in Figure 1. 26, have been assessed for their cytotoxic activity. Many of 
the isomers have shown much higher activities than cisplatin.
56
 These complexes are 
discussed in more detail in chapter 5.  
 
Figure 1. 26 The α-isomer of cis -[Ru(azpy)2Cl2] (X= Cl, azpy= 2-(phenylazo)pyridine). 
 
1.5.3  Ruthenium Dinuclear Complexes 
Using a mononuclear drug complex as a template to create dinuclear complexes with 
different properties is a common method to follow. This approach has been used in the 
polypyridyl complexes 1 and 2, Figure 1. 27. Complex 1 showed low DNA binding 
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affinities,
53
 however as with the mononuclear case the phenanthroline analogue, complex 
2, conveyed stronger binding activity
57
 with binding being mainly electrostatic. 
 
Figure 1. 27 Dinuclear ruthenium polypyridyl complexes.
53
 
 
Investigating different chain lengths allowed optimum conditions for DNA binding to be 
found, with complex 2b exhibiting the strongest enhancement of binding affinity.
53
 
Luminescent enhancement upon DNA binding was also observed for all complexes of this 
family
58
 and DNA photocleavage studies detected single strand breaks mediated by both 
type I (radical mediated) and type II (singlet oxygen mediated) cleavage.
59
  
 
A range of similar dinuclear complexes comprising an intercalating portion are shown in 
Figure 1. 28. Much work has been carried out on these complexes and recently it has been 
shown that the kinetic recognition of AT rich DNA is possible.
 60
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(1)
(2)
 
Figure 1. 28 Dinuclear polypyridyl complexes.
60
 
 
Both enantiomeric forms of complexes (1) and (2) display fast binding through 
intercalation to poly(dAdT)2. 
 
A further complex comprising both phenanthroline moieties and an intercalating portion is 
the dinuclear threading intercalator,
61
 Figure 1. 29, based on the mononuclear complex 
[Ru(phen)2dppz]
2+
. This compound has been investigated for anticancer activity and shows 
cytotoxicity in some cell lines. A three to four fold increase in cytotoxicity is shown over 
the mononuclear analogue.
18
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Figure 1. 29 A dinuclear threading bisintercalator constructed using a flexible dppz 
ligand.
18
 
 
This complex binds to DNA through intercalation of the dppz moieties between DNA base 
pairs, with the rest of the molecule threading through the DNA. The observation of the 
DNA light switch effect is further evidence for this binding mode, as shielding of the dppz 
nitrogens from the aqueous environment upon DNA binding is required for emission.
62
  
 
A dinuclear ruthenium complex, [{Ru(phen)2}2-(µ-bpm)]
4+
, Figure 1. 30, was investigated 
for its ability to recognise and bind to DNA bulge sites. The meso (ΔΛ) diastereoisomer 
showed the strongest binding to the tridecanucleotide d(CCGAGAATTCCGG)2 which 
contains a single adenine bulge site and was selective to this sequence compared with non-
bulge containing nucleotides.
 63
  
=
 
Figure 1. 30 The structure of ΔΔ-[{Ru(phen)2}2-(µ-bpm)]
4+
.
63
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NMR analysis revealed that the binding of the meso isomer caused less structural 
perturbations in the DNA minor groove than the ΔΔ or ΛΛ isomers.63 This study confirms 
the potential of dinuclear ruthenium complexes as DNA bulge probes.  
 
Dinuclear derivatives of the pianostool organometallic ruthenium(II) complexes, Figure 1. 
31, also show a good activity against cancer cell lines.
64
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Figure 1. 31 Structure of the dinuclear pianostool ruthenium complex. 
 
This complex caused an unwinding of plasmid DNA over twice that of the mononuclear 
counterpart and has been shown to inhibit DNA directed RNA synthesis in vitro. The 
compound gives rise to interstrand crosslinks of DNA, analogous to those caused by 
cisplatin.
64
 
 
A dinuclear ruthenium(II) complex has been shown to promote the formation of and 
stabilise the human telomeric repeat AG3(T2AG3)3 quadruplex. The complex, 
[Ru2(obip)L4]
4+
, where obip = 2-(2-pyridyl)imidazo[4,5-f][1,10]-phenanthroline and 
L=2,2′-bipyridine, Figure 1. 32, induced the formation of an antiparallel G-quadruplex 
structure in the absence of metal cations.
7
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Figure 1. 32 Ball and stick representation of [Ru2(obip)L4]
4+
.
7
 
 
Binding stoichiometry was consistent with a 1:1 [quadruplex][complex] binding mode, 
suggesting interactions of the complex with a single guanine tetramer. Details of binding 
sites and biological activity are currently under investigation. It has been reported that 
telomerase inhibition activity of drugs is strongly related to their ability to stabilise the G-
quadruplex structure. This complex is therefore a promising candidate for displaying 
anticancer activity. 
 
1.6  Iron Anticancer Agents 
1.6.1  Iron as a Metal Centre  
To date, iron has not been widely used in the search for anticancer agents. This is perhaps 
surprising as it is essential in many biological processes and well tolerated by the body, 
unlike toxic heavy metals such as platinum or ruthenium.  Iron is kinetically less inert than 
ruthenium, but being in the same periodic group this transition metal is interesting to 
investigate for its DNA binding and anticancer properties. 
 
1.6.2  Iron Mononuclear Complexes 
Well-established examples of iron anticancer agents are the ferrocene derivatives of the 
breast cancer drug tamoxifen, Figure 1. 33. This complex displays potent activity against 
 31 
both estrogen-dependent and estrogen-independent breast cancer cell lines. Tamoxifen 
alone is active only against estrogen-dependent cells and ferrocene is not cytotoxic.
65
 The 
activity of the ferrocene-tamoxifen derivatives (ferrocifens) in estrogen-independent cells 
is attributed to the redox properties of the Fe(II) complex causing oxidative damage to 
DNA. The mechanism of action of ferrocifens in estrogen-dependent cells is likely to be 
similar to that of tamoxifen itself.
66
  
 
Figure 1. 33 Ferrocifen, a ferrocene derivative of tamoxifen.
66
 
 
A recent study on ferrocene tamoxifen derivatives with modified side chains has 
established the minimal structural requirements to obtain cytotoxicity and it appears that 
the presence of both a ketone function adjacent to the ferrocene group and two phenols are 
needed for optimum activity, Figure 1. 34.
67
 
 
Figure 1. 34 A ferrocene tamoxifen derivative.
67
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A further example of an organic anticancer agent being linked to an iron moiety in order to 
covey differing activities is iron-bleomycin
68
 (FeBLM), Figure 1. 35. Bleomycin binds to 
DNA in the minor groove or through partial intercalation.
69
 The FeBLM complex, 
however, causes oxidative damage to DNA in the presence of O2 and H2O2, causing DNA 
double strand scission.
70
 It is likely that the coordinated iron(II) in this complex is oxidised 
in the Fenton reaction: LFe
2+
 + H2O2 → LFe
3+
 + HO• + HO–, (L= ligand bound to iron, in 
this case bleomycin). The production of highly reactive oxygen radical species is then 
damaging to DNA and other biomolecules.
71
  Iron is the most abundant metal ion in 
biological systems likely to catalyse this reaction, therefore it is usually transported and 
stored in specific proteins such as ferritin in order to prevent or minimise this damaging 
reaction.
72
 
 
Figure 1. 35 The structures of bleomycin A2 and B2. Nitrogen atoms involved in metal 
ion binding are underlined.
70
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The Co(III)-bleomycin complex has been characterised,
73
 however the exact structure of 
the iron-bleomycin complex remains a subject of discussion. A proposed binding mode is 
illustrated in Figure 1. 36.
 
 
 
Figure 1. 36 Proposed structure of FeBLM.
70
 
 
The addition of a nucleobase to a η4-butadiene–Fe(CO)3 
74
 or a ferrocenyl group,
 75
 Figure 
1. 37, conveys good cytotoxic activity and induces apoptosis.
 76
  
(1) (2)
 
Figure 1. 37 η4-butadiene–Fe(CO)3 (1) and ferrocene (2) complexes (where TDS= 
thexyldimethylsilyl) with an appended nucleobase.
76
 
 
Complex 1 is also active against leukaemia cells resistant to common cytostatic drugs. The 
exact mechanism of action of these complexes is currently under investigation.
 
 
 
Iron(II) complexes containing a pentadentate ligand, Figure 1. 38, have been shown to 
display cytotoxicities in the range 0.13-68.5 µM. Complex (1) induces cell cycle arrest in 
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HeLa cells and causes cell death by apoptosis, possibly via the creation of reactive oxygen 
species. Both complexes cause DNA strand breaks.
77
 
(2) R = Ph
(1) R= H
 
Figure 1. 38 Iron(II) complexes with pentapyridyl ligands.
77
 
 
1.6.3  Iron Dinuclear Complexes 
An additional example of an organometallo drug, created using a known organic 
compound is the Bis(Fe(II)EDTA-distamycin) fumaramide complex,
 78
 Figure 1. 39. 
 
Figure 1. 39 The bis(Fe(II)EDTA-distamycin)furamamide complex.
78 
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This complex shows sequence specific recognition of B-DNA, binding to sites of AT rich 
DNA in the minor groove, causing double stranded DNA cleavage.
79
 
 
1.7  Supramolecular Helical Drug Agents 
Hannon and co-workers have developed an extensive family of metallo-supramolecular 
helicates which interact with DNA in a number of ways and show activity against cancer 
cell lines. The parent complex of this group is the dinuclear iron(II) complex, [Fe2L3]
4+
, 
where L = C25H20N4, Figure 1. 40. This triple stranded complex was designed to mimic 
natural protein DNA recognition motifs, and is readily synthesised from commercially 
available starting materials.
80
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Figure 1. 40 Ligand L and X-ray crystal structure of the [Fe2L3]
4+ 
cation.
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[Fe2L3]
4+ 
binds to DNA and has also been shown to induce substantial DNA coiling in 
linear plasmid DNA, wrapping up the DNA duplex in an intra-molecular fashion,
82
 Figure 
1. 41. This remarkable structural effect is not observed with conventional small synthetic 
DNA binders. 
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[Fe2L3]
4+
 
Figure 1. 41 AFM images showing coiling of linear plasmid DNA induced by 
[Fe2L3]
4+
.
82 
 
[Fe2L3]
4+ 
has also been shown to bind in the heart of a DNA three-way junction structure, 
through electrostatic and π-π stacking interactions. This is an unprecedented new mode of 
DNA binding,
83
 illustrated in Figure 1. 42. Furthermore, [Fe2L3]
4+ 
shows cytotoxic action, 
through cell stasis and apoptosis, with activity at concentrations comparable to those for 
cisplatin. [Fe2L3]
4+ 
was also found to be non-genotoxic and non-mutagenic, a desirable 
characteristic in a new anticancer agent.
81
 
 
Figure 1. 42 Crystal structure of the major groove side view of [Fe2L3]
4+
bound in the 
heart of a DNA three-way junction.
83
 
 
It is important to note that [Fe2L3]
4+ 
exists as two enantiomers. Separation of enantiomers 
has been achieved using a cellulose column with sodium chloride solution as eluent.
84
 The 
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differential binding of the M (left-handed / negatively twisted) and P (right handed) 
enantiomers has been studied through CD, LD and AFM imaging. These studies have 
shown that both enantiomers bind strongly to DNA with one of each enantiomer bound per 
helix turn.
85
 The M-enantiomer is the stronger major groove binder, inducing severe DNA 
bending and coiling, while the P enantiomer shows much less dramatic binding.
86
 Most 
recently the cylinder has been shown to possess antimicrobial activity, in both gram 
positive and negative bacteria.
 87
 [Fe2L3]
4+ 
is discussed in more detail in chapters 3 and 4. 
 
A number of modifications have been made to the parent iron complex in order to 
investigate different DNA binding modes and cytotoxic activities, for example additions to 
the ligand, such as extra methyl groups
88
 or the attachment of peptides.
89
 These complexes 
show differing DNA binding to the parent complex, discussed in more detail in chapter 3. 
 
The ruthenium analogue of the iron parent complex, [Ru2L3]
4+
, Figure 1. 43, where L = 
C25H20N4 has also been studied.  DNA binding of this complex is similar to that of the 
parent, through non-covalent interactions, however the presence of ruthenium metal 
centres means an enhancement of luminescence is observed upon DNA binding.
90
 
Anticancer activity is also different to that of the parent cylinder with activity restricted to 
breast cancer cell lines. [Ru2L3]
4+
is discussed in more detail in chapter 3. 
NN
N N
 
Figure 1. 43 Ligand L and X-ray crystal structure of the [Ru2L3]
4+
 cation.
91
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A range of ruthenium(II) dinuclear isomers: γγ, γα, γβ, ββ and αα-[Ru2L2Cl4] where 
L
2
=C23H18N6, Figure 1. 44, have also been synthesised,
92
 based on the mononuclear 
[Ru(azpy)2Cl2] complexes.  
γγ γα γβ
αα ββ
L’
γγ γα γβ
αα ββ
L’
 
Figure 1. 44 Ligand L
2
 and X-ray crystal structure of γγ-[Ru2L
2
2Cl4], one of a range of 
isomers synthesised.
92
 
 
These compounds have been investigated for their DNA binding and cytotoxic activities 
and display a broad range of activities, from the ββ isomer with no activity to the γγ isomer 
which displays ~40 times higher activity than cisplatin.
93
 These complexes are discussed in 
more detail in chapters 5 and 6.  
 
1.8  Summary 
There have been many complexes synthesised and investigated to date, utilising a number 
of different metal centres to convey differing structures and properties. Complexes 
discussed in section 1.7 are molecules of study herein and in the following chapters the 
design, synthesis and characterisation of a novel metallo-supramolecular complex is also 
presented. The biological properties, including DNA binding of these anticancer agents 
will be reported. A number of these complexes have the potential to be used as DNA 
recognition agents and represent a promising step forward in the field of supramolecular 
drug design. 
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2.1.   Chemicals 
Unless otherwise stated, all chemicals and reagents were purchased from Sigma Aldrich 
(UK) of the highest quality available and used without further purification. 
 
2.2  Physical Measurements 
1
H NMR spectra were measured on a Bruker 400/300 DPX spectrometer. Spectra were 
recorded in the deuterated solvent stated and calibrated on residual solvent peaks. All 
spectra were obtained at 25 °C. Electrospray Ionisation (ESI) analyses were performed on 
a Micromass LCT Time of Flight Mass Spectrometer in positive ionisation mode.  
 
2.3  Synthesis 
2.3.1  Ligand Synthesis 
2.3.1.1  Ligand L Synthesis 
Ligand L (N,N’-bis(pyridin-2-ylmethylene)-4,4‟-diaminodiphenylmethane), Figure 2. 1, 
was made according to literature procedure.
1
 4,4‟methylenedianiline (1.57 g, 8.00x10-3 
mol) in 25 ml ethanol was added to two equivalents of pyridine-2-carboaldehyde (1.40 ml, 
1.50x10
-2
  mol) in 25 ml ethanol and the solution stirred for four hours. The resulting 
yellow precipitate (1.95 g, 5.00x10
-3
   mol) was filtered and recrystallised from ethanol. 
Yield: 65 %   
1
H NMR (CD2Cl2):  8.72 (2H, d, J = 3.9 Hz, H6),  8.62 (2H, s, Him),  8.23 (2H, d, J = 
8.1 Hz, H3),  7.85 (2H, t, J = 7.5 Hz, H4),  7.41 (2H, t, J = 7.0 Hz, H5),  7.30 (8H, m, 
Ha/b),  4.09 (2H, s, CH2). 
ESI MS: m/z 399 [(C25H20N4) + Na]
+
. 
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Ligand L has been previously synthesised,
1
 therefore a full characterisation is not 
presented here. 
 
Figure 2. 1 Ligand L with NMR numbering scheme. 
 
2.3.1.2  Ligand L
1
 Synthesis 
Ligand L
1
 (N,N’-Bis(1-pyridin-2-yl-ethylidene)-4,4‟-diaminodiphenylmethane), Figure 2. 
2, was synthesised following literature procedure.
2
 4,4‟methylenedianiline (0.630 g, 
3.00x10
-3
 mol) and 10 g 3Å dry molecular sieves were stirred in 100 ml toluene at room 
temperature for 10 minutes until dissolution of 4,4‟methylenedianiline. 2-Acetylpyridine 
(0.710 ml, 2.00x10
-2
 mol) was then added to the solution and the mixture left to stir at 
room temperature for three days. The solution was then filtered to remove the molecular 
sieves and the filtrate concentrated by rotary evaporation to yield a yellow oil (1.07 g, 
3.00x10
-3
 mol). Yield: 84 %. 
1
H NMR (CDCl3):  8.68 (2H, d, J = 4.0 Hz, H6),  8.04 (2H, broad d, J = 7.9 Hz, H3),  
7.97 (2H, td, J = 7.5 Hz, J = 1.5 Hz, H4),  7.45 (2H, dd, J = 7.5 Hz, J = 1.3 Hz, H5),  
6.92 (2H, d, J = 8.3 Hz, Hb),  6.67 (2H, d, J = 8.3 Hz, Ha),  3.71 (2H, s, CH2), 2.77 (6H, 
s, CH3).  
ESI MS: m/z 405 [(C27H24N4) + H]
+
. 
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Ligand L
1
 has been previously synthesised,
2
 therefore a full characterisation is not 
presented here. 
 
Figure 2. 2 Ligand L
1
 with NMR numbering scheme. 
 
2.3.1.3  Ligand L
2
 Synthesis 
Ligand L
2
, (bis(1, 4-phenylazo-2-pyridine)), Figure 2. 3, was synthesised according to 
literature procedure,
3
 and purified according to a new procedure. 2-Nitrosopyridine was 
synthesized as follows; 2-aminopyridine (9.40 g, 9.90x10
-2
 mol) with dimethylsulphide 
(8.00 ml, 0.108 mol) were dissolved in 100 ml dry DCM. n-chlorosuccinimide (13.3 g, 
9.90x10
-2
 mol) was dissolved in 250 ml dry DCM and added dropwise to the above over 
one hour at -20 ºC. This solution was stirred at -20 ºC for an hour then at room temperature 
for a further hour. A solution of sodium methoxide (4.05 g, 7.50x10
-2
 mol) in 75 ml dry 
methanol was then added and stirred for 10 minutes at room temperature. Water (150 ml) 
was then added and stirred overnight. The organic (lower) layer was separated. The 
aqueous layer was washed with DCM (50 ml x 2), with DCM washes added to the organic 
layer. This was then washed with water (50 ml x 2) then dried with magnesium sulphate, 
filtered and evaporated on a rotary evaporator to yield an orange/ brown oil which was left 
in the fridge overnight. All of the oil was then dissolved in 100 ml dry DCM and added to 
a solution of meta chloro perbenzoic acid (20.1 g, 0.116 mol) in 500 ml dry DCM after 
cooling to 0 ºC. This was then stirred at 0 ºC for 90 minutes. Dimethylsulphide (4.00 ml, 
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5.40x10
-2
 mol) was then added and stirred at 0 ºC for 30 minutes. 500 ml saturated aqueous 
sodium carbonate solution was then added and stirred for one hour, followed by the 
separation of the green/yellow (lower) organic layer. The aqueous layer was washed with 
DCM (2x 50 ml) which was then added to the organic layer and washed with water (2 x 50 
ml), dried with magnesium sulphate, filtered, evaporated to dryness and stored at 4 ºC 
overnight to yield dark brown crystals. These were recrystallised from ethanol (1.10 g, 
1.00x10
-2
 mol).   
2-Nitrosopyridine (0.100 g, 9.25x10
-4
 mol) was dissolved in 30 ml DCM. 4, 4-
methylenedianiline (0.0910 g, 4.61x10
-4
 mol) was added, followed by 10 drops of glacial 
acetic acid at which point the solution turned orange.  This mixture was stirred at room 
temperature for 18 hours. The resulting orange solution was evaporated to dryness and 
purified via an optimised isocratic HPLC method with a 10 % water, 90% methanol 
solvent system (Dionex Summit HPLC system with Chromeleon software, using a Summit 
P580P high pressure binary gradient pump and Summit UVD 170s UV/Vis Multi-channel 
detector with prep flow cell and Luna 10uC18 250 mm x 30 mm column, Phenomenex). 
Pure ligand L
2
 (0.180 g, 4.76 x10
-4
 mol) has a retention time of 10.84 minutes. Yield: 51 % 
1
H NMR (CDCl3): δ 8.75 (2H, dq, J = 4.7, 0.75 Hz, H6), 8.03 (4H, d, J = 8.5 Hz, Ha/b), 
7.92 (2H, td, J = 7.9, 1.9 Hz, H4/5), 7.83 (2H, dt, J = 7.9, 1.0 Hz, H3), 7.40 (6H, m, Ha/b + 
H4/5), 4.17 (2H, s, CH2).  
ESI MS: m/z 379 [(C23H18N6) +H]
+
. 
Ligand L
2
 has been previously synthesised,
3
 therefore a full characterisation is not 
presented here. 
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Figure 2. 3 Ligand L
2
 with NMR numbering scheme. 
 
2.3.2  Metal Complex Synthesis 
Unless stated otherwise charged metal complexes were isolated with chloride counterions, 
due to good aqueous solubility and the fact that chloride ions are the most commonly used 
in commercial drugs.
4
 
 
2.3.2.1  [Fe2L3]
4+
 Synthesis 
[Fe2L3]
4+
 was synthesised according to literature procedure.
1
 Ligand L (0.320 g, 8.55 x10
-4
 
mol) in 50 ml methanol was stirred for 30 minutes to dissolve. Iron(II) chloride 
tetrahydrate (0.120 g, 5.91x10
-4
  mol) also in methanol was added and an immediate colour 
change to vivid purple was observed. The solution was refluxed for three hours, evaporated 
to dryness, re-dissolved and precipitated with ether, followed by filtration and washing 
(0.350 g, 2.54 x10
-4
 mol). Yield: 86%. 
1
H NMR (MeOD):  9.21 (2H, s, Him),  8.75 (2H, d, J = 7.0 Hz, H3),  8.51 (2H, t, J = 
6.5 Hz, H4),  7.90 (2H, t, J = 6.1 Hz, H5),  7.49 (2H, d, J = 4.2 Hz, H6),  7.08 (4H, s, 
Ha/b),  5.62 (4H, s, Ha/b),  4.08 (2H, s, CH2).  
ESI MS: m/z 310 [Fe2(C25H20N4)3]
4+
.  
UV-Vis in water, max/nm (ε/ dm
3
mol
-1
cm
-1
): 324 (32900), 570 [shoulder 525] (16900). 
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[Fe2L3]
4+
 has been previously synthesised,
1
 therefore a full characterisation is not presented 
here. 
 
2.3.2.2  [Fe2L
1
3]
4+
 Synthesis 
[Fe2L
1
3]
4+
 was synthesised according to literature procedure.
2
 Ligand L
1
 (0.199 g, 4.93 
x10
-4
  mol) in 50 ml methanol was added to iron(II) chloride tetrahydrate (0.0670 g, 3.36 
x10
-4
  mol) in 50 ml methanol. The solution immediately turned purple, characteristic of 
iron(II) tris-pyridylimine compounds, and was further refluxed for three days. The solution 
was then evaporated, precipitated with an excess of NH4PF6 (0.610 g, 4.00x10
-3
 mol) in 
methanol and stirred for two hours. This was then placed at 4 ºC for 45 minutes followed 
by filtration on a membrane filter. Ion exchange was then carried out by adding 3.08 g 
Dowex (chloride form) in 50 ml methanol. This was stirred at room temperature for three 
hours before filtering on filter paper and washing with methanol, giving a purple solid 
(0.180 g, 1.23x10
-4
 mol).  Yield: 73.15 %. 
1
H NMR (MeOD):  8.78 (2H, d, J = 7.8 Hz, H3),  8.50 (2H, t, J = 7.8 Hz, H4),  7.81 (2H, 
t, J = 6.3 Hz, H5),  7.42 (2H, dd, J = 6.3 Hz, J = 1.1 Hz, Ha/a'/b/b'),  7.26 (2H, d, J = 6.3 
Hz, H6),  6.89 (2H, dd, J = 6.3 Hz, J = 1.7 Hz, Ha/a’/b/b’),  5.57 (2H, dd, J = 8.3 Hz, J = 1.5 
Hz, Ha/a'/b/b'),  4.79 (2H, dd, J = 8.3 Hz, J = 1.5 Hz, Ha/a'/b/b'),  4.64 (6H, s, CH3),  4.10 
(2H, s, CH2). 
ESI-MS: m/z 331 [Fe2(C27H24N4)3]
4+
. 
UV-Vis in water, max/nm (ε/ dm
3
mol
-1
cm
-1
): 324 (32900) 570 [shoulder 525] (16900). 
[Fe2L
1
3]
4+
 has been previously synthesised,
2
 therefore a full characterisation is not 
presented here. 
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2.3.2.3  [Ru(DMSO)4Cl2] Synthesis 
[Ru(DMSO)4Cl2] was prepared according to literature procedure.
5
 RuCl3 (1.00 g, 5.00x10
-3
 
mol) was refluxed in 5 ml DMSO for five minutes, cooled and evaporated to half volume. 
20 ml acetone was added to precipitate a yellow powder which was filtered and dried (1.00 
g, 2.00x10
-3
 mol). Yield: 43 %. 
 
2.3.2.4  γγ -[Ru2L
2
2Cl4] Synthesis 
γγ -[Ru2L
2
2Cl4] was synthesised according to published procedure
3
 through a mixture of 
[Ru(DMSO)4Cl2] (0.075 g, 1.55x10
-4
 mol) and the bispyridylazo ligand L
2
 (0.0580 g, 1.54 
x10
-4
 mol) heated under reflux in 40 ml acetone for 18 hours. After ~ one hour a colour 
change to dark green was observed. The reaction was cooled after 18 hrs and the green 
precipitate isolated by filtration and washed with acetone and diethylether to afford 0.0520 
g of crude product, consisting of the desired product and insoluble polymeric material. The 
crude product was purified on a neutral alumina (Brockman type I, Camag 100-250 mesh) 
column with DCM : acetonitrile (1:1) as eluent. The first fraction was collected (0.0100 g, 
9.09 x10
-6
 mol).  Yield: 12 %.  
1
H NMR (DMSO-d6) δ 9.07 (1H, d, J = 5.6 Hz, H6),  8.76 (1H, d, J = 7.7 Hz, H3), 8.43 
(1H, t, J = 7.7 Hz, H4), 8.04 (1H, t, J = 6.0 Hz, H5), 7.24 (2H, d, J = 8.2 Hz, Ha), 7,11 (2H, 
d, J = 8.4 Hz, Hb), 4.32 (2H, s, CH2).  
ESI-MS: m/z 1065 [Ru2L
2
2Cl3]
+
.  
UV-Vis in chloroform, max/nm (ε/ dm
3
mol
-1
cm
-1
): 304 (24800), 430 (17300), 642 (17100). 
γγ -[Ru2L
2
2Cl4] has been previously synthesised,
3
 therefore a full characterisation is not 
presented here. 
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2.3.2.5  ββ-[Ru2L
2
2Cl4] Synthesis 
ββ-[Ru2L
2
2Cl4] was synthesised according to procedure,
3
 from a mixture of 
[Ru(DMSO)4Cl2] (0.230 g, 4.75x10
-4
 mol) and the bispyridylazo ligand L
2
 (0.180 g, 
4.76x10
-4
 mol) heated under reflux in 50 ml methoxyethanol for 24 hrs. After cooling, the 
solution was filtered and solvent removed by evaporation. The crude compound (0.0700 g) 
was dissolved in chloroform and isolated by precipitation with diethylether. The crude 
precipitate was purified via neutral alumina column chromatography (Brockman type I, 
Camag 100-250 mesh) eluted with DCM : acetonitrile (2:1). The first small light purple 
band was discarded and the second large purple band collected. Solvent was evaporated to 
half volume and the compound precipitated with diethyl ether, yielding a blue powder 
(4.00x10
-3
 g, 3.27x10
-6 
mol).  Yield: 1 %. 
1
H NMR (CD2Cl2) (prime numbering is used for the pyridine ring and corresponding 
phenyl ring trans to Cl ligand) δ 9,61 (1H, d, J = 5.70 Hz, H6), 8.62 (1H, d, J = 7.49 Hz, 
H3), 8.61 (1H, d, J = 7.49 Hz, H3‟), 8.23 (1H, t, J = 7.84, 1.43 Hz, H4), 8.05 (1H, t, J = 
8.20, 1.78 Hz, H4‟), 7.88 (1H, t, J = 7.49, 1.07 Hz, H5), 7.38 (2H, m, H5‟+ H6‟), 7.24 (2H, d, 
J = 8.2 Hz, Ha‟), 7.17 (2H, d, J = 8.20 Hz, Hb), 7.17 (2H, d, J = 8.55 Hz, Hb‟), 6.48 (2H, d, 
J = 8.20 Hz, Ha), 4.00 (2H, q, CH2).  
ESI-MS: m/z 1123 [(Ru2L
2
2Cl4)
 
+ Na]
+
.  
UV-Vis in chloroform, max/nm (ε/ dm
3
mol
-1
cm
-1
): 300 (32200), 380 (39300), 572 (22200). 
ββ-[Ru2L
2
2Cl4] has been previously synthesised,
3
 therefore a full characterisation is not 
presented here. 
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2.3.2.6  ββ-[Ru2L
2
2(NO3)4] Synthesis 
ββ-[Ru2L
2
2(NO3)4] was synthesised
6
 from pure ββ-[Ru2L
2
2Cl4] (4.00x10
-3
 g,  3.27x10
-6
 
mol) in a minimum acetone and AgNO3 (2.00x10
-3
 g,  1.42 x10
-5
 mol) in 50 ml water. This 
was refluxed for three hours in the dark. The solution was then filtered to remove AgCl 
and evaporated to dryness. The product was taken up in chloroform and precipitated with 
diethylether to yield a blue/purple powder (3.00x10
-3
 g, 2.24 x10
-6
 mol.) Yield: 68 %.  
1
H NMR (acetone-d6) (prime numbering is used for the pyridine ring and corresponding 
phenyl ring trans to Cl ligand) δ 9,24 (1H, d, J = 6.25 Hz, H6), 8.76 (1H, d, J = 8.09 Hz, 
H3), 8.70 (1H, d, J = 7.72 Hz, H3‟), 8.53 (1H, t, J = 8.46, 7.35 Hz, H4), 8.33 (1H, t, J = 
7.72 Hz, H4‟), 8.19 (1H, t, J = 7.72 Hz, H5), 7.67 (2H, d, J = 8.46 Hz, Ha‟) 7.61 (1H, m, 
H5‟), 7.50 (1H, d, J = 7.35 Hz, H6‟), 7.20 (2H, d, J = 8.82 Hz, Hb), 7.14 (2H, d, J = 8.46 
Hz, Hb‟), 6.46 (2H, d, J = 8.46 Hz, Ha), 4.12 (2H, s, CH2).  
ESI-MS: m/z 1146 [Ru2L
2
2(NO3)3]
+
. 
UV-Vis in acetone, max/nm (ε/ dm
3
mol
-1
cm
-1
): 270 (23700), 377 (30400), 529 (14800). 
ββ-[Ru2L
2
2(NO3)4] has been previously synthesised,
6
 therefore a full characterisation is not 
presented here. 
 
2.3.2.7  [Ru2L
2
2(bpy)2]
4+
 Synthesis 
[Ru2L
2
2(bpy)2]
4+
 (NO3
-
 counterions) was synthesised by a new procedure. To a solution of 
ββ- [Ru2L
2
2(NO3)4] (0.0110 g, 9.11 x10
-6
 mol) in water, an excess of 2, 2-bipyridine 
(0.0350 g, 2.24 x10
-4
 mol) was added in acetone. The solution was refluxed for three hours, 
cooled and filtered to give a dark red solution. The solution was then evaporated and 
washed with chloroform to yield a red powder (0.0100 g, 6.58 x10
-6
 mol). Yield: 72 %.
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1
H NMR (CD3CN) (also see section 6.2.2) (C/E represent pyridine rings; A/D represent 
bipyridine rings; δ 8.99 (1H, d, J = 8.19 Hz, H3C), 8.94 (1H, d, J = 8.19 Hz, H3E), 8.50 
(1H, m, J = 8.19 Hz, H4E), 8.42 (1H, tt, J = 7.94 Hz, H4C), 8.28 (1H, d, J = 8.19 Hz, H3A), 
8.21 (1H, t, J = 7.94 Hz, H4A), 8.04 (1H, d, J = 8.45 Hz, H3D), 7.96 (1H, t, J = 7.17, 7.94 
Hz, H4D), 7.91 (1H, d, J = 5.63 Hz, H6C), 7.81 (2H, m, H5/6E), 7.72 (2H, m, H6D/5C), 7.61 
(1H, t, J = 5.63, 6.14 Hz, H5A), 7.56 (1H, t, J = 7.43, 5.89 Hz, H5D), 7.20 (2H, d, J = 8.19 
Hz, Hb‟), 7.10 (1H, d, J = 5.63 Hz, H6A), 6.94 (2H, d, J = 8.45 Hz, Ha‟), 6.71 (2H, d, J = 
8.19 Hz, Hb), 6.06 (2H, d, J = 8.45 Hz, Ha), 3.82 (2H, m, CH2).  
ESI-MS: m/z 318 [Ru2L
2
2(bpy)2]
4+
, 424 [Ru2L
2
2(bpy)2]
3+
, 636 [Ru2L
2
2(bpy)2]
2+
.  
UV-Vis in water, max/nm (ε/ dm
3
mol
-1
cm
-1
): 266 (44900), 382 (36400), 508 (18400).  
IR: 2163, 1998, 1602, 1272 cm
-1
. 
 
2.4  DNA Binding Studies 
2.4.1  UV-Visible Absorbance Spectroscopy 
Information about the structure and environment of a species in a sample, or the 
identification of transitions between energy levels within a molecule can be determined 
using UV-Visible spectroscopy. More specifically, in metal complexes electromagnetic 
radiation in the range 200 nm to 700 nm can excite electrons from p-, d- and - bonding or 
lone pair orbitals into unfilled non-bonding or anti-bonding orbitals. The wavelength at 
which the molecule absorbs is then a direct measure of the separation between the energy 
levels.  The absorption of light in a solution is exponentially related to the number of 
molecules of the absorbant in solution and to the length of the light pathway through the 
sample, defined as:  
A = log10 (I0 / I), where I0 = intensity of incident light, I = intensity of emergent light.  
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The absorbance may be used to find the concentration of a solution of a single absorbing 
species using the Beer-Lambert law
7
:  
A =  c l 
A = absorbance (arbitrary units),  = extinction coefficient (a constant for a particular 
wavelength of that species measured in mol
-1
 dm
3
 cm
-1
), c = concentration (mol dm
-3
), l = 
path length of cell (cm).  
 
DNA is commonly analysed using UV-Visible spectroscopy. The characteristic band of 
DNA, Figure 2. 4, has a maximum centred around 260 nm. This corresponds to the π→π* 
transitions of the delocalised π electrons from the DNA bases. Perturbations in this 
standard spectrum can give information about substrate binding or environment.  
Experimentally, UV-Visible spectroscopy has been used in this thesis for assessing 
stability of metal complexes, to assess isomerisation processes of complexes and in parallel 
with emission experiments to assess the effect on metal complexes due to DNA binding. 
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Figure 2. 4 UV-Visible spectrum of B-DNA. 
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UV-Visible spectra were recorded on a Cary 5000 UV-Vis-NIR Spectrophotometer 
(Varian). 
 
2.4.2  Circular Dichroism 
2.4.2.1  Principles of Circular Dichroism 
Circular dichroism (CD) is a technique used to study the optical activity of chiral 
molecules and to probe their interactions with other compounds.
8
 This method is therefore 
ideal for the study of DNA and its interaction with metal complexes. CD is defined as the 
difference in absorption (A) of left and right circularly polarised light, measured as a 
function of wavelength:  
CD (λ) = Al (λ) – Ar (λ) 
Because chiral molecules do not have a reflection plane, the rearrangement of their 
electrons will not have one either. This means the interaction between the chiral molecule 
and left and right handed photons will be different, giving rise to a CD signal. Within 
DNA, the units responsible for inducing chirality are the ribose sugar moieties. However, 
this chiral sugar backbone has no important transitions in the spectral region and the CD 
spectrum of DNA arises from the CD induced into the transitions of the bases as a result of 
their coupling with the backbone sugars. For this reason the structural conformation of 
DNA, for example its polymorph forms B, Z and A can be easily deduced, Figure 2. 5. 
Peaks between 200 nm and 300 nm result from interactions of helically stacked bases. 
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Figure 2. 5 Schematic CD spectra of B, Z and A DNA.
9
 
 
As with the DNA bases, upon DNA binding achiral molecules acquire an induced CD 
signal (ICD) and the normal B-DNA signal may be perturbed, allowing interactions and 
DNA changes to be probed. 
 
2.4.2.2  CD Experimental Procedure 
Spectra were collected in 1 cm pathlength cuvettes using a Jasco J-715 spectropolarimeter. 
Fresh samples were made with constant concentrations of ct-DNA (300 μM), NaCl (20 
mM) and sodium cacodylate buffer (10 mM). The concentration of metal complex was 
varied with the final ratios of DNA base: metal complex being between 60:1 and 8:1.  
Two stock solutions were prepared; the first of metal complex and the second with a 
solution of double concentration DNA (DNA (600 μM), NaCl (40 mM) and sodium 
cacodylate buffer (20 mM)). After the addition of X μL of metal complex solution to an 
original 300 μM DNA solution, an equivalent addition of the second, double concentration 
DNA stock solution was added. This results in the concentrations of DNA, NaCl and 
sodium cacodylate buffer remaining unaltered throughout the titration.              
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2.4.3  Linear Dichroism 
2.4.3.1  Principles of Linear Dichroism 
This technique studies the optical anisotropy of molecules.
8
 It is commonly used to probe 
the orientation of long molecules such as DNA and can therefore be used to probe DNA-
ligand systems. Linear dichroism (LD) is defined as the difference between the absorption 
(A) of light linearly polarised parallel and perpendicular to an orientation axis, measured as 
a function of wavelength: 
LD () = A () - A() 
Electromagnetic radiation consists of an electric and a magnetic component. These may be 
thought of as waves, which oscillate perpendicular to each other and to the direction of 
propagation of the wave, Figure 2. 6. 
Electric component
Magnetic component
Direction of propagation of wave
 
Figure 2. 6 Components of electromagnetic radiation. 
 
Linearly polarised photons, for example, will all have their electric component oscillating 
in the same direction. The absorbtion of a photon of radiation causes the electron 
distribution in the molecule to be reorganised, with the linear, net direction of this change 
defining the transition polarisation. So LD may be used to give the orientation of the 
transitions within a molecule.  Flow LD is a specific method of obtaining an LD spectrum, 
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used in this thesis. It is commonly used with systems which are intrinsically oriented or 
may be oriented during the experiment, such as DNA (min length ~250 bp). When a 
solution of DNA is flowed between the narrow walls of a flow couette cell, Figure 2. 7, the 
DNA is oriented by viscous drag. This alignment ensures that the electronic transitions 
normally interacting with the incident light are aligned so can interact coherently with the 
polarised light. The flow cell consists of a fixed outer cylinder and a rotating solid quartz 
inner cylinder, separated by a gap of 0.5 mm giving a total pathlength of 1 mm.  
 
Rotating quartz cylinder
y
x
z
Sample gap
Quartz window
 
Figure 2. 7 Schematic diagram of an LD flow couette cell.
10
 
 
A typical LD spectrum of B-DNA is shown in Figure 2. 8. The ct-DNA signal at 258 nm 
arises due to the orientation and electronic transitions of the DNA bases. In B-DNA these 
are arranged at approximately right angles (86°) to the direction of orientation, so the base 
π-π* signals give rise to a negative signal. The signal at 195 nm corresponds to transitions 
within the phosphodiester backbone.  
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Figure 2. 8 Linear Dichroism spectrum of B-DNA 
 
A small molecule free in solution is not large enough to be oriented so will not display an 
LD signal. Similarly, a molecule bound randomly to DNA will also not be oriented. A 
complex bound uniformly to DNA will not only possess an LD signal in its own absorption 
region, but it may also cause the characteristic DNA signals to be perturbed. The sign and 
amplitude of these signals can be used to give information about predominant binding 
modes such as intercalation, major/minor groove binding or covalent binding to DNA 
bases. 
2.4.3.2  LD Experimental Procedure 
Spectra were collected using a flow couette cell (Krometek) in a Jasco J-715 
spectropolarimeter adapted for LD measurements. The same series of samples were 
prepared and analysed as for the above CD method (section 2.4.2.2). 
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2.4.4  Ethidium Bromide Displacement Assay 
2.4.4.1  Principles of the Ethidium Bromide Displacement Assay 
Ethidium bromide (EB), Figure 2. 9, binds to DNA through intercalation and displays a 20-
fold increase in fluorescence upon binding.
11
 For this reason EB is commonly used in 
fluorescence assays to assess DNA-complex interactions.
12
 Fluorescence can be defined as 
the emission of radiation caused by a molecular transition from an excited state to a ground 
state. The absorption of a photon in some molecules can result in the raising of the 
molecule to an excited electronic state without subsequent loss of all of its energy due to 
radiationless decay.
 
In the case of EB, UV radiation at 375 nm is absorbed by the dye when 
bound to DNA. A photon is then re-emitted at 590 nm in the red-orange region of the 
visible spectrum.
 13 
 Free EB does not emit in this way due to quenching of the emission by 
surrounding solvent molecules.  
Br-
 
Figure 2. 9 The structure of ethidium bromide. 
 
A method of assessing the ability of a compound to bind to DNA is to load DNA with EB 
and measure the fluorescence. Increasing concentrations of DNA binding complex are then 
added to the solution and resulting fluorescence recorded. If DNA binding of the complex 
is stronger than that of EB, the EB will be displaced from the DNA and thus fluorescence 
of the solution will decrease.  This theory may be used to determine the apparent 
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equilibrium constant for drug binding.
14
 This method can be used to detect various modes 
of DNA binding (not only intercalation) as, for example, complex binding in the major 
groove may disrupt the DNA enough to cause removal of the EB from the DNA. 
 
2.4.4.2  Ethidium Bromide Displacement Experimental Procedure 
The emission of an ethidium bromide (EB) solution (1.30 x10
-6 
mol) (3.1 µl 0.1 mg/ml EB 
solution, 6 µl Tris base, 590 µl H2O) was recorded as a control (Varian cary eclipse 
fluorescence spectrophotometer, excitation λ 540 nm, emission λ 560-750 nm). 1.5 µl ct-
DNA solution (3.90 x10
-6
 mol) (1.5 µl 1.55 x10
-3
 ct-DNA, 3.1 µl 0.1 mg/ml EB, 6 µl 1 M 
Tris base, 590 µl H2O) was then added and resulting emission measured. 1 µl metal 
complex (2.50 x10
-5
 mol) was added to the solution, emission recorded, and this process 
(addition of 1 µl metal complex) repeated until emission dropped to below half of the 
starting value. For each emission recording the original EB emission was subtracted and 
results normalised. The following equation was used to calculate apparent binding 
constant: 
EB binding constant (M
-1
) x [EB] (mol) = Kapp (M
-1
) x C50% (mol) 
 
2.4.5  DNA Emission Studies 
2.4.5.1  Principles of the Emission Assay 
The measurement of the emission intensity of small molecules has become a powerful 
analytical tool in biological sciences because of its capacity to yield information on 
molecular association, motion and separation. Enhancement of the fluorescence of d
6
 
transition metal complexes has been used for DNA and oxygen sensing as well as cell 
imaging purposes.
15
 Enhancement of fluorescence upon DNA binding is due to the 
 62 
protective environment of the DNA which reduces quenching from solvent molecules 
which may deactivate the excited state through hydrogen bonding. In the assay used 
herein, the concentration of metal complex remains constant while the concentration of 
DNA is increased. The fluorescence response can therefore be probed, to assess DNA-
metal complex interactions. 
 
2.4.5.2  Emission Experimental Procedure 
Samples of ct-DNA (2.00x10
-3
 M), NaCl (20 mM) and sodium cacodylate buffer (10 mM) 
were prepared. The concentration of DNA was varied with ratios of DNA base: metal 
complex between 1:1 and 10:1. Two stock solutions of metal complex were prepared. The 
first of metal complex (19.2 µM) and the second with double concentration (38.4 µM).  
After the addition of X μL of DNA solution to the original metal complex solution (19.2 
µM), an equivalent addition of the second, double concentration metal complex stock 
solution was added. This results in the concentration of metal complex remaining unaltered 
throughout the titration. After each successive addition emission was recorded in a PTI 
fluorescence system, with illumination from a PTI L-201M source using a 75 W xenon arc 
lamp. The detection system was a Hamamatsu R928 PMT in a PTI model 814 
analog/photon-counting photomultiplier (λ exc = 512 nm; λ em = 700-900 nm). UV-
Visible spectra were recorded of each sample in parallel with emission. 
 
2.4.6  DNA Photocleavage  
2.4.6.1  Principles of the DNA Photocleavage Assay 
A further use of small-molecule DNA binders is in the development of molecular probes 
for therapeutics such as photodynamic therapy. This usually depends on the complexes 
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ability to associate with biological molecules such as DNA.16 Light is then used in order to 
activate the complex, causing damage to biological molecules and killing the target cell. 
For example, complexes with a long-lived, low-energy triplet excited state are capable of 
generating singlet oxygen, which then induces DNA damage. The assay used in this thesis 
probes the ability of metal complexes to cause DNA cleavage in the presence of UVA 
light. 
 
2.4.6.2  DNA Photocleavage Experimental Procedure 
DNA was radiolabelled with α-dATP (as per kit instructions, New England Biolabs): 
Linear plasmid DNA (4 µl, BS SK(-) 159 bp) was incubated with 0.4 µl dTTP (10 mM), 
0.4 µl dCTP (10mM), 0.4 µl dGTP (10 mM), 2 µl 10x Ecopol buffer, 0.4 µl Klenow exo- 
DNA polymerase, 2.5 µl α-dATP* and 9 µl H2O for 40 minutes at room temperature. The 
solution was then deprotonated and desalted using a kit (Wizard SV gel and PCR cleanup 
system, Promega): 25 µl DNA membrane binding solution was added to the DNA and 
centrifuged at 15000 x g for one minute before being transferred into a new tube and 650 
µl membrane wash solution added with further centrifugation of one minute. 500 µl wash 
solution was then added with centrifugation for a further 5 minutes. The elution step was 
then followed: the filter was transferred into a new tube and 50 µl nuclease free water was 
added and centrifuged for one minute. This was repeated 2 x with 40 µl H2O. This was 
then repeated with 50 µl H2O, left for 5 minutes and centrifuged for one minute. The total 
volume was transferred into a new eppendorf and freeze-dried for future use.  
 
Maxam gilbert solutions for DNA footprinting were then prepared for specific cleavage at 
guanine bases: radiolabelled DNA (~1200 CPS) (prepared as above) was incubated with 
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100 µl DMS buffer (50 mM sodium cacodylate, pH 8 with HCl, 1mM EDTA) to which 0.5 
µl DMS was added and incubated for four minutes on ice. Following this, 25 µl DMS stop 
buffer (1.5 M sodium acetate pH 7, 1 M Mercapto ethanol, 100 µg/ml ct-DNA) was added. 
For specific cleavage at guanine and adenine bases: radiolabelled DNA (~1200 CPS) 
(prepared as above) was incubated with 100 µl H2O. 25 µl formic acid was added and the 
solution incubated for four minutes at room temperature. Following this, 200 µl G and A 
stop buffer (0.3 M sodium acetate, 0.1 mM EDTA and 100 µg/ml ct-DNA) was added. 
DNA of both guanine cleaved and adenine and guanine cleaved samples was precipitated 
by the same method: 800 µl cold ethanol was added followed by incubation at -80 ºC for 
30 minutes. Samples were then washed with 2 x 500 µl ethanol before being centrifuged at 
184000 x g for 25 minutes, then placed in a heating block at 90 ºC to remove any 
remaining ethanol. Samples were then cleaved: Samples were dissolved in 90 µl H2O 
followed with the addition of 10 µl piperidine, vortexed and left for 30 minutes at 90 ºC. 
Following this, samples were freeze dried, re-dissolved in 40 µl H2O and further freeze 
dried. This was repeated 2 x. Prior to use samples were dissolved in 5 µl H2O. 
 
For DNA photocleavage solutions were prepared as follows; control: 0.5 µl DNA*, 3.4 µl 
H2O, 0.5 µl Tris base, 0.5 µl ct-DNA (1.55 x10
-3
) Metal complex solutions: 0.5 µl DNA*, 
0.5 µl Tris base, 0.5 µl ct-DNA (1.55 x10
-3
), metal complex (3.88 x 10
-5
 M stock solution) 
and H2O to make 20:1 and 10:1 DNA base: metal complex ratio. Samples were incubated 
for 3.5 hrs at 90 ºC before loading, with half the sample being incubated in the dark and 
half under a UVA lamp. 
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Samples were subsequently loaded onto a denaturing gel: 13 % polyacrylamide (from 8 ml 
24 % denaturing gel, 16 ml 8 % denaturing gel) (40 % denaturing gel: 38 g acrylamide, 2 g 
bis-acrylamide in 200 ml deionised H2O), (24 % denaturing gel: 60 ml 40 % denaturing 
gel, 50 g urea, 5 ml 20 x TBE buffer in 100 ml H2O). Gel thickness of 0.35 mm. 14 µl 
TEMED and 28 µl 25 % APS were added to the gel solution to set and the gel left for an 
hour before use. Metal complex samples as well as control and maxam gilbert reference 
samples were loaded onto the gel and run for three hrs at room temperature, 35 W. Gels 
were visualised using the BAS 2500 FUJIFILM bioimaging analyser and radioactivities 
associated with bands were quantified with AIDA image analyser software (Raytest, 
Germany). 
 
2.4.7  DNA Three Way Junction Binding 
2.4.7.1  Principles of the Three Way Junction Binding Assay 
Polyacrylamide gel electrophoresis can be used to separate DNA of various length 
/charge/3D architecture through the application of an electric field to a gel matrix. 
Experiments described in this thesis were designed to mimic previous experiments,
17
 using 
DNA oligos of 14 base pairs long. These were designed to be able to form a DNA three 
way junction structure in the presence of a stabilising molecule, with each arm of the 3-
way junction structure being 7 base pairs in length, Figure 2. 10. This has been shown to be 
the minimum length of DNA needed in order to form stable structures in a polyacrylamide 
gel.
18
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Strand 1 – 5‟CGGAACGGCACTCG 
Strand 2 – 5‟CGAGTGCAGCGTGG 
Strand 3 – 5‟CCACGCTCGTTCCG 
 
Figure 2. 10 Oligos used in polyacrylamide gel electrophoresis experiments and the 
three way junction structure proposed to form.
17 
 
The conditions of this experiment were modified a number of times in order to find the 
most successful method. At 4 ºC there is formation of a three way junction structure, with a 
high percentage of double strand formation with all compounds tested. For this reason, gels 
were carried out at 25 ºC in order to suppress the formation of the double stranded species 
and to see more clearly three way junction stabilisation.  
 
2.4.7.2  Three Way Junction Assay Procedure 
Oligonucleotides were obtained pure.
19
 DNA strand 1 was radioactively labelled at the 5‟ 
end using 
32
P radiolabelled ATP in order for any DNA structures formed to be visualised 
on the gel. Samples were analysed with 15 % Polyacrylamide gel electrophoresis.  
 
To an eppendorf (in order) the following components were added; 4 l H2O, 1 l 10x PNK 
Buffer, 2.5 l 3.30x10-6M ATP, 0.41 l strand 1, 1 l [γ32P]-ATP and 1 l kinase. The 
solution was incubated for 40 minutes at 37 ºC. Strand 1 was then purified by removal of 
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unreacted [γ32P]-ATP:  A 1 ml plastic syringe was packed by centrifugation with sephadex 
G50-fine, followed by the addition of 100 l water to the column and further 
centrifugation. This procedure was repeated 3x. 90 l water was then added to the eluent 
which was subsequently added back into the column, further centrifuged and collected in 
an eppendorf. The sample was then freeze dried and dissolved in 20 l water before use. 
The Nativ Gel (15 % polyacrylamide, thickness 0.35 mm) was made as follows: 12 ml 30 
% polyacrylamide (29 g acrylamide, 1 g bis-acrylamide, up to 100 ml H2O), 1.2 ml 20x 
TBE, 240 l 1 M NaCl, 10.5 ml H2O. Directly before use 25 l TEMED and 30 l APS 
(25%) were added to the gel solution. 
 
DNA samples were prepared by adding stoichiometric amounts of oligonucleotides (1.07 x 
10
-5
 M each strand) in buffer (20mM NaCl, 2x TB). Dilutions of metal complexes were 
made in buffer (1x TB (50mM tris and boric acid (pH 8.3)), 10mM NaCl). Metal complex 
solutions were incubated with oligonucleotide solution for 15 minutes at room temperature 
followed by incubation on ice for 25 minutes. Loading buffer was then added and the 
samples loaded onto the gel. The gel was run for 1 hr at 5-7 W. Gels were visualised using 
the BAS 2500 FUJIFILM bioimaging analyser and radioactivities associated with bands 
were quantified with AIDA image analyser software (Raytest, Germany). 
 
2.5  Cell Culture and Cell Studies 
2.5.1  Cell Lines 
Human breast cancer cell lines: T47D, MDA-MB-231. 
Human ovarian cancer cell lines: SKOV-3, A2780-P (parental cell line), A2780-R 
(cisplatin resistant cell line). 
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Human myeloid leukaemia cell line: HL-60. 
 
2.5.2  Cell Maintenance 
All solutions and equipment used for cell maintenance were either obtained sterile or, 
when appropriate, autoclaved before use. Cell culture was undertaken in sterile conditions 
in a class 1 tissue culture hood (Aura B4, Bio Air, Italy). 
 
All cell lines were maintained at 37 
o
C in a humidified chamber (5 % CO2, 95 % air; 
MCO-15AC, Sanyo, Japan) in flat bottomed cell culture flasks (Falcon, UK) in continuous 
logarithmic culture.  A2780-P, A2780-R, MDA-MB-231 and T47D cell lines were 
maintained in Dulbecco‟s Modified Eagle‟s Medium (DMEM) (+ 4.5 g/l glucose, 
Invitrogen Corporation, UK) supplemented with 10% fetal bovine serum (Invitrogen), 1 % 
2 mM l-glutamine (Sigma), 1% 1 mM sodium pyruvate (Sigma), 1 % 10 mM Hepes buffer 
(Sigma) and antibiotics (Antibiotics Antimycotic 100 diluted to 1, Sigma). HL-60 and 
SKOV-3 cell lines were maintained in RPMI-1640 medium (-L-glutamine, Invitrogen 
Corporation, UK) supplemented as above.  
 
Adherent cell lines were subcultured twice weekly using a trypsin-EDTA protocol: 
Media was removed and cells were washed with 5 ml phosphate buffered saline solution 
(PBS tablets (0.01 M phosphate buffer, 0.003 M KCl and 0.137 M NaCl, pH 7.4) Sigma, 
UK). PBS was then removed and replaced with 3 ml of trypsin-EDTA (10x solution (0.5% 
trypsin, 0.2% EDTA), diluted to 1x, Sigma, UK). The flask was then sealed and placed in 
the humidified chamber until all cells were detached from the surface of the flask. 
Following detachment, 10 ml of supplemented medium was added to the flask and the 
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resulting cell suspension mixed gently using a sterile pipette. Cell suspension was then 
transferred to a sterile 15 ml centrifuge tube (Falcon) before centrifugation at 1500 rpm for 
5 minutes. Following centrifugation, supernatant was removed and the cell pellet was 
resuspended in 1 ml of supplemented medium. An aliquot was taken and transferred into a 
75 cm
2
 cell culture flask with supplemented medium, sealed, placed in the humidified 
chamber and allowed to grow to confluence for further use. Cell suspensions prepared in 
this manner were also used to seed various sized flasks, plates and/or dishes at various cell 
densities in preparation for experimental use (detailed information on seeding density is 
described for each protocol). Cell densities were determined using a haemocytometer 
(Neubauer improved). Non adherent cell lines were reseeded every 48hrs, by splitting 1:3 
with supplemented medium. 
 
If needed, cells were cryopreserved. Cell pellets were resuspended in 1 ml of fetal bovine 
serum with 10 % DMSO as a cryoprotectant. Cell suspensions were then transferred into 2 
ml cryovials (Nalgene, USA). Vials were stored at -80 
o
C overnight, then removed into a 
liquid nitrogen storage vessel for long-term storage. 
 
2.5.3  Cellular Uptake 
2.5.3.1  Uptake into Cytosol of Cell 
In order to assess the uptake and stability of metal complexes in the cytosol of the cell, 
cells were incubated with metal complex followed by splitting of the cells into cell 
membrane and cytosol extracts. A UV spectrum of the cytosol extract should show the 
distinctive MLCT peaks of the metal complex, if the complex has been able to enter the 
cell and maintain its structure throughout the experiment.  
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2.5.3.2  Cellular Uptake Assay Procedure 
MDA-MB-231 cells were seeded at near confluence in T75 flat bottom culture flasks (nunc) 
and left for 24 hrs to adhere (37 ºC, 5 % CO2). Medium was then removed and cells 
washed with 10 ml warm PBS. 9 ml metal complex (100 µM) or control (supplemented 
medium) was then added to the cells and incubated for a further 24 hrs (37 ºC, 5 % CO2). 
Cells were then trypsinised (1 % trypsin EDTA protocol, section 2.5.2) and the resulting 
cell pellet washed with 1 ml cold PBS. 1 ml cold RIPA buffer (Sigma) was then added to 
the cell pellet and cells vortexed to resuspend, followed by incubation on ice for 10 
minutes. Cells were then centrifuged, with resulting pellet being membrane extracts and 
the supernatant being the cytosol of the cell. A UV-Visible spectrum was recorded of the 
supernatant (in PBS). 
 
2.5.4  Competitive Fluorescence Binding Studies 
2.5.4.1  Principles of the Hoechst Displacement Assay 
This assay is used to probe the DNA binding ability of small molecules in live cells, using 
the minor groove binding fluorescent DNA stain, Hoechst 33258, Figure 2. 11.  
 
Figure 2. 11 The structure of Hoechst 33258. 
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This molecule stains both naked and cellular DNA and when excited at 350 nm has a 
distinct emission peak at 450 nm, Figure 2. 12. 
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Figure 2. 12 DNA-bound Hoechst 33258 emission at 450 nm after excitation at 350 nm. 
 
To probe cellular DNA binding of metal complexes, cells are incubated with Hoechst, 
followed with increasing concentrations of metal complex. If the complex binds to nuclear 
DNA, the Hoechst molecule may be displaced from the minor groove of the DNA and thus 
emission at 450 nm will decrease. The rate and extent to which the emission at 450 nm 
decreases with increasing compound concentration can allow the degree of DNA binding 
to be probed.  Although the Hoechst molecule resides in the minor groove of the DNA, 
perturbations caused by another molecule binding to other areas of DNA can be sufficient 
to eject the Hoechst. Therefore this test is not only an indication of minor groove binding, 
but indicates more general DNA binding interactions. 
 
2.5.4.2  Hoechst Displacement Assay Procedure 
The procedure used is described by Matsuba et al.
20
 HL-60 cells were preincubated with 10 
µM Hoechst 33258 in 0.5 ml RPMI cell culture medium at 37 °C for 20 minutes. Metal 
complexes (concentrations ranging between 0 and 100 µM) were dissolved in 10 µM 
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Hoechst solution and added to the cell solution, followed by a further 20 minute incubation 
at 37 °C. Cells were then concentrated by centrifugation, washed once with chilled PBS, 
resuspended in chilled PBS and fluorescence measured.  
 
Fluorescence spectra were recorded in a PTI fluorescence system with illumination from a 
PTI L-201M source using a 75 W xenon arc lamp. The detection system was a Shimadzu 
R298 PMT in a PTI model 814 analog/photon-counting photomultiplier (λ exc = 350 nm, λ 
emm = 400–550 nm). 
 
2.5.5   Cell Line Testing Using the MTT Cell Viability Assay 
2.5.5.1  Principles of the MTT Assay 
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide) 
colorimetric assay is used to determine the mitochondrial reductive function of cells and 
hence is a good indicator of cell death or inhibition of growth.
21
 MTT is a water soluble 
dye that is able to cross cell surface membranes and is reduced to a blue, water insoluble 
formazan product, Figure 2. 13, by the mitochondrial enzyme succinate dehydrogenase. 
The formazan product, when dissolved in DMSO, has a distinct absorbance maximum at 
590 nm. Absorbance at this wavelength is directly proportional to the number of viable 
cells within the population.
22
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Mitochondrial reductase
MTT Formazan
 
Figure 2. 13 The reduction of MTT to a formazan product in the MTT assay 
 
After incubation of cells with a range of concentrations of metal compound the MTT assay 
can be used to obtain an IC50 value. This is the concentration of compound where 50 % of 
cells in a population are viable. 
 
2.5.5.2  Cell Line Testing Procedure 
Cells from confluent monolayers were removed from flasks using a 1% trypsin-EDTA 
protocol (see section 2.5.2). Cell viability before drug treatment was established using the 
trypan blue dye exclusion test, with a Neubauer hemocytometer (Hawksley Medical and 
Laboratory Equipment). The trypan blue exclusion assay provides a measure of membrane 
integrity, based on the principle that the dye is excluded from cells with an intact 
cytoplasmic membrane, whereas cells with damaged membranes cannot exclude the dye 
and are stained blue.
23
 Due to differing growth rates, varying cell densities were seeded for 
each cell line in 100 l of complete medium in 96-multiwell flatbottom microtiter plates 
(Corning Costar); A2780-P, A2780-R = 4000 cells/well; MDAMB-231 = 10000 cells/well; 
T47D = 25000 cells/well. Plates were incubated at 37 C, 5% CO2 for 24 hrs to allow cell 
adhesion prior to metal compound testing. Stock solutions of metal complex were freshly 
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prepared in complete medium with a range of concentrations between 3 and 200 µM. Each 
concentration was tested in quadruplicate with 100 l of complete medium as control and 
plates were incubated for 72 hrs. 
 
2.5.5.3  MTT Assay Procedure 
Following incubation of cells with metal complex, 50 l MTT solution (5mg/ml in PBS, 
Sigma Chemical Co, UK) was added to each well and incubated for a further two hrs. 
Medium was subsequently removed from wells and any resulting formazan crystals 
solubilised in 100 l DMSO per well. Culture plates were rocked gently for 30 minutes 
before optical density was measured using a microplate reader (Bio Rad) at 590 nm against 
a DMSO blank (100 μl). Sample readings were blank adjusted and converted into 
percentage versus untreated controls. 
 
2.5.6  Increased Molar Incubation Assay 
This test was designed to probe the response of MDA-MB-231 breast cancer cells to an 
increased molar incubation of metal complex. The volume added was kept constant and the 
concentration of metal complexes was varied. 10000 cells/well were seeded in 100 µl 
complete medium in 96 well, flat-bottomed, microtitre plates (Corning Costar) and 
incubated for 24 hrs (37 ºC, 5 % CO2) to adhere. Following this incubation, medium was 
removed and cells were washed with 50 µl warm PBS which was then also removed. Cells 
were then treated with 75 µl metal complex (in medium) of concentrations between 3.125 
and 100 µM, in quadruplicate. Remaining wells were incubated with 75 µl medium as a 
control. This method was repeated with volumes of 100, 150 and 200 µl. Plates were 
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incubated for 72 hrs before cell viability was assessed via the MTT assay (see section 
2.5.5.3). 
 
2.5.7  Extended Incubation Assay 
This test was intended to follow the response of MDA-MB-231 cells to metal complexes 
over extended time periods. 10000 cells/well were seeded in 100 µl complete medium per 
well of 96 well, flat-bottomed, microtitre plates (Corning Costar) and incubated for 24 hrs 
at 37 °C, 5 % CO2 to adhere. Cells were then treated with 100 µl metal compound 
concentrations between 6.5 and 200 µM, followed by further incubation of 1-6 days. At the 
end of each incubation period cell viability was established using the MTT assay (see 
section 2.5.5.3). 
 
2.5.8  Cellular Recovery Assay 
This test was carried out in order to assess the ability of MDA-MB-231 cells to recover 
from incubation with metal complexes. 10000 cells/well were incubated in 100 µl medium 
in 96-multiwell flatbottom microtiter plates (Corning Costar) for 24 hrs to adhere (37 °C, 5 
% CO2). Cells were then treated with 100 µl of 100 µM metal complex in quadruplicate 
and incubated for 3 or 18 hrs. Following these incubation periods medium was removed, 
cells were washed with 50 µl warm PBS which was then removed and replaced with 200 
µl fresh medium. Cells were then incubated for a further 1-6 days and at the end of each 
incubation period cell viability was established using the MTT assay (section 2.5.5.3). 
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2.5.9  Time Lapse Phase Contrast Microscopy 
2.5.9.1  Principles of Time Lapse Microscopy 
Microscopy techniques used in conjunction with a time lapse video camera are a powerful 
tool which can be used to record details of cells over periods of time. This allows the 
investigation of cellular events such as mitosis, necrosis or apoptosis during drug 
treatment.
24
 Phenotype and morphology of cells can also be monitored. The microscope 
and camera are housed inside a purpose built incubator so that the cells can be filmed in 
the correct environment for the experiment. 
 
2.5.9.2  Time Lapse Microscopy Experimental Procedure 
5x10
4
 cells/well were seeded in 0.5 ml complete medium per well of 24 well flatbottom 
plates (Corning Costar). Plates were incubated for 24 hrs (37 ºC, 5 % CO2) for cells to 
adhere. Cells were then treated with metal complex concentrations of 50, 100, and 200 µM 
and medium as a control. Plates were incubated at 37 ºC, 5 % CO2 in a purpose built 
incubator attached to a time lapse microscope (Nikon 2000, 20x, phase contrast). Images 
were recorded every 2 minutes for 18 hrs. 
 
2.5.10  Fluorescent Rhodamine Phalloidin Staining of Actin Cytoskeleton 
2.5.10.1 Principles of the Phalloidin Fluorescence Assay 
Phalloidins are small, naturally occurring molecules that bind to the actin in cells and alter 
its polymerization. They are widely used to study the role of actin in biological processes.
25
 
In this assay, phalloidin, Figure 2. 14, a high-affinity probe which binds to actin at the 
junction between subunits, specific to F-actin is conjugated to the orange-fluorescent dye 
tetramethylrhodamine B isothiocyanate (TRITC). The fluorescence of rhodamine 
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phalloidin can therefore be measured showing the distribution of F-actin in permeabilised 
cells. F-actin is a protein which makes up part of the cellular cytoskeleton and is 
responsible for cellular motility, along with other biological components of the cell. The 
distribution of F-actin after incubation with a drug molecule can give information about 
disruptions to the cellular cytoskeleton caused by the drug. 
 
Figure 2. 14 The structure of phalloidin. 
 
2.5.10.2 Phalloidin Fluorescence Assay Procedure 
5x10
4
 cells/well were seeded in 0.5 ml supplemented medium per well of 24 well 
flatbottom culture plates (Corning Costar) on top of sterile microscope coverslips. Plates 
were incubated for 24 hrs (37 ºC, 5 % CO2) for cells to adhere to coverslips. Wells were 
then treated with metal complex concentrations of 50, 100 and 200 µM and medium as a 
control. Plates were incubated for a further four hrs at 37 ºC, 5 % CO2. Following 
incubation media was removed from wells and cells were fixed with 500 µl 4 % 
paraformaldehyde, added on top of the microscope slides and incubated for 10 minutes at 
room temperature. Wells were then washed with 500 µl PBS x 3 (room temperature). This 
was followed by removal of microscope slides from wells, which were then placed cell 
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side down onto 100 µl drops of NH4Cl (50 mM). These were left for 10 minutes at room 
temperature to neutralise the paraformaldehyde. Slides were then washed 3 x in PBS and 
placed (cell side down) onto 100 µl 0.1 % Triton-X in PBS. These were incubated for 4 
minutes at room temperature to permeabilise cell membranes. Following this incubation 
slides were placed onto 100 µl drops of fluorescent rhodamine phalloidin (TRITC 
Phalloidin, Sigma, 4 µl 75 µM in 800 µl PBS) for 20 minutes at room temperature. Slides 
were then washed 3 x with PBS and 3 x with water, before being placed cell side down on 
microscope slides, onto 5 µl mowiol (6 ml glycerol, 2.4 g mowiol (Calbiochem), 6 ml 
water, 12 ml Tris-Cl pH 7.5-8.5). Slides were kept at 37 ºC for an hour before fluorescence 
images were recorded on a Zeiss Axiovert 135TV microscope with 63x (1.25 NA Plan 
NEOFLUAR Ph3) objective lens. A TRITC filter set and a mercury lamp were used for 
fluorescent illumination. Images were captured using a QIimaging QIcam 1394 driven by 
Qcapture pro software. 
 
2.5.11  Alkaline Comet Assay 
2.5.11.1 Principles of the Comet Assay 
The single cell gel electrophoresis or “comet” assay, originally described in 1984 by 
Ostling and Johanson
26
 is used to assess the genotoxic potential of compounds through 
their ability to induce strand breaks in the DNA of eukaryotic cells. A number of 
modifications have been made to this assay to assess different forms of DNA damage.
27
 
The method used herein is the alkaline comet assay, used to assess single strand breaks in 
DNA.
28
 After incubation of cells with metal compound, cells are embedded in agarose, 
lysed, electrophoresed and stained in order to image the DNA by fluorescence. During 
electrophoresis, intact DNA remains tightly wound in the nucleoid, or comet head. Loops 
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of DNA around any strand breaks migrate out towards the positively charged anode, 
resulting in the formation of a comet tail. The more strand breaks, the further the 
movement and the more intense the DNA tail. Hence, the extent of DNA damage is 
measured by the „tail length‟ of the DNA, Figure 2. 15. 
Head Tail
 
Figure 2. 15 Fluorescence microscope images of cells without (left) and with (right) 
DNA damage after electrophoresis.
29
 
 
2.5.11.2 Comet Assay Procedure 
The method used is based on that of Singh et al.,
28
 modified by Lee et al.
30
 A2780 human 
ovarian cancer cells were seeded at a density of 1.25 x 10
6
 cells/well in 6 well flatbottom 
culture plates and allowed to adhere for 24 hrs (37 ºC, 5 % CO2). Cells were then treated 
with three concentrations of metal compound, the top concentration being just above the 
calculated IC50 value for this cell line. Following incubation at 37 ºC for 24 hrs, cells were 
washed with cold PBS and gently scraped into fresh PBS (1 ml). Cells were then 
centrifuged (8000 x g, 5 minutes) and the resulting pellet resuspended in PBS (100 µl). An 
aliquot of resuspended cells (5 µl) was then placed into a sterile tube with low melting 
point agarose (300 µl), prewarmed to 300 ºC. This was then transferred to a glass 
microscope slide (150 µl per slide, VWR International) which had been pre-coated with 
0.5 % normal melting point agarose. Cell solution on slides were then covered with glass 
coverslips (VWR International) and slides placed on a metal tray over ice for 10 minutes to 
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allow the agarose to solidify. Coverslips were then removed and slides incubated for 1 hr at 
4 °C in cold lysis buffer (2.5 M NaCl, 0.1 M Na2EDTA, 10 mM Tris base, 1 % sodium N - 
lauryl sarcosinate, 10 % DMSO and 1 % Triton X-100). Following lysis slides were placed 
in a horizontal electrophoresis tank containing cold electrophoresis buffer (300 mM NaOH, 
1 mM Na2EDTA) and DNA allowed to unwind without electrophoresis for 20 minutes. 
Slides were then subjected to electrophoresis (25 V, 0.8 Vcm
-1
, 20 minutes) followed by 
washing (3 x 5 minutes) with cold neutralisation buffer (0.4 M Tris base, pH 7.5). Slides 
were subsequently stained by adding 50 µl Sybr gold solution (1 x solution, Invitrogen) 
and covered with cover slips. Slides were left in the dark at 4 ºC prior to examination. 
Slides were examined at 320 x magnification using a fluorescence microscope (Zeiss 
Axiovert 10, Germany) fitted with a 515 - 560 nm excitation filter and a barrier filter of 
590 nm. A USB digital camera (Merlin, Allied Vision Technologies) received the images, 
which were analysed using a personal computer-based image analysis system, Comet assay 
IV (Perceptive instruments). Images of one hundred randomly selected nuclei were 
analysed per slide.  
 
Measurement of mean percent tail intensity was chosen to assess the extent of DNA 
damage as this has been shown to suffer much less from inter-run variation than other 
comet parameters, due to its independence of electrophoresis voltage and run time.
31
 
Median values of three separate experiments were analysed using an ANOVA and post hoc 
Student‟s t test.32 
 
 
 81 
2.6  Ames Bacterial Mutagenicity Assay 
2.6.1  Principles of the Ames Test  
The Ames bacterial reverse mutation assay is a test recognised as an initial screening 
process to establish the mutagenic potential of new drugs. It has been established that 
compounds which do not exhibit activity in the Ames test are normally found to be non-
carcinogenic.
33
 This short term bacterial reverse mutation assay uses specially constructed 
tester strains of Salmonella typhimurium which are unable to grow due to the absence of 
the amino acid histidine. This is caused by a mutation in one of the genes responsible for 
its biosynthesis. A mutagen incubated with these bacteria will result in many new 
mutations, a small proportion of which can reverse the original mutation, allowing the 
synthesis of histidine and the proliferation of the bacteria as discrete colonies.  Potential 
mutagens are able to enter these strains easily as the lipopolysaccharide barrier that 
normally coats the surface of Salmonella is incomplete. Two strains were used in order to 
ensure a thorough investigation of mutagenic potential. Base pair or point mutations 
(TA100 strain) affect only a single base whereas frameshift mutations (TA98 strain) 
involve the insertion or deletion of a number of nucleotides. 
 
 
This test can also be used to probe potential in vivo mutagenicity using activated rat liver 
S9 enzymes, a variety of mixed function oxidase enzymes.
34
 Some carcinogenic 
compounds are biologically inactive unless metabolised into their active forms. In humans 
this can be carried out by cytochrome-based metabolic activation, usually in the liver. As 
bacterial enzymes do not have this function a mammalian exogenous source is needed. 
Positive controls (known mutagens and promutagens) are also incubated with the bacteria, 
with and without S9 in order to check the bacteria and the S9 mix. A small amount of 
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histidine is added to allow the bacteria to grow for a short time. After this histidine is 
exhausted only bacteria that have undergone a reverse mutation in their histidine 
production gene are able to continue to grow. Some bacteria revert spontaneously, so 
results are compared to a negative control.  For a compound to be considered a mutagen 
there must be a dose-dependent increase in the number of revertant colonies, as verified by 
at least two independent experiments. A minimum cut-off increase between a mutagenic 
and non-mutagenic response is usually a 2-3 fold increase in revertants relative to negative 
controls.
35  
 
2.6.2  Ames Test Procedure 
All experimental methods were carried out in sterile conditions and only one strain of 
Salmonella was used on any one day to avoid cross contamination. All reagents and 
equipment were sterilised before use. 
 
16 hrs prior to the experiment master cultures of Salmonella typhimurium were prepared 
according to the method of Marron and Ames.
36
 10 ml of nutrient broth was inoculated 
with a loopful (10 µl) of bacteria. Light was excluded and the bacteria incubated on a 
rotary shaker at 37 ºC. The culture was kept on ice during the experiment. Minimal agar 
plates (11.5 g Agar, 700 ml water, 15 ml Vogel-Bonner salts (MgSO4.7H2O, citric acid 
monohydrate, K2HPO4, NaNH4PO4.4H2O), 38 ml 40% glucose) were made prior to use. 
The bacteria were checked with positive controls of 4-nitroquinoline-N-oxide for TA98 
and sodium azide for TA100 both before and during the experiment. On the day of the 
experiment top agar (0.6 g agar bacteriological, 0.5 g NaCl in 100 ml water) was enriched 
with 0.05 mM histidine and biotin (1ml per 9ml agar) and kept at 42 ºC for use. Rat liver 
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S9 enzymes (20 µl S9 per plate, 8 mM MgCl2, 33 mM KCl, 5 mM glucose-6-phosphate, 4 
mM NADP, 100 mM sodium phosphate, pH 7.4), (Tebu-Bio) were freshly prepared and 
kept on ice. Dilutions of metal compounds and controls (concentrations of active 
compounds between 0.1 and 100 µM, inactive compounds between 0.4 and 250 µM) were 
prepared on the day of the experiment in a sterile environment using a minimum of DMSO 
for water insoluble compounds and PBS for water soluble compounds. Negative controls 
were also prepared with DMSO and PBS to check for contamination. Compounds and 
controls (prepared both with and without S9) were incubated with bacteria for 20 minutes 
at 37 ºC then removed to an ice bath to stop bacterial growth until plated onto a minimal 
agar plate with molten top agar. These were incubated in the dark for 48 hrs at 37 ºC. After 
24 hrs background bacterial lawn was checked and after 48 hrs resulting colonies were 
counted. Values reported are higher in the TA100 strain due to the naturally higher 
reversion frequency of this strain.
35
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Chapter 3 
 
 
DNA Three-Way Junction Binding and In Vitro 
Studies of Triple Stranded Supramolecular 
Cylinders  
 
Original synthesis and characterisation of [Fe2L3]
4+
 was carried out by Dr. C. Painting, 
University of Warwick.  
Original synthesis and characterisation of [Fe2L
1
3]
4+
 was carried out by Dr. L. Childs, 
University of Warwick. 
L, L
1
, [Fe2L3]
4+
 and [Fe2L
1
3]
4+
 were remade for all biological testing discussed in this 
chapter.  
Synthesis and characterisation of [Ru2L3]
4+
 was carried out by A. Leczkowska, University 
of Birmingham. 
Synthesis and characterisation of [Fe2L
p
3]
4+
 was carried out by Dr. L. Cardo, University 
of Birmingham. 
 
87 
3.1  Introduction 
This chapter describes how the binding of helical complexes to DNA three-way junctions 
correlates with their in vitro anticancer activities. Complexes used were: 
[Fe2L3]
4+
 where L = C25H20N4, Figure 3. 1;  
[Fe2L
1
3]
4+
 where L
1
 = C27H24N4, Figure 3. 2; 
[Ru2L3]
4+
 where L = C25H20N4, Figure 3. 3; 
[Fe2L
p
3]
4+
, ligand shown in Figure 3. 4.   
 
Polyacrylamide gel electrophoresis studies were carried out in order to compare the ability 
of these complexes to bind to and stabilise a specific DNA three-way junction structure. 
Cellular uptake, stability and activity against cancer cell lines of these complexes will also 
be discussed in order to elucidate parameters required for successful DNA binding and 
anticancer activity. 
NN
N N
 
Figure 3. 1 Ligand L and X-ray crystal structure of the [Fe2L3]
4+ 
cation discussed in 
this chapter. Hydrogen atoms and anions have been omitted for clarity.
1
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Figure 3. 2 Ligand L
1
 and X-ray crystal structure of the [Fe2L
1
3]
4+ 
cation. Hydrogen 
atoms and anions are omitted for clarity.
2
 
 
NN
N N
 
Figure 3. 3 Ligand L and X-ray crystal structure of the [Ru2L3]
4+ 
cation. Hydrogen 
atoms and anions have been omitted for clarity.
3
 
 
LpNH2CO-SER-GLY-GLY GLY-GLY-SER-CONH2
 
Figure 3. 4 The peptide conjugated ligand used in the synthesis of the triple stranded 
complex, [Fe2L
p
3]
4+
.
4
 
 
3.1.1  Helical Complexes and their DNA Binding 
Binding of all the helicates discussed in this chapter to double stranded DNA have been 
investigated previously. [Fe2L3]
4+
 was found, through CD, LD and AFM studies to bind via 
a non-covalent binding mode to double stranded DNA, spanning around five base pairs and 
causing extensive coiling of calf thymus DNA.
5
 A simulation of this binding using 
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computational methods can be seen in Figure 3. 5, revealing a bend of 45 ± 15 º per 
[Fe2L3]
4+
.
6
 
 
Figure 3. 5 Conformations of DNA in the presence of [Fe2L3]
4+
 taken from the start 
(left) and after 2 ns (right) of MD simulations using the CHARMM22 force field.
6
 
 
Circular dichroism studies of [Fe2L
1
3]
4+
 with ct-DNA show interactions indicating some 
binding, and retention of B-DNA conformation, with a possible binding preference for AT-
DNA.
7
  Linear dichroism studies show signals indicating a bending or coiling effect on 
double stranded DNA (though a much weaker effect than for [Fe2L3]
4+
). Computational 
analysis has found [Fe2L
1
3]
4+
 to bind in the major groove of DNA, however, in a mode 
where the complex is not completely contained and instead reorients so that only one end 
resides within the groove.
8
 
 
DNA binding studies of [Ru2L3]
4+
 revealed a binding mode very similar to that of the 
parent [Fe2L3]
4+
 complex, however the loss of linear dichroism signal upon DNA binding 
was slightly less pronounced for [Ru2L3]
4+
 indicating slightly less of a bending/coiling 
effect.
9
 
90 
The peptide conjugated [Fe2L
p
3]
4+ 
complex displayed the weakest DNA interactions of all 
the cylinders discussed in this thesis, showing no induced CD signals and only weak LD 
interactions.
10
  
 
3.1.2  [Fe2L3]
4+
 Three-Way Junction Binding 
DNA junction structures are incredibly important and abundant in nature, being present 
whenever DNA is processed or replicates. An example of a matched three-way junction 
structure is shown in Figure 3. 6. 
 
Figure 3. 6 Example of a fully matched three-way junction structure.
11
 
 
An exciting property of the parent [Fe2L3]
4+
 cylinder is its ability to bind in the heart of and 
stabilise a DNA three-way junction structure, Figure 3. 7. This binding is unique and 
represented the first new form of DNA recognition discovered for 40 years.
12
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Figure 3. 7 Crystal structure of [Fe2L3]
4+ 
residing within a DNA three-way junction. 
[Fe2L3]
4+ 
is represented as space filling, DNA as wire frame. Hydrogen atoms and anions 
have been omitted for clarity. 
13
 
 
3.2  Results and Discussion 
3.2.1  Three-Way Junction Binding of [Fe2L3]
4+ 
and [Fe2L
1
3]
4+
 
It is proposed that the binding and stabilisation of the three-way junction structure caused 
by [Fe2L3]
4+
 may be the foundation of its in vitro activity, as the formation of a three-way 
DNA junction structure is a major step in the DNA replication process.
14
 In order to 
investigate this, three-way junction binding of the bulkier [Fe2L
1
3]
4+
 cylinder was 
investigated (see section 2.4.7). It was anticipated that the larger dimensions
8
 of this 
complex due to the extra methyl groups on each ligand, will mean binding in the heart of 
the three-way junction is prevented due to steric hindrance between the methyl moieties 
and three-way junction aryl rings, Figure 3. 8. 
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Figure 3. 8 Representation of [Fe2L
1
3]
4+
 (methyl groups yellow) inside a DNA three-
way junction (green) showing potential hindrance between methyl groups and DNA aryl 
rings. 
 
Polyacrylamide gel electrophoresis was carried out to mimic previous experiments with 
[Fe2L3]
4+
. Three strands of non-palindromic DNA oligonucleotides 14 bases long were 
used. DNA sequences were designed in order to form a fully matched, non bulged three- 
way junction structure with arms 7 base-pairs in length, Figure 3. 9. Strand 1 was labelled 
at the 5’ end with radioactive phosphorous-32 in order to visualise DNA structures on the 
gel. Gels were carried out at 25 ºC, as it has been shown that DNA three-way junction 
structures with seven base pairs per arm are not stable in a gel at 25 ºC, even in the 
presence of high concentrations of divalent cations.
15
 Running the gel at 25 ºC therefore 
gives a good indication of the ability of the helicates to stabilise the three-way junction 
structure. 
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Strand 1 – 5’CGGAACGGCACTCG 
Strand 2 – 5’CGAGTGCAGCGTGG 
Strand 3 – 5’CCACGCTCGTTCCG 
 
Figure 3. 9 Oligonucleotides used in gel electrophoresis studies and the three-way 
junction proposed to form
15
 
 
Varying concentrations of [Fe2L3]
4+
 and [Fe2L
1
3]
4+
 were incubated with the DNA 
oligonucleotides, with final [three-way junction (3 DNA strands): complex] ratios being 
1:2, 1:1, 2:1 and 3:1. A current was applied to the gel in order to separate DNA structures 
formed during the incubation according to their size, charge and density. An example gel 
profile obtained through phosphorimaging, showing the presence of single strand, duplex 
and three-way junction DNA is shown in Figure 3. 10. AIDA image analyser software was 
used to quantify the percentage of three-way junction on the gel by profiling bands and 
integrating the area of peaks.  
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Figure 3. 10 Phosphorimaging gel profile showing three-way junction stabilisation of 
[Fe2L
1
3]
4+
 and [Fe2L3]
4+
 with control (three DNA strands and no complex). 
 
The percentage of three-way junction present (as a percentage of all DNA structures 
present in each lane on the gel) is shown in Figure 3. 11. 
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Figure 3. 11 Percentage three-way junction formed against [three-way junction: 
complex] ratios for [Fe2L3]
4+
 and [Fe2L
1
3]
4+
. Graph represents mean ± SEM from three 
independent experiments. 
 
Three-way junction stabilisation caused by [Fe2L
1
3]
4+
 is minimal. There is some indication 
of a dose response for this complex, and the percentage of three-way junction present 
95 
increases from ~ 2 % at a 3:1 three-way junction: complex ratio, to 6 % at a 1:2 three-way 
junction : complex ratio.  It is possible that this minimal effect is due to the tetracationic 
charge of the complex, as polycations are known to stabilise higher order DNA 
structures.
16
  
 
Stabilisation caused by [Fe2L3]
4+
 is up to 40 %, at a 1:2 three-way junction : complex ratio, 
with an increase in stabilisation of the three-way junction structure with an increase in 
helicate concentration.  This is in agreement with previous results for this complex.
15
 
These are very interesting results and clearly show that a very small change in dimensions 
in [Fe2L
1
3]
4+
 of 2Å
8
 has a huge effect on the stabilisation of the three-way junction 
structure. In this case it is the exact size and shape of the parent [Fe2L3]
4+
 which is so 
essential for binding and stabilisation.  
 
It is also interesting to note the stabilisation of a DNA duplex in the gel. Bands can be seen 
for both [Fe2L3]
4+
 and [Fe2L
1
3]
4+
, however the extent of duplex stabilisation is minimal and 
does not exceed 1.4 % of all DNA structures on the gel. This duplex DNA structure is not 
present in the control, so it may be an effect due to the tetracationic charge of the 
complexes causing an association of the DNA strands through the negatively charged DNA 
phosphate backbone.  There may also be stabilisation of a Y-shaped fork of two DNA 
strands.  At the branch point of a Y-shaped DNA junction there are four bases, rather than 
the 6 found at the three-way junction branch-point, nevertheless these 4 bases may form a 
binding site similar to that of the three-way junction. 
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3.2.2  Three-Way Junction Binding of [Ru2L3]
4+
 
[Ru2L3]
4+ 
has very similar dimensions to the parent [Fe2L3]
4+
complex
3
, Figure 3. 12, 
however it displays a number of other properties such as fluorescence upon DNA binding, 
DNA photocleavage and increased stability,
17
 making it an attractive alternative to the 
parent iron complex. It is therefore important to investigate the extent of [Ru2L3]
4+ 
three-
way junction binding. This will also show whether it is simply dimensions of the complex 
which must be correct for three-way junction binding, or if other factors, such as metal ion 
may play a role.  
 
Figure 3. 12 Comparison of X-ray crystal structures of [Ru2L3]
4+
 (yellow) and [Fe2L3]
4+
 
(red) showing analogous dimensions. Hydrogen atoms and anions have been omitted for 
clarity.
3
 
 
Varying concentrations of [Ru2L3]
4+
 were incubated with the DNA oligonucleotides before 
being subjected to gel electrophoresis. An example gel profile is shown in Figure 3. 13 
with the relevant data for [Fe2L3]
4+ 
(previous gel, Figure 3. 10) shown
 
as a comparison. 
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Figure 3. 13 Phosphorimaging gel profile showing three-way junction stabilisation of 
[Ru2L3]
4+
 and [Fe2L3]
4+
 with control (three DNA strands and no complex). 
 
The amount of three-way junction present (as a percentage of all DNA structures present in 
each the lane on the gel) is presented in Figure 3. 14.  
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Figure 3. 14 Percentage three-way junction formed against [three-way junction: 
complex] ratios for [Fe2L3]
4+
 and [Ru2L3]
4+
. Graph represents mean ± SEM from three 
independent experiments. (Solid line = SEM [Fe2L3]
4+
, Dashed line = SEM [Ru2L3]
4+
). 
 
Three-way junction binding of [Ru2L3]
4+
 is almost identical to that of [Fe2L3]
4+
, with 
binding increasing from ~12 % at a 3:1 three-way junction: complex ratio, to 40 % at a 1:2 
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three-way junction: complex ratio. This is not an unexpected result, as the charge and three 
dimensional shape of both complexes are very similar. Clearly these are two properties 
which have a large effect on three-way junction binding, and in this case the metal ion does 
not influence binding or stabilisation. There is also some stabilisation of the DNA duplex 
with [Ru2L3]
4+
. Again, this is possibly due to the tetracationic charge of the complex. 
 
3.2.3  Three-Way Junction Binding of [Fe2L
p
3]
4+
 
A complex with larger diameter, [Fe2L
1
3]
4+
, causes a large decrease in three-way junction 
binding and stabilisation as compared to the parent [Fe2L3]
4+ 
complex. Therefore it is 
interesting to investigate the effect on three-way junction binding of a cylinder with the 
same core dimensions, but with appended peptides, [Fe2L
p
3]
4+
, creating a much longer 
structure. An example gel profile is shown in Figure 3. 15 with the relevant data for 
[Fe2L3]
4+ 
(previous gel, Figure 3. 10) shown
 
as a comparison. 
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Figure 3. 15 Phosphorimaging gel profile showing three-way junction stabilisation of 
[Fe2L
p
3]
4+
 and [Fe2L3]
4+
 with control (three DNA strands and no complex). 
 
Three-way junction binding of [Fe2L
p
3]
4+
 is minimal, with stabilisation of the DNA three-
way junction structure ranging from 0.02-0.45 % (as a percentage of all DNA structures 
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present in each lane on the gel). This minimal binding, which may simply be caused due to 
the charged nature of the complex, shows how important all dimensions of the complex are 
for successful three-way junction binding. This result might also indicate that the 
complexes slot into a pre-formed three-way junction structure, rather than the DNA strands 
assembling around them, as [Fe2L
p
3]
4+
 has the same core structure as the parent [Fe2L3]
4+
. 
 
3.2.4  In Vitro Cell Testing of [Fe2L3]
4+
 and [Fe2L
1
3]
4+
 
The range of DNA three-way junction binding and stabilisation caused by the complexes 
discussed herein presents a very exciting question: Does three-way junction binding 
correlate with anticancer activity? In order to examine this question, in vitro cell testing of 
[Fe2L3]
4+
, [Fe2L
1
3]
4+
 and cisplatin (control) was carried out (see section 2.5.5). IC50 values, 
including those previously reported for [Ru2L3]
4+ 18
 and [Fe2L
p
3]
4+ 4
 are shown in Table 3. 
1. Cell lines chosen were the human ovarian cancer A2780-P, its cisplatin resistant 
analogue A2780-R and the breast cancer MDA-MB-231 cell line. 
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 A2780-P A2780-R Rf (A2780) MDA-MB-231 
[Fe2L3]
4+
 8.7 ± 1.1 13.1 ± 2.3 1.5 34.8 ± 5.3 
i
 
[Fe2L
1
3]
4+
 > 100
ii
 > 100
ii
 - > 100
ii
 
[Ru2L3]
4+ 18
 72.0 ± 3.3 152.0 ± 4.3 2.1 Not tested 
[Fe2L
p
3]
4+ 4
 9 ± 2 Not tested - 34.0 ± 6 
Cisplatin 4.4 ± 0.8 19.3 ± 1.8 3.6 35.2 ± 5.2 
 
Table 3. 1 IC50 values (µM) in A2780-P, A2780-R and MDA-MB-231 cell lines for 
[Fe2L3]
4+
, [Fe2L
1
3]
4+
, [Ru2L3]
4+
, [Fe2L
p
3]
4+ 
and cisplatin. Results represent mean ± SD of 
3 separate experiments. Resistance factors are displayed for A2780 cell line; Rf = IC50 
(A2780-R)/ IC50 (A2780-P).  
 
[Fe2L3]
4+
, which exhibits stabilisation of the DNA three-way junction structure,
 
has an 
activity comparable to that of cisplatin in the MDA-MB-231 and A2780 cell lines. With an 
Rf factor of 1.5 for the A2780 cell line, this complex shows no cross resistance with 
cisplatin. These results may implicate three-way junction binding and stabilisation as a 
potential mode of action of this complex. 
 
[Fe2L
1
3]
4+ 
is inactive in all cell lines tested and causes only minimal stabilisation of the 
DNA three-way junction structure. This may confirm the above hypothesis that effective 
stabilisation of a DNA three-way junction leads to cell death, an exciting result. However, 
                                               
i This result is discussed further in Chapter 4. 
ii Due to comparisons being drawn with cisplatin a maximum concentration of 100 µM was tested for all 
compounds. Therefore above this value compounds are classed as inactive and an accurate IC50 value cannot 
be calculated. 
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other factors may need to be taken into consideration, for example the uptake of complexes 
into the cell.  
 
[Fe2L
p
3]
4+
 has comparable activity to both [Fe2L3]
4+
 and cisplatin in both cell lines tested, 
yet shows minimal three-way junction stabilisation on the gel. This may indicate that 
modes of cell death are different for complexes with differing supramolecular 
architectures, as in this case three-way junction stabilisation is not a likely mode of action. 
 
[Ru2L3]
4+
 is known to be less active against ovarian cancer cell lines,
18
 as compared to the 
parent [Fe2L3]
4+
 complex, yet these compounds show almost identical three-way junction 
binding.  This further confirms that a number of factors, as well as supramolecular 
architecture need to be taken into consideration, such as the choice of metal ion. One 
mechanism of cytotoxicity might be three-way junction stabilisation, however, this result 
illustrates that modes of action may be different in different cell lines.  
 
3.2.5  Uptake of [Fe2L
1
3]
4+
 In Live Cells 
Both [Fe2L3]
4+
 and [Ru2L3]
4+
 are able to cross cell membranes intact and enter the 
cytoplasm of the cell, as shown through experiments with HL-60 cells.
18
 It is important to 
determine at this stage if observed inactivity of [Fe2L
1
3]
4+
 is caused due to lack of DNA 
binding interactions or if the complex is simply not able to enter cells intact. Uptake of 
[Fe2L
1
3]
4+
 into the cytosol of the breast cancer cell line, MDA-MB-231 was assessed by 
UV-Visible spectroscopy, Figure 3. 16 (see section 2.5.3.2). Cells were treated with 
[Fe2L
1
3]
4+
 for 24 hours, following which, whole cell protein was extracted. 
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Figure 3. 16 Difference absorption spectrum of whole cell protein extract from MD-
AMB-231 cells after 24 hr treatment with [Fe2L
1
3]
4+
, showing presence of compound.  
 
The distinctive UV-Visible spectrum
7
 of [Fe2L
1
3]
4+ 
can be seen, indicating the presence of 
this complex in the protein extract. This result shows that it is possible for [Fe2L
1
3]
4+
 to 
cross the cell membrane and enter the cytosol of the cell intact. It should be noted, 
however, that although [Fe2L
1
3]
4+
 is clearly able to enter the cell, membrane extracts of 
MD-AMB-231 treated cells are highly coloured, shown in Figure 3. 17. This is indicative 
of a large amount of [Fe2L
1
3]
4+
 and to some extent the parent [Fe2L3]
4+
 being associated 
with the cell membrane during the incubation period. 
 
Figure 3. 17 MDA-MB-231 cell membrane extracts after 24 hr treatment with medium 
(left), [Fe2L3]
4+ 
(centre) and [Fe2L
1
3]
4+ 
(right). 
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3.2.6   Stability of [Fe2L3]
4+
 and [Fe2L
1
3]
4+
 
The stability of [Ru2L3]
4+
 in water has been assessed previously and was found to have 
good stability over long periods of time at room temperature.
3
 The stability of [Fe2L
p
3]
4+
 
has also been assessed
10
 and was found to be stable for a period of ~ 2 hours, in aqueous 
buffer at 20 ºC, after which time hydrolysis of the imino bonds in the ligands causes the 
complex to break down. This may be a reason for this complexes inability to stabilise the 
three-way junction structure, or for its activity in vitro, however this has not been 
determined at this stage.  
 
It is important to determine and compare stabilities of [Fe2L3]
4+
 and [Fe2L
1
3]
4+
 in order to 
elucidate further reasons for differing binding and activity. The stability of [Fe2L3]
4+
 and 
[Fe2L
1
3]
4+
 in water at 37 ºC can be seen in Figure 3. 18 and Figure 3. 19 (see section 2.4.1). 
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Figure 3. 18 UV-Visible spectra of [Fe2L3]
4+ 
(40 µM) in water at 37 ºC over a period of 
72 hours.  
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Figure 3. 19 UV-Visible spectra of [Fe2L
1
3]
4+ 
(40 µM) in water at 37 ºC over a period of 
72 hours. 
 
The stability of [Fe2L
1
3]
4+ 
in water is good and although there is a small decrease in 
intensity of the bands, peaks do not shift wavelength, showing retention of the complex in 
solution. The stability of [Fe2L3]
4+
 is not as good, and there is a reduction of ~50 % in 
intensity of the bands over this time period. There is, however, no wavelength shift so the 
complex that remains in solution is [Fe2L3]
4+
. 
 
The constituents (ligand, FeCl2) of the parent [Fe2L3]
4+
 have been assessed for anticancer 
activity
18
 and were found to be inactive. This should rule out activity caused simply 
through instability of the complex, and furthermore it is known that the time period it takes 
for [Fe2L3]
4+ 
to enter the cell nucleus is less than 20 minutes,
19
 during which time the 
complex is stable. Therefore, it can be concluded that the stabilities of [Fe2L3]
4+
 and 
[Fe2L
1
3]
4+
 are not directly responsible for their differing in vitro anticancer activities.  
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3.3  Conclusions and Further Work 
The specific three dimensional shape of complexes appears to be important for the 
stabilisation of a DNA three-way junction structure under the conditions used herein. 
Changing the diameter of the parent [Fe2L3]
4+
 complex by as little as 2Å in [Fe2L
1
3]
4+ 8
 
reduces this stabilisation dramatically. A change in metal ion does not appear to be as 
important, with [Ru2L3]
4+
 binding being analogous to that of [Fe2L3]
4+
. When it comes to 
anticancer activity, however, it has been shown that there are other factors which need to 
be taken into consideration. For breast cancer cell lines, where both [Fe2L3]
4+ 
and [Ru2L3]
4+
 
display a good activity, with [Fe2L
1
3]
4+
 being inactive, it would appear that three-way 
junction binding is playing a major role in cytotoxicity, an exciting result. Activity of 
[Fe2L
p
3]
4+
 in this cell line may be due to stability issues, this being the least stable of all the 
complexes. For ovarian cancer cell lines where only [Fe2L3]
4+ 
and [Fe2L
p
3]
4+
 display good 
activity, it would appear that there are factors other than three-way junction binding to 
consider. This may range from the choice of metal ion to interaction with other cellular 
targets not previously considered. This needs to be the subject of further investigation.  
 
To date, it has not been possible to separate the enantiomers of [Fe2L
1
3]
4+
.
20
 It is unlikely 
that either enantiomer will convey a significantly higher anticancer activity however it may 
be the case that one enantiomer has slightly differing DNA binding, as is the case for the 
parent [Fe2L3]
4+
. Synthesis of the ruthenium analogue of [Fe2L
1
3]
4+ 
and investigation of 
anticancer activity would be beneficial in order to understand the role of the metal ion in 
this complex. 
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Chapter 4 
 
 
In Vitro Studies of an Iron Triple Stranded 
Supramolecular Cylinder 
 
Original synthesis and characterisation of [Fe2L3]
4+
 was carried out by Dr. C. Painting, 
University of Warwick.  
L and [Fe2L3]
4+
 were remade for all biological testing discussed in this chapter.  
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4.1  Introduction 
This chapter details in vitro biological studies of the triple stranded iron cylinder, [Fe2L3]
4+
 
where L = C25H20N4, Figure 4. 1.  
NN
N N
 
Figure 4. 1 Ligand L and X-ray crystal structure of the [Fe2L3]
4+ 
cation discussed in this 
chapter. Hydrogen atoms and anions have been omitted for clarity.
1
  
 
 In order for this promising drug compound to progress further towards the clinic its effects on 
human cell lines and mode of action must be investigated. It is anticipated that a highly 
charged compound of this nature will interact with many biological molecules en-route to 
nuclear DNA, causing various effects. In this chapter, studies are carried out on the highly 
dedifferentiated, invasive, hormone independent, breast cancer cell line MDA-MB-231.
2
 
These studies are designed in order to probe the response of the cells to incubation with the 
[Fe2L3]
4+
 cylinder,
 
including changes in cell morphology and the cells’ potential for recovery. 
How these effects differ from those of the traditional alkylating agent cisplatin (a clinical 
agent that binds in a covalent manner to DNA causing direct mutation and cell death),
3
 will be 
discussed.  
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The impact of this work is not only in elucidating the mechanism of action and increasing 
understanding of the drug in the current study, but also in assessing the suitability of methods 
currently used for initial in vitro drug screening of novel compounds with unknown modes of 
action.  
 
4.1.1  The Supramolecular [Fe2L3]
4+
 Cylinder and its Biological Action 
DNA binding interactions of the [Fe2L3]
4+
 helicate were discussed in chapters 1 and 3. DNA 
binding in whole, live cells has also been assessed, via a Hoechst (a minor groove binding 
dye) displacement assay.
4
 Quenching of the Hoechst emission confirmed that [Fe2L3]
4+
 is able 
to enter the nucleus of live cells and interact with nuclear DNA, Figure 4. 2. 
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Figure 4. 2 Quenching of Hoechst emission by [Fe2L3]
4+
 in HL-60 cells. Concentration of 
[Fe2L3]
4+ 
indicated in top left corner.
4
  
 
[Fe2L3]
4+ 
displays cytotoxicity in all cell lines tested, including MRC-5, a non-tumour cell 
line,
5
 Table 4. 1. 
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Cell Line HBL100 T47D SKOV-3 HL-60 MRC-5 
[Fe2L3]
4+
 27 ± 5 52 ± 10 35 ± 5 18 ± 3 19 ± 3 
Cisplatin 4.9 ± 0.3 28.0 ± 1.7 6.0 ± 0.3 7 ± 1 < 3 
 
Table 4. 1 Cytotoxicities (IC50 in µM) of [Fe2L3]
4+ 
and cisplatin,
 
after 72 hour continuous 
treatment
 
of a panel of tumour cell lines, as assessed by the MTT assay. Results represent 
mean of three separate experiments ± SD.
5
  
 
Crucially, [Fe2L3]
4+ 
does not exhibit any genotoxicity or mutagenicity, a huge drawback of 
many current anticancer agents, and the reason for the emergence of secondary cancers caused 
by their use as treatment.
6
 These biological tests have been presented in a recent paper.
5 
 
4.2  Results and Discussion 
4.2.1  In Vitro Cell Testing of [Fe2L3]
4+ 
Cell line testing was carried out on the breast cancer cell line, MDA-MB-231, as [Fe2L3]
4+
 had 
not been previously tested against this cell line. The MTT assay (See section 2.5.5) was used 
to assess toxicity, with calculation of an IC50 value after 72 hours continuous incubation with 
[Fe2L3]
4+
,
 
Table 4. 2.  
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Cell Line MDA-MB-231 
[Fe2L3]
4+
 34.8 ± 5.3 
Cisplatin 35.2 ± 5.2 
 
Table 4. 2 Cytotoxicities (IC50 in µM) of [Fe2L3]
4+ 
and cisplatin,
 
after 72 hour continuous 
treatment
 
of MDA-MB-231, as assessed by the MTT assay.
 i
 Results represent mean of three 
separate experiments ± SD. 
 
These results confirm this cell line as a good choice for further investigation, as both [Fe2L3]
4+ 
and cisplatin have very similar IC50 values. 
 
4.2.2  In Vitro Effect of Increased Molar Incubation of [Fe2L3]
4+ 
 
It was noted during routine dose range-finding experiments
ii
, that cellular toxicity appeared to 
be not only related to the concentration of [Fe2L3]
4+
 incubated with the cells, but that when a 
higher volume was incubated (higher number of moles [Fe2L3]
4+
) more cell death was 
observed, Figure 4. 3. 
 
                                                 
i
 Parallel experiments with [Fe2L3]
4+
, medium and MTT showed no interactions, confirming the MTT assay as a 
suitable method for assessing cell viability.  
ii
 Experiments carried out in the lab of Dr. Boris Kysela, University of Birmingham Medical School 
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            75 µM [Fe2L3]
4+
, 1 ml media              75 µM [Fe2L3]
4+
, 3 ml media 
 
Figure 4. 3 Standard light-microscopy photographs of MRC-5 VA cells treated with 
varying volumes of [Fe2L3]
4+
, illustrating reduced number of cells with increased molar 
incubation.
iii
  
 
In order to investigate this observed effect, MDA-MB-231 cells were treated with varying 
volumes of [Fe2L3]
4+
, keeping concentrations constant and therefore changing the number of 
moles [Fe2L3]
4+ 
incubated with cells. Cell viability was assessed via the MTT assay and IC50 
calculated using a range of concentrations (see section 2.5.6). Figure 4. 4 shows IC50 values 
obtained for [Fe2L3]
4+ 
and cisplatin against incubation volume. 
                                                 
iii
 Pictures created in the lab of Dr. Boris Kysela, University of Birmingham Medical School 
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Figure 4. 4 Activity against the breast cancer cell line MDA-MB-231 of [Fe2L3]
4+
 and 
cisplatin following 72 hour incubation with varying volumes of compound, as assessed using 
the MTT assay. Data are reported as IC50 versus volume. Graph represents mean ± SEM from 
three independent experiments. 
 
 
It is clear that as the incubation volume of [Fe2L3]
4+ 
is increased the IC50 value decreases 
dramatically (increase in toxicity). This was unexpected and from the literature appears 
unprecedented. As seen for cisplatin, where a change in incubation volume has no effect on 
observed IC50 value, it is usually concentration that is important for determining cell stasis or 
death. In this case a one way ANOVA returned a p value of > 0.05 (0.98) showing no 
statistical significance of an increase in incubation volume on IC50 value for cisplatin. For 
[Fe2L3]
4+
, a one way ANOVA returned a p value of < 0.05 (0.046) showing that the increase in 
incubation volume on IC50 value is statistically significant and an increase in number of moles 
incubated causes an increase in toxicity.  
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These results may imply a mechanism of action of [Fe2L3]
4+ 
where the maximum uptake is not 
dependent upon concentration, as is the case with cisplatin, but that the cell takes up and 
concentrates [Fe2L3]
4+ 
within it. There are a number of explanations for this observed effect; 
that [Fe2L3]
4+ 
can enter the cell passively and/or actively but that the DNA binding constant is 
sufficiently strong that most is bound to biomolecular targets; alternatively, the observed 
concentration of [Fe2L3]
4+ 
in the cells could be caused by an active uptake mechanism which is 
not balanced by efflux (active or passive). 
 
4.2.3  Impact of [Fe2L3]
4+
 on Cellular Morphology 
It was also noted that cells treated with [Fe2L3]
4+
 displayed an altered cellular phenotype when 
compared to both those treated with cisplatin and negative controls. Figure 4. 5.  
Control [Fe2L3]
4+ 100 µM [Fe2L3]
4+  3.125 µM
Cisplatin 100 µM Cisplatin  3.125 µM
 
Figure 4. 5 Standard light microscopy photos showing MDA-MB-231 cells after 24 hour 
continuous treatment with [Fe2L3]
4+
 and cisplatin, with medium as control. 
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The difference in cellular phenotype of cells treated with [Fe2L3]
4+
, cisplatin and medium is 
clear and this phenotype persists for the remainder of the 72 hour incubation. [Fe2L3]
4+ 
treated
 
cells have rounded up and lack any lamellipodia. It would appear on first sight that the cells in 
this state are dead, however there is no visual evidence of apoptosis or necrosis and as will be 
seen, mitochondrial function is retained and the cells are able to recover from this state (see 
section 4.2.8). This altered cellular phenotype may be evidence of a previously unexplored 
mode of action for [Fe2L3]
4+
. 
 
4.2.4  In Vitro Time Lapse, Phase Contrast Imaging with [Fe2L3]
4+
 
From the standard light microscope photos discussed above it is not clear exactly what 
morphological changes have occurred to the cell, as the altered phenotype is present at the first 
time point of 24 hours. The next step was therefore to investigate the progression of 
morphological events throughout the first 24 hours of the incubation. This was achieved 
through time-lapse video microscopy, a technique often used to monitor cells over continuous 
periods.
7
 (See section 2.5.9). Images were recorded every two minutes for a period of 18 
hours. Figure 4. 6- Figure 4. 12 show video stills from incubations with varying concentrations 
of [Fe2L3]
4+
, cisplatin and control (medium). Also see attached video CD (video speed = 
50ms/frame or 25 frames/second). 
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20 µm
3.23 5.03 6.43 8.23
10.03 11.43 13.23 15.03
 
Figure 4. 6 Video stills (time indicated in right hand corner in hours) taken during 
continuous treatment of MDA-MB-231 cells with medium (control). 20x. 
20 µm
3.23 5.03 6.43 8.23
10.03 11.43 13.23 15.03
 
Figure 4. 7 Video stills (time indicated in right hand corner in hours) taken during 
continuous treatment of MDA-MB-231 cells with 200 µM [Fe2L3]
4+
. 20x. 
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20 µm
3.23 5.03 6.43 8.23
10.03 11.43 13.23 15.03
 
Figure 4. 8 Video stills (time indicated in right hand corner in hours) taken during 
continuous treatment of MDA-MB-231 cells with 100 µM [Fe2L3]
4+
. 20x. 
20 µm
3.23 5.03 6.43 8.23
10.03 11.43 13.23 15.03
 
Figure 4. 9 Video stills (time indicated in right hand corner in hours) taken during 
continuous treatment of MDA-MB-231 cells with 50 µM [Fe2L3]
4+
. 20x. 
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20 µm
3.23 5.03 6.43 8.23
10.03 11.43 13.23 15.03
 
Figure 4. 10 Video stills (time indicated in right hand corner in hours) taken during 
continuous treatment of MDA-MB-231 cells with 200 µM cisplatin. 20x. 
20 µm
3.23 5.03 6.43 8.23
10.03 11.43 13.23 15.03
 
Figure 4. 11 Video stills (time indicated in right hand corner in hours) taken during 
continuous treatment of MDA-MB-231 cells with 100 µM cisplatin. 20x. 
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20 µm
3.23 5.03 6.43 8.23
10.03 11.43 13.23 15.03
 
Figure 4. 12 Video stills (time indicated in right hand corner in hours) taken during 
continuous treatment of MDA-MB-231 cells with 50 µM cisplatin. 20x. 
 
Cells in control wells displayed normal cellular behaviour; extensive movement of cells 
accompanied by some lamellipodia extensions at leading edges and limited membrane 
ruffling.
8
 Widespread cell division can also be seen and hence cell number increases 
throughout the incubation. Incubation with cisplatin does not change the morphology or 
mobility of the cells, however, in agreement with the literature a lack of cell division is evident 
(aberrant mitosis followed by apoptosis).
9
 
 
A clear dose response can be seen for [Fe2L3]
4+ 
treated cells. Extensive membrane ruffling 
(protrusions on the dorsal surface of cells) is present after a period of ~three hours. This is 
unusual behaviour for this cell line, implicating the disruption of a number of cell signalling 
processes affecting one or more of the actin cytoskeleton, integrin production, 
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lamellipodia/filopodia and cell movement. It is also evident that cell division has ceased. After 
a period of ~8 hours membrane ruffling is no longer evident and cell mobility stops altogether, 
although the cells maintain their adhesion to the culture surface. After a period of ~11 hours, 
the cells appear to lose some of this adhesion and round up, losing contact with neighbouring 
cells. There is, however, no evidence of necrosis, nor are cellular fragmentation or budding 
observed, as would be expected with apoptosis.
10
 It is likely, therefore (when coupled with 
previous evidence of [Fe2L3]
4+
 causing cell cycle arrest and induction of apoptosis)
5
 that the 
cells are in an early-apoptotic state. 
 
This effect is not observed with most metal based drugs, however, a similar cell rounding, or 
‘ballooning’ effect, coupled with loss of contact with neighbouring cells has been documented 
in a photo-activatable platinum pro-drug, Figure 4. 13, after exposure to UV irradiation.
11
 
 
Figure 4. 13 A platinum diazide complex which exhibits cell ballooning and light activated 
destruction of cancer cell nuclei.
11
  
 
Diverse cell surface receptors control structural rearrangements in the actin cytoskeleton in 
response to external stimuli. It is not unreasonable to assume that the presence of [Fe2L3]
4+
 
could disrupt any number of these signals. All signals eventually converge inside the cell on a 
family of GTPases-the Rho protein family (Ras superfamily), often implicated in cancers.
12
 
Indeed signalling pathways are an attractive target for anticancer drug development.
13
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Disruption of the cellular cytoskeleton would cause all the events observed, however there are 
so many different pathways involved with cytoskeleton maintenance that it is not possible to 
know at this stage which of these are being disrupted. However, it would appear from this 
evidence that DNA binding may not be the only mechanism of action of [Fe2L3]
4+
, or that the 
downstream effects of such DNA binding have been underestimated. 
 
4.2.5  Actin labelling of Cellular Cytoskeleton after Incubation with [Fe2L3]
4+ 
A change in actin dynamics and cytoskeleton structure is observed for both NAMI-A
14
 and 
RAPTA,
15
 both potent antimetastatic agents. Taking into account the unusual membrane 
ruffling activity of cells when treated with [Fe2L3]
4+
, it seemed pertinent to assess if there is 
any disruption to the actin cytoskeleton. This was achieved by staining [Fe2L3]
4+ 
treated 
MDA-MB-231 cells with the fluorescent dye rhodamine phalloidin which detects F-actin 
filaments (see section 2.5.10). This test was carried out after a four hour incubation period in 
order to assess the extent of actin disruption during the membrane ruffling phase. Phalloidin 
stained actin filaments after incubation with varying concentrations of [Fe2L3]
4+ 
and medium 
(control) can be seen in Figure 4. 14 to Figure 4. 15. 
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Figure 4. 14 Phalloidin stained actin filaments of MDA-MB-231 cells after four hour 
continuous incubation with medium (control). 
 
 
Figure 4. 15 Phalloidin stained actin filaments of MDA-MB-231 cells after four hour 
continuous incubation with 200 µM [Fe2L3]
4+
. 
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Figure 4. 16 Phalloidin stained actin filaments of MDA-MB-231 cells after four hour 
continuous incubation with 100 µM [Fe2L3]
4+
. 
 
 
Figure 4. 17 Phalloidin stained F-actin filaments of MDA-MB-231 cells after four hour 
continuous incubation with 50 µM [Fe2L3]
4+
. 
 
A clear dose response can be seen with increasing concentrations of [Fe2L3]
4+
. Stress fibres 
(thin fibres throughout the body of the cells) are present in both control and [Fe2L3]
4+
 treated 
cells, however the normal triangular shape of cells in the control is perturbed in [Fe2L3]
4+ 
treated cells. Furthermore, the edges of [Fe2L3]
4+ 
treated cells are irregular and there are a 
greater number of broad, rounded lamellipodia extrusions from the cells along with a number 
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of ‘blobs’ of actin, correlating with membrane ruffling seen at this time point. This result 
confirms that the irregular membrane activity seen in time-lapse microscopy experiments may 
be caused, at least in part, to a disruption in actin polymerisation and architecture. However, it 
cannot be confirmed at this stage the exact binding modes or interactions causing this 
disruption, only that disruption of actin polymerisation may be involved. 
 
4.2.6  In Vitro Extended Incubation of Cells with [Fe2L3]
4+
 
The effects of [Fe2L3]
4+
 on cells have, thus far, been investigated over a maximum time period 
of 72 hours.  With these experiments showing unexpected results, differing substantially to 
those of cisplatin, it is interesting to examine the fate of the cells over a longer period of time. 
An IC50 test is most commonly carried out at 24-72 hour time periods. However, it has been 
suggested that such short incubations may not correlate with in vivo activity.
16
 To assess the 
activity of [Fe2L3]
4+
 and cisplatin over an extended period, cell viability over a range of 
concentrations and hence IC50 values were determined for periods of up to six days, Figure 4. 
18 (see section 2.5.7). 
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Figure 4. 18 Activity against the breast cancer cell line MDA-MB-231 with [Fe2L3]
4+
 and 
cisplatin following 48, 72, 96, 120 and 144 hour continuous incubations, as assessed using the 
MTT assay. Data are reported as IC50 versus time. Graph represents mean ± SEM from three 
independent experiments. 
 
At the 24 hour time period both [Fe2L3]
4+
 and cisplatin showed activities of  > 500 µM, so it is 
assumed that although these compounds may have entered the cell and potentially bound to 
nuclear DNA, their action has not yet been sufficient to cause any cell death. At the 48 and 72 
hour time points both [Fe2L3]
4+
 and cisplatin display similar IC50 values. However, over a 
longer time period it is clear that the cellular toxicity of [Fe2L3]
4+
 does not continue to increase 
as dramatically as that of cisplatin, with the total reduction in IC50 being 38 % for [Fe2L3]
4+
 
(one-way ANOVA returning a value of > 0.05 (0.2) showing no statistical significance). This 
is compared to 73 % reduction in IC50 for cisplatin (one-way ANOVA returning a value of < 
0.001 (9.09x10
-5
) showing high statistical significance in reduction of IC50 over the 2-6 day 
period). The final IC50 value of [Fe2L3]
4+
 is more than twice that of cisplatin. 
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4.2.7  Recovery of Cells After Three Hour Incubation with [Fe2L3]
4+ 
It is interesting to determine if cells are able to recover from the membrane ruffling phenotype 
induced though incubation with [Fe2L3]
4+
. For comparison, cell density (as optical density 
measurement after application of the MTT assay) with [Fe2L3]
4+ 
(100 µM), cisplatin (100 µM) 
and control (medium) was plotted for periods of up to six days of continuous treatment. Figure 
4. 19 (see section 2.5.7). 
0
0.2
0.4
0.6
0.8
1
1.2
0 50 100 150
Time (hours)
O
.D
Control
[Fe2L3]4+
Cisplatin
.
0.4
0.6
0.8
1
i )
O
.D
Contr l
[Fe2L3]4+
Cisplatin
Control
[Fe2L3]
4+
Cisplatin
O
.D
 
Figure 4. 19 Continuous treatment of MDA-MB-231 cells with [Fe2L3]
4+ 
and cisplatin (100 
µM) over periods of 1-6 days. Optical density from the MTT assay is plotted against time with 
medium as control. Results represent mean of three separate experiments ± SEM.  
 
With continuous treatment it would appear that [Fe2L3]
4+  
and cisplatin have a very similar 
effect on the cells, causing their numbers to remain constant for approximately 24 hours, then 
to decrease rapidly, followed by a plateau in cell density at ~ 96 hours. The control shows a 
steady increase in cell number over the time period of the incubation.  
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Figure 4. 20 shows the dramatic change seen after three hours incubation with [Fe2L3]
4+
 (100
 
µM) or cisplatin (100 µM), followed by incubation with medium only for a further 1-6 days 
(see section 2.5.8). 
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Figure 4. 20 Treatment of MDA-MB-231 cells with [Fe2L3]
4+ 
and cisplatin (100 µM) over a 
period of three hours, followed by incubation with medium only for a period of 1-6 days. 
Optical density from the MTT assay is plotted against time with medium as control. Results 
represent mean of three separate experiments ± SEM.  
 
[Fe2L3]
4+ 
treated cells recover to almost equal density of the control, showing that the change 
in morphology seen previously is not permanent, that [Fe2L3]
4+
 must be present in order to 
exert an effect and can be washed from the cell. Recovery to a normal cellular phenotype is 
also observed under a light microscope. Cisplatin treated cells are able to recover to some 
extent, however cell density declines again after ~96 hours.  
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4.2.8  Recovery of Cells after 18 Hour Incubation with [Fe2L3]
4+
 
With recovery from the three hour, membrane ruffling phase clearly possible, the question 
remains as to whether cells are able to recover from the 18 hour time point, Figure 4. 21 (see 
section 2.5.8). At this stage the cells are no longer dividing, balled up and completely 
stationary. (This phenotype persists throughout the remainder of the continuous incubation 
experiments). 
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Figure 4. 21 Treatment of MDA-MB-231 cells with [Fe2L3]
4+ 
and cisplatin (100 µM) over a 
period of 18 hours, followed by incubation with medium only for a period of 1-6 days. Optical 
density from the MTT assay is plotted against time with medium as control. Results represent 
mean of three separate experiments ± SEM.  
 
It is clear that cells incubated with [Fe2L3]
4+ 
are able to recover, and continue to replicate at a 
similar rate to control cells, however, some cells were clearly killed during the incubation 
period and cell density never reaches that of the control. Recovery to a normal cellular 
phenotype can also be seen under a light microscope. Cisplatin treated cell density declines 
throughout.  
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These results give further indication that [Fe2L3]
4+ 
activity may be caused via disruption of a 
number of cell signalling processes and a continuous presence of the drug is needed in order to 
block signalling pathways. This does not, however, rule out DNA binding as a mode of action, 
but more likely confirms that there is more than one mode of action, and that [Fe2L3]
4+
 can be 
easily washed from the cell. 
 
4.3  Conclusions and Further Work 
In this study, the effects on the breast cancer cell line, MDA-MB-231 of the cylindrical, di-
iron tetracationic drug candidate, [Fe2L3]
4+
, were investigated. A toxicity study, using IC50 
value, showed that observed cellular toxicity relates to the overall amount of compound 
(number of moles) rather than the concentration. This is an exciting result, and this 
phenomenon has not previously been documented.  
 
Further differences between [Fe2L3]
4+
 and cisplatin are documented through changes to 
morphology and phenotype of cells, as well as the ability of cells to recover with removal of 
[Fe2L3]
4+
. This can give clues about potential modes of action, in this case relating to cell 
signalling and the actin cytoskeleton. 
 
Time course experiments show that [Fe2L3]
4+ 
enters the cell and exerts its activity over the first 
72 h, but thereafter its activity declines. This may be useful in the clinic as it could allow 
same-dose readministration. 
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The mechanism of entry and exact mode of action of [Fe2L3]
4+ 
needs to be investigated further. 
It would be beneficial to carry out the experiments described in this chapter with the 
analogous ruthenium cylinder [Ru2L3]
4+
, as this drug compound has a different spectrum of 
activity yet very similar DNA binding interactions to [Fe2L3]
4+
. 
 
4.3.1  Impact on In Vitro drug assays 
Significantly, these results demonstrate that methods currently employed to assess toxicity of 
new drug candidates may not be appropriate for non-covalent binding drugs or drugs with an 
unknown mode of action, unless careful consideration is paid to incubation time and volume. 
Promising non-covalent drug activity may be missed if the time point and volume selected for 
an IC50 assay are inadvertently inappropriate for that compound. Another example of this is 
that of the phase (II) clinical trial drug NAMI-A, which exhibits selective metastases 
inhibition in vivo and in vitro invasion inhibition, both unrelated to cellular cytotoxicity.
17
 The 
results presented here have implications for the way in vitro toxicity testing is used to assess 
novel non-covalent DNA-binding drugs.
18
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Chapter 5 
 
 
In Vitro Studies of Double Stranded Ruthenium 
Supramolecular Cylinders 
 
Original synthesis and characterisation of the range of complexes discussed in this chapter 
was carried out by Dr A. Hotze, University of Birmingham.  
Ligands and metal complexes were remade for all biological testing discussed in this 
chapter.  
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5.1     Introduction 
This chapter details mutagenicity, toxicological and cellular studies of the unsaturated 
ruthenium(II) isomeric complexes; ββ-, γγ-[Ru2L
2
2Cl2] and ββ-[Ru2L
2
2(NO3)2], where L
2
 is 
the bis pyridyl azo ligand C23H18N6, Figure 5. 1. Due to the wide range of cytotoxicities and 
the promising anticancer activity of a number of these complexes
1
 further biological 
studies are warranted. With a cisplatin style of coordinative DNA interaction combined 
with the supramolecular size and helical nature of the ruthenium triple stranded [Ru2L3]
4+ 
complex (discussed in chapter 3) the unsaturated ruthenium complexes discussed herein 
bridge the fields of supramolecular architecture and anticancer drug design.  
 
Figure 5. 1 The bis pyridyl azo ligand, L
2
 used in the synthesis of ruthenium complexes. 
Hydrogen atoms have been omitted for clarity.  
 
An optimised route to the synthesis of ligand L
2
 will be discussed, as this is a complex 
synthesis involving a number of steps. Also, some studies into the thermodynamics of 
isomerisation of these complexes will be detailed. 
 
5.1.1     Mononuclear Ruthenium Azopyridine Complexes 
Ruthenium is well suited to medicinal applications due to its low rate of ligand exchange, 
easily accessible oxidation states (Ru(II), (III) and (IV)) and its ability to mimic iron when 
binding to certain biological molecules.
2
 For these reasons a number of ruthenium drug 
complexes have been synthesised to date. Most relevant to this chapter are the 
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ruthenium(II) isomeric complexes of the form [RuL
(azpy)
2Cl2] where L
(azpy)
 = C11H9N3, 
Figure 5. 2, synthesised in the lab of Reedijk.  
 
Figure 5. 2 Schematic diagram of ligand L
(azpy)
 and the five theoretically possible 
isomers of the [RuL
(azpy)
2Cl2] complexes. The letters indicate Cl ligands, pyridine nitrogen 
atoms (Np) and azo nitrogen atoms (Na) respectively.
 3
 
 
There exist five possible geometric isomers labelled according to literature,
3
 with the 
structure of the α, β, γ and δ isomers having been confirmed by X-ray crystallography and 
NMR. The final isomer (ε) was found to be unstable.3 The anticancer properties of the α, β 
and γ isomers have been evaluated, with several displaying higher activity than cisplatin. 
Furthermore, it was determined that contrary to traditional belief, it is not necessary for 
these complexes to have the chloride ligands in a cis position in order for them to display 
anticancer activity. This is demonstrated by the γ isomer displaying higher cytotoxicity in 
all cell lines tested, Table 5. 1. This was an important structure activity relationship 
discovery for this range of complexes, the molecular reasons for which are still under 
investigation.
4
 
135 
 
 A498 EVSA-T H226 IGROV M19 MCF-7 WIDR 
α-[RuL(azpy)2Cl2] 0.27 0.063 0.48 0.27 0.064 0.27 0.27 
β-[RuL(azpy)2Cl2]
 
8.8 0.96 13.3 3.4 0.75 6.23 11.4 
γ-[RuL(azpy)2Cl2]
 
0.20 0.019 0.17 0.041 0.017 0.052 0.065 
Cisplatin 7.5 1.4 10.9 0.6 1.9 2.3 3.2 
 
Table 5. 1 IC50 values (µM) of several isomers of [RuL
(azpy)
2Cl2] and cisplatin against a 
panel of tumour cell lines.
4
 
 
5.1.2      Unsaturated Dinuclear Ruthenium Helicates 
Five dinuclear isomers of the complex [Ru2L
2
2Cl2], Figure 5. 3 have been previously 
synthesised in the Hannon group.  It was anticipated, based on the mononuclear 
counterparts and steric constraints that only the α, β and γ isomers could exist. Indeed the 
dinuclear γγ, γα, γβ, αα and ββ, isomers have been synthesised.1,5 
γγ γα γβ
αα ββ
L’
 
Figure 5. 3  Crystal structures of [Ru2L
2
2Cl2] isomers synthesised in the Hannon group. 
Hydrogen atoms have been omitted for clarity.
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The γγ complex is not helical, but shows a metallo-cyclophane structure.1 The 
remaining four complexes are double-helicates, with the γα and γβ complexes being a 
new class of helix where the chiral twist is induced by only one of the metal centres 
(the α/β centre). The αα isomer is a more typical helix, with both metals displaying 
the same chirality. Finally, the crystal structure of the ββ complex shows an 
asymmetrical double helical structure. This may be an artefact of crystal packing as a 
solvent molecule resides near the phenyl rings.
5
  
 
The poor solubility of the above complexes led to the synthesis of the water soluble 
ββ-[Ru2L
2
2(NO3)2] analogue, Figure 5. 4, through replacement of the chloride ions. 
 
Figure 5. 4 Crystal structure of the ββ-[Ru2L
2
2(NO3)2] complex. Hydrogen atoms 
are omitted for clarity.
5
 
 
In this structure both ligands have a roof type arrangement and there is monodentate 
coordination of the NO3 moieties through an oxygen atom. The chloride to nitrate 
ligand exchange was only carried out with the ββ isomer, reasons for which will be 
discussed later in this chapter.  
 
5.1.2.1     Biological Studies of Unsaturated Dinuclear Ruthenium Helicates 
Due to the low water solubility and neutral charge of the chloride complexes, no DNA 
binding interactions were observed. However, CD and LD DNA binding studies were 
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possible with the water soluble ββ-[Ru2L
2
2(NO3)2] complex, revealing weak CD 
interactions with a decrease in both DNA bands, similar to those observed for 
transplatin
6
 (but less severe). LD interactions indicated some binding and 
bending/coiling of the DNA strand. B-DNA conformation was retained throughout 
both CD and LD titrations.
5
 ββ-[Ru2L
2
2(NO3)2] was incubated with the model base 9-
ethylguanine followed by ESI mass spectrometry analysis. This revealed the 
formation of the mono-adducts ββ-[(9-Etgua-H)Ru2L
2
2], ββ-[(9-Etgua)Ru2L
2
2(H2O)2] 
and the bis-adduct ββ-[(9-Etgua)2Ru2L
2
2].
5
 It is assumed that the bis-adduct is due to 
the coordination of one model base per ruthenium atom, as in the mononuclear case 
coordination of only one model base is possible due to steric constraints.
4
 All these 
studies suggest binding of ββ-[Ru2L
2
2(NO3)2] in the major groove of DNA along with 
some coordinative binding.  
 
The cytotoxicities of the dinuclear ruthenium complexes along with their 
mononuclear counterparts are shown in Table 5. 2 against the ovarian cancer cell line 
A2780-P and the cisplatin resistant cell line, A2780-R. 
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 A2780-P (µM) A2780-R (µM) Rf 
γγ-[Ru2L
2
2Cl4] 0.08 0.07 0.88 
γα-[Ru2L
2
2Cl4] 0.36 4.9 13.6 
γβ-[Ru2L
2
2Cl4] 2.07 3.9 1.9 
ββ-[Ru2L
2
2Cl4] Not active Not active - 
ββ-[Ru2L
2
2(NO3)4] 1.2 8.2 6.8 
α-[RuL(azpy)2Cl2] 0.85 0.98 1.2 
β-[RuL(azpy)2Cl2] 1.9 8.9 4.7 
β-[RuL(azpy)2(NO3)2] 9.7 12.1 1.2 
cisplatin 2.9 20 6.9 
 
Table 5. 2 IC50 values (µM) of γγ-, γα-, γβ-, ββ-[Ru2L
2
2Cl4] and ββ-[Ru2L
2
2(NO3)4] 
with mononuclear counterparts and cisplatin as reference compounds in the A2780-
P/R ovarian cancer cell lines with resistance factors (Rf = IC50 A2780-R/ IC50 A2780-
P). 
4, 5, 7
 
 
The cytotoxicities of the γγ and γα complexes are very high and all complexes, 
excluding the ββ-Cl4 complex, show lower IC50 values (higher activity) than cisplatin. 
It is also interesting to note that the γγ- and γβ- compounds have an Rf factor of less 
than 2, indicating these complexes may not be susceptible to the resistance 
mechanisms present in the A2780-R cell line. The spectrum of activities of the 
dinuclear compounds are very similar to those of the mononuclear counterparts.
7
 The 
only notable difference is the ββ-Cl4 complex, where the mononuclear isomer shows 
good activity, although being a factor of 10 less active than the other mononuclear 
compounds.
4
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5.2     Results and Discussion 
5.2.1     Synthesis and Isomerisation Studies 
The synthesis of the bispyridyl azo ligand was carried out according to published 
methods (see section 2.3.1) and purified via an optimised isocratic HPLC method with 
a 10 % water, 90 % methanol solvent system. 
 
An attempt was made to remove the chloride ligands from the γγ-[Ru2L
2
2Cl4] isomer 
however this was not possible at temperatures lower than ~ 40 °C. It is hypothesised 
that this is due to the trans orientation of the chlorides which has also been 
documented for the mononuclear counterparts.
8
 Above this temperature a change of 
colour is observed from green to blue. This was further investigated to see if it was an 
isomerisation process. It was found that 100 % isomerisation to the ββ isomer had 
occurred. This isomerisation process can be carried out at 40 ºC for a number of days 
or through reflux in a high boiling point solvent for a few hours. In the mononuclear 
case isomerisation to a β isomer is also observed above 40 ºC.9 This shows that in this 
case the ββ-[Ru2L
2
2Cl4] isomer is the thermodynamically favoured product. 
 
The only reported isolation of the αα-[Ru2L
2
2Cl4] isomer was on a single occasion 
after standing the γα-[Ru2L
2
2Cl4] isomer in an NMR tube at room temperature. In 
order to investigate this isomerisation process further, the reaction of a 40 µM sample 
was followed by UV-Visible spectroscopy. At room temperature no change was 
observed however at 50 °C a colour change and a hypsochromic shift (to shorter 
wavelength) occurred. No isosbestic points were present in the spectrum, however, 
showing it is unlikely that full isomerisation to the αα-[Ru2L
2
2Cl4] isomer has 
occurred, Figure 5. 5. 
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Figure 5. 5 UV-Visible spectra of 40 µM γα-[Ru2L
2
2Cl4] in deuterated chloroform 
every hour over 18 hours at 50 °C. 
 
Unfortunately, when this reaction was scaled up in order to obtain enough sample for 
NMR characterisation, no change in compound was seen. Thus the αα-[Ru2L
2
2Cl4] 
isomer may only be stable under certain conditions.    
 
5.2.2     In Vitro DNA Binding Studies of ββ-[Ru2L
2
2(NO3)4] 
It is clear from previous CD, LD and model base studies that the ββ-[Ru2L
2
2(NO3)4] 
complex binds to naked DNA in a covalent manner
5
, therefore the next step is to 
consider the DNA binding in live cells. This could clarify DNA binding as a potential 
mode of anticancer activity. A whole-cell Hoechst displacement assay (see section 
2.5.4) was used to assess if ββ-[Ru2L
2
2(NO3)4] was able to enter live cells and bind to 
nuclear DNA, Figure 5. 6. 
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Figure 5. 6 Emission of 10 µM Hoechst- 33258 with HL-60 cells when treated with 
varying concentrations of ββ-[Ru2L
2
2(NO3)4].  λ exc. = 350 nm. 
 
This test involved the preloading of HL-60, a human myeloid leukaemia cancer cell 
line, selected as it can be grown in suspension rather than as an adherent cell line, 
with 10 µM Hoechst- 33258, a minor groove DNA binder. Following this incubation, 
varying concentrations of ββ-[Ru2L
2
2(NO3)4] were added and the resulting Hoechst 
fluorescence measured. After excitation at 350 nm, an emission centred at 450 nm is 
expected for Hoechst bound to DNA. If the Hoechst molecule is ejected from DNA 
through competitive binding of another agent, the resulting emission at 450 nm will 
decrease. It would therefore be expected that the more ββ-[Ru2L
2
2(NO3)4] that binds 
to DNA, the more Hoechst will be ejected and the resulting emission at 450 nm will 
decrease. Figure 5. 6 clearly indicates that increasing the concentration of ββ-
[Ru2L
2
2(NO3)4] incubated with the cells causes an increase in Hoechst emission. This 
increase is seen up to a ββ-[Ru2L
2
2(NO3)4] concentration of 25 µM, the opposite 
response to that expected. At 50 µM ββ-[Ru2L
2
2(NO3)4] the emission is lowered. It 
should be noted, however, that ruthenium absorbs in the excitation region of this 
assay, which may affect the results observed. 
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In order to test the interaction between ββ-[Ru2L
2
2(NO3)4] and Hoechst, without the 
presence of DNA, a 10 µM solution of Hoechst was incubated with increasing 
concentrations of ββ-[Ru2L
2
2(NO3)4], Figure 5. 7. 
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Figure 5. 7 Emission of 10 µM Hoechst with varying concentrations of ββ-
[Ru2L
2
2(NO3)4]. λ exc. = 350 nm. 
 
500 nm is the emission wavelength expected for free Hoechst, and it was found that 
increasing concentrations of ββ-[Ru2L
2
2(NO3)4] quenches the Hoechst emission. 
 
It appears that ββ-[Ru2L
2
2(NO3)4] is increasing the amount of Hoechst bound to 
nuclear DNA within the HL-60 cells. The exact mechanism of this interaction is still 
under investigation, however one hypothesis is that the ββ-[Ru2L
2
2(NO3)4] may be 
disrupting the cell membrane, allowing more Hoechst to enter the cell from solution 
and bind to nuclear DNA. At a ββ-[Ru2L
2
2(NO3)4] concentration of 50 µM the 
decrease in emission intensity may be caused by complete disruption of the cell 
membrane, allowing Hoechst to be displaced from the DNA by ββ-[Ru2L2(NO3)4] in 
solution.  
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5.2.3     Mutagenicity Studies of γγ-, ββ-[Ru2L
2
2Cl4] and ββ-[Ru2L
2
2(NO3)4] 
The γγ-, ββ-[Ru2L
2
2Cl4] and ββ-[Ru2L
2
2(NO3)4] isomers were tested for compound 
related mutagenicity using the Ames bacterial reverse mutation assay (see section 
2.6). This range of complexes, representing the most and least cytotoxic as well as the 
water soluble derivative are important to investigate to confirm that activity is not 
accompanied by mutagenicity. In order to ensure a thorough investigation of 
mutagenic potential two Salmonella strains were used to test for frameshift (TA98 
strain) and base pair/point mutations (TA100 strain). These bacterial strains carry a 
mutation which makes them unable to synthesise the amino acid histidine, which is 
essential for bacterial growth. Incubation with a mutagenic compound will reverse 
this inherent mutation, leading to the bacteria being able to synthesise histidine and 
hence grow (these bacteria are termed revertants). The test is extended to probe 
mutagenicity of potential in vivo products of metabolism by repeating experiments 
with an incubation step including activated rat liver S9 enzymes, a variety of mixed 
function oxidase enzymes.
10
 The number of revertant bacterial colonies present after a 
48 hour incubation period are counted and compared to both positive and negative 
controls. A mutagenic response is usually defined as a 2-3 fold increase in revertants 
relative to negative controls.
11
 
 
Figure 5. 8 to Figure 5. 10 show the number of bacterial revertants after incubation 
with the three complexes for the salmonella typhimurium TA98 strain. 
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Figure 5. 8 Number of bacterial revertants of Salmonella typhimurium TA98 after 
incubation with varying concentrations of γγ-[Ru2L
2
2Cl4]. Results represent mean ± 
SEM. Positive control/Mutagen: 4-nitroquinoline-N-oxide. S9 control/Promutagen: 
chrysoidine Y. Negative control: PBS. 
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Figure 5. 9 Number of bacterial revertants of Salmonella typhimurium TA98 after 
incubation with varying concentrations of ββ-[Ru2L
2
2(NO3)4]. Results represent mean 
± SEM. Positive control/Mutagen: 4-nitroquinoline-N-oxide. S9 control/Promutagen: 
chrysoidine Y. Negative control: PBS. 
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Figure 5. 10 Number of bacterial revertants of Salmonella typhimurium TA98 after 
incubation with varying concentrations of ββ-[Ru2L
2
2Cl4]. Results represent mean ± 
SEM. Positive control/Mutagen: 4-nitroquinoline-N-oxide. S9 control/Promutagen: 
chrysoidine Y. Negative control: PBS. 
 
It is clear from all positive controls that the bacteria and S9 liver enzyme mix are 
functioning correctly with >400 revertants in each case. In conjunction with statistical 
ANOVA results to assess the significance of the data, mutagenicity of the complexes 
can be determined. Figure 5. 8 shows that γγ -[Ru2L
2
2Cl4] does not cause significantly 
more mutations than negative controls both with or without S9 activation, with p 
values of 0.93 and 0.24 respectively (when p > 0.05 shows no statistical significance). 
There is no dose response confirming that this compound is not a mutagen under these 
conditions.  
 
From Figure 5. 9 it can be seen that ββ-[Ru2L
2
2(NO3)4] (without S9 enzymes) is toxic 
(most/all bacteria are killed) at high doses. This is not the case in the presence of S9 
enzymes and it is therefore probable that the complex binds to proteins/bio-molecules 
within the mixture or is chemically modified by the enzymes, so is unable to exert its 
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toxic effect on the bacteria. Again, with S9 a p value of 0.082 indicates no 
significance.  
 
There is a small increase in mutagenicity in the presence of S9 enzymes for the 
highest dose of ββ-[Ru2L
2
2Cl4], Figure 5. 10, however a post-hoc students t-test 
showed this to be the only statistically significantly data point. Without S9 p = 0.966 
confirming no dose response. It should be noted that the concentrations used were 
very high, and for the active compounds the dose incubated with the bacteria was far 
higher than the IC50 values of the complexes. 
 
Figure 5. 11 to Figure 5. 13 show the number of bacterial revertants for the salmonella 
typhimurium TA100 strain. Values reported are higher than with the TA98 strain due 
to the naturally higher reversion frequency of the TA100 strain.
11
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Figure 5. 11 Number of bacterial revertants of Salmonella typhimurium TA100 after 
incubation with varying concentrations of γγ-[Ru2L
2
2Cl4]. Results represent mean ± 
SEM. Positive control/Mutagen: Sodium Azide. S9 control/Promutagen: chrysoidine 
Y. Negative control: PBS. 
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Figure 5. 12 Number of bacterial revertants of Salmonella typhimurium TA100 after 
incubation with varying concentrations of ββ-[Ru2L
2
2(NO3)4]. Results represent mean 
± SEM. Positive control/Mutagen: Sodium Azide. S9 control/Promutagen: chrysoidine 
Y. Negative control: PBS. 
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Figure 5. 13 Number of bacterial revertants of Salmonella typhimurium TA100 after 
incubation with varying concentrations of ββ-[Ru2L
2
2Cl4]. Results represent mean ± 
SEM. Positive control/Mutagen: Sodium Azide. S9 control/Promutagen: chrysoidine 
Y. Negative control: PBS. 
 
As is the case for the TA98 strain, none of the complexes showed mutagenicity with 
or without S9 activation. For γγ-[Ru2L
2
2Cl4], p = 0.11 (with S9), 0.19 (without S9) 
and for ββ-[Ru2L
2
2(NO3)4], p = 0.22 (with S9). Again, this complex was toxic to the 
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bacteria at the highest doses without S9. It is also interesting to note that with both 
bacterial strains, the only complex which indicated any likelihood of being mutagenic 
was the inactive ββ-[Ru2L
2
2Cl4] compound in the presence of S9 where p = 0.045 
(with S9), 0.19 (without S9). 
 
From this data we can conclude that none of the active compounds cause point or 
frameshift mutations under these conditions. It has been established that compounds 
which do not exhibit activity in the Ames test are normally found to be non-
carcinogenic
12
 so this is an important result, as mutagenic potential is a huge clinical 
drawback of other covalent DNA binders such as cisplatin. 
 
5.2.4        Genotoxicity Studies of γγ-[Ru2L
2
2Cl4] and ββ-[Ru2L
2
2(NO3)4] 
Genotoxic potential (causing DNA strand breaks) is a major drawback of many 
current anticancer agents such as cisplatin. In order to assess the genotoxic potential 
of γγ-[Ru2L
2
2Cl4] and ββ-[Ru2L
2
2(NO3)4], the alkaline comet assay was used to detect 
DNA single strand breaks in the human ovarian cancer cell line A2780 (see section 
2.5.11). In this test, cells are incubated with compound, followed by cell lysis, DNA 
staining and electrophoresis. The larger the DNA ‘comet’ resulting from 
electrophoresis, the more DNA strand breaks are present. Figure 5. 14 and Figure 5. 
15 show mean % tail intensity from comets for the compounds γγ-[Ru2L
2
2Cl4] and ββ-
[Ru2L
2
2(NO3)4]. 
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Figure 5. 14 Mean % tail intensity of comets from incubation of A2780 cells with γγ-
[Ru2L
2
2Cl4] and cisplatin. Data represents mean of three independent experiments ± 
SEM. Negative control: DMEM medium. 
 
Concentrations tested were up to the IC50 value of the complex. A one-way ANOVA 
to assess the significance of the dose response for γγ-[Ru2L
2
2Cl4] returned a p value of 
0.53 and it is clear from Figure 5. 14 that mean % tail intensity is not significantly 
higher for γγ-[Ru2L
2
2Cl4] than for the negative control, indicating that treatment does 
not cause DNA single-strand breaks in this cell line. The negative control displayed is 
that of medium, but statistical tests were also repeated with DMSO (γγ-[Ru2L
2
2Cl4] 
solvent), showing no significance. The results displayed for cisplatin are the highest 
and lowest doses tested, and a p value of 0.017 indicates that this data is significant, 
with cisplatin causing a high number of DNA strand breaks in this cell line.  
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Figure 5. 15 Mean % tail intensity of comets from incubation of A2780 cells with 
ββ-[Ru2L
2
2(NO3)4] and cisplatin. Data represents mean of three independent 
experiments ± SEM. Negative control: DMEM medium. 
 
In the case of ββ-[Ru2L
2
2(NO3)4] there is also no indication of direct DNA damage, 
with a one-way ANOVA p value of 0.28 indicating no significant dose response.   
 
Negative activity in this test for both these cytotoxic compounds is another important 
result, as the potent genotoxicity of drugs in current clinical use is often responsible 
for the formation of secondary cancers (especially leukaemias).
13
 
 
5.3     Conclusions and Further Work 
Some of the synthetic strategies used to make this intriguing set of dinuclear 
ruthenium double stranded isomers have been investigated and it has been confirmed 
that, like the mononuclear counterparts, the ββ isomer is thermodynamically favoured 
over the γγ isomer.  
 
Some very interesting results have been obtained with the water soluble, ββ-
[Ru2L
2
2(NO3)4] complex, a derivative of the original chloride compound. Results 
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show that the mechanism of action may be different to that initially expected, of 
covalent DNA binding. Results presented here may indicate that this compound is 
interacting with the cell membrane; however it is not known at this stage whether or 
not this is a contributing factor to cell death. 
 
Furthermore, and possibly most importantly, mutagenicity and genotoxicity studies 
have shown that the highly anticancer active γγ-[Ru2L
2
2Cl4] and ββ-[Ru2L
2
2(NO3)4] 
compounds are not mutagenic and do not cause DNA single strand breaks. These 
anticancer agents have been compared throughout to those of cisplatin, which 
although a successful agent in the clinic, does possess all these undesirable properties.  
 
This range of ruthenium compounds, combining both a covalent cisplatin style of 
DNA binding with a supramolecular structure have not only improved anticancer 
activity in the cell lines tested, but have eliminated other negative effects responsible 
for a number of side effects in the clinic. This work is clearly an important step 
forward in the field of supramolecular anticancer drug design. 
 
It is anticipated that further cell membrane studies with the ββ-[Ru2L
2
2(NO3)4] 
complex will generate interesting and important results. It is also necessary to 
compare these results to those of the original chloride complexes, to elucidate possible 
modes of action, as the interaction of ββ-[Ru2L
2
2(NO3)4] with Hoechst in live cells is 
a very interesting and unusual finding. It may also be beneficial to extend work 
carried out into mutagenicity of the ββ-[Ru2L
2
2(NO3)4] compound. This compound is 
toxic to the bacteria at the highest doses, however in the presence of S9 liver enzymes 
this is not the case, and the bacteria continue to grow at a background level. It would 
152 
 
be interesting to compare this result with cellular cytotoxicity of the compound after 
incubation with S9 enzymes to confirm whether cytotoxicity is also affected. 
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Chapter 6 
 
 
Design, Synthesis and Biological Studies of a Novel 
Ruthenium Supramolecular Cylinder 
155 
6.1  Introduction 
This chapter details the molecular design, synthesis, characterisation, biophysical and in 
vitro studies of a dinuclear, helical ruthenium(II) complex containing bis-pyridyl-azo and 
bipyridine ligands; [Ru2L
2
2(bpy)2]
4+
, where L
2
 = C23H18N6 and bpy = C10H6N2, Figure 6. 1. 
This complex was designed to exhibit  non-covalent DNA binding interactions and was 
synthesised via an optimised route from the biologically active unsaturated ruthenium(II) 
double stranded complex ββ-[Ru2L
2
2(NO3)4] (discussed in chapter 5).  
 
Figure 6. 1 Ligand L
2
 and representation of the [Ru2L
2
2(bpy)2]
4+
 cation discussed in 
this chapter. 
 
Ruthenium compounds have been used in varied applications and have attracted much 
attention due to their diverse chemical and physical properties. There is a large amount of 
evidence to indicate cytotoxicity correlates with DNA binding
1,2,3,4
 and in order to improve 
the performance of ruthenium drugs a number of ligand modifications have been made 
with the intention of changing the physical or biological properties. These include the 
attachment of carboxylato groups or extended aromatic surfaces
5
 in order to, for example, 
change ligand exchange kinetics or solvation properties. Modifying the ligand surface of a 
known drug molecule in order to change its physical and biological properties is the 
approach used in this chapter.  
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6.1.1  Mononuclear Ruthenium Complexes 
The mononuclear ruthenium(II) azpy complexes, [Ru2L
(azpy)
2Cl2] Figure 6. 2 (also 
discussed in section 5.1.1), are a good example of how altering ligand surface can change 
important properties of the molecule. This range of compounds is also structurally related 
to the dinuclear compound discussed in this chapter. All mononuclear azpy complexes 
isolated displayed potent cytotoxicities.
6
  
 
Figure 6. 2 Structures of the Δ enantiomers of α-, β- and γ-[RuL(azpy)2Cl2].
6
 
 
The α isomer, with the Cl, N-pyridine and N-azo elements being cis, trans and cis 
respectively, (see nomenclature from chapter 5) is the most active complex, with 
cytotoxicities in the range 0.063-0.98 µM. The β isomer (Cl, N-pyridine and N-azo 
elements all cis) is the least active (0.75-11.4 µM) against the panel of tumour cell lines 
tested.
7
 As is the case for the structurally similar complex cis-[Ru(bpy)2Cl2],
8
 steric 
constraints mean the coordination of only one guanine residue to each azpy complex is 
possible. Model-base adducts with α-[RuL(azpy)2Cl2] are kinetically more stable than with 
β-[RuL(azpy)2Cl2], suggesting that differing DNA binding abilities due to specific ligand 
orientations are a potential explanation as to why α is the most, and β the least active 
isomer.
9
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It has been shown with the mononuclear azpy complexes that exchanging the chloride 
ligands for other mono- or bidentate ligands can be used as a way of tailoring properties 
and refining structure activity relationships. In all cases the replacement of the chloride 
ligands caused an increase in IC50 value (decrease in cytotoxicity) of the complex, Table 6. 
1. This can be useful in order to define the important features required for DNA binding 
and hence activity of complexes.  
 A2780 A498 
α-[RuL(azpy)2Cl2] 0.85 0.27 
α-[RuL(azpy)2(NO3)2] 8.5 - 
α-[RuL(azpy)2(ox)] 6.3 - 
α-[RuL(azpy)2(mal)] 7.9 - 
α-[RuL(azpy)2(bpy)] - 89.8 
β-[RuL(azpy)2Cl2] 1.9 8.8 
β-[RuL(azpy)2(NO3)2] 9.7 - 
β-[RuL(azpy)2(bpy)] - 92.0 
[RuL
(azpy)
3] - 55.4 
[RuL
(azpy)
(bpy)2] - 77.8 
Cisplatin 2.3 7.5 
 
Table 6. 1 IC50 values (µM) of mononuclear ruthenium(II) complexes with cisplatin as 
reference in the A2780-P ovarian and A498 renal carcinoma cell lines. (ox = oxalate, mal 
= malonate, bpy = 2, 2-bipyridine) (-) indicates complex not tested in this cell line.
7 
 
In the ovarian cell line A2780-P, the cytotoxicity of the α isomer was reduced from 0.85 
µM to 8.5 µM with the addition of two nitrate moieties, to 6.3 µM with the addition of an 
158 
oxalate anion and to 7.9 µM with the addition of a malonate.  The β isomer similarly 
showed a reduction in cytotoxicity from 1.9 µM for the parent chloride complex to 9.7 µM 
for the nitrate complex.
7
 It should also be noted, however, that removing the chloride 
ligands also dramatically increases the solubility of these compounds in aqueous media-a 
desirable property. 
 
A further example utilising the bipyridine ligand is that of the mononuclear mer-
[RuL
(azpy)
3]. The IC50 of this complex is 55.4 µM in the A498 cell line. This is increased to 
77.8 µM for the complex [RuL
(azpy)
(bpy)2] and further to 89.8 µM for the complex α-
[RuL
(azpy)
2(bpy)]. β-[RuL
(azpy)
2(bpy)] has the highest IC50 of this range of complexes at 92.0 
µM
7
 
 
6.1.2  Ruthenium Helicates 
There have been a limited number of ruthenium helicates synthesised to date, the most 
relevant of which are those published by the Hannon group.
1
 The single stranded Ru(II) 
complex, [Ru2L(bpy)4]
4+ 10
where L = C25H20N4, Figure 6. 3, has two bipyridine moieties on 
each ruthenium centre. 
 
Figure 6. 3 Representation of the [Ru2L(bpy)4]
4+
 cation.
 
Hydrogen atoms and anions 
are omitted for clarity.
10
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The DNA binding of the enantiomers of this complex were investigated using circular 
dichroism and fluorescent displacement assays. Results showed that the complex has a 
bending effect (possibly through electrostatic binding outside of the grooves) which causes 
the DNA to coil.
10
 This compound is inactive against cancer cell lines, an interesting result 
which will be discussed later in this chapter. 
 
A further supramolecular, helical complex is the triple stranded, di-ruthenium(II) complex; 
[Ru2L3]
4+ 11
 where L = C25H20N4, Figure 6. 4 (also discussed in chapters 1 and 3). 
NN
N N
 
Figure 6. 4 Ligand L and X-Ray crystal structure of the [Ru2L3]
4+
 cation. Hydrogen 
atoms and anions are omitted for clarity.
12
 
 
This cylinder is based on the parent iron(II) triple stranded complex, [Fe2L3]
4+
 (also 
discussed in chapters 1, 3 and 4) and indeed the structures are almost identical, Figure 6. 5. 
The central iron(II) atoms were replaced with ruthenium(II) in order to benefit from the 
extra stability and photophysical properties of these metal centres. 
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Figure 6. 5 Comparison of X-ray crystal structures of ruthenium (yellow) and iron (red) 
supramolecular cylinders.
12
 
 
[Ru2L3]
4+
 displays very strong DNA binding and DNA coiling as well as a fluorescence 
response upon DNA binding.
12
 It also displays some anticancer activities within the range 
of cisplatin.
11
 Interestingly however its anticancer activity is restricted to breast cancer cell 
lines and the complex shows limited activity in any of the ovarian cancer cell lines tested.
13  
 
6.2  Results and Discussion 
6.2.1  Molecular Design Approach 
The target complex lies (in design) between the single and triple stranded dinuclear 
ruthenium(II) complexes discussed above. It is a dinuclear double stranded complex with 
additional blocking ligands completing the coordination sphere of each ruthenium(II) 
centre, Figure 6. 6. 
 
Figure 6. 6 Ligand L
2
 and representation of the desired structure, [Ru2L
2
2(X)4]. Ligand 
X may be any mono- or bidentate ligand.  
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It is hoped that this complex will improve upon the single stranded design, having a 
reduced flexibility but not all the structural features of the triple stranded cylinder. Some of 
the important structural and design characteristics needed for non-covalent DNA 
recognition, binding and anticancer activity might hence be elucidated. The synthetic 
procedure developed was designed so that a range of different ligands may be added to the 
original design in order to create a compound with a tunable ligand surface. Properties may 
therefore be tailored for different chemical or biological interactions and to study the effect 
of different DNA binding on anticancer properties. Herein the bipyridine complex, Figure 
6. 1, is presented as the first complex in this series.  
 
6.2.2  Synthesis of ββ -[Ru2L
2
2(bpy)2]
4+ 
The synthesis of this compound from ββ-[Ru2L
2
2(NO3)4] is presented in Figure 6. 7, with 
the starting material being the unsaturated ββ-[Ru2L
2
2(Cl)4] compound discussed in chapter 
5. This isomer was initially chosen as the chloride ligands can be easily removed, with 
retention of the ββ- configuration. This is also the only isomer of this range of compounds 
that is not active against cancer cell lines and it would therefore be attractive to see if a 
change in binding mode to a non-covalent interaction would confer some activity.  
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2,2-bipyridine,
120 oC, 2hrs
 
Figure 6. 7 Schematic of reaction procedure from the neutral, unsaturated ββ- 
[Ru2L
2
2(NO3)4] complex to the desired ββ -[Ru2L
2
2(bpy)2]
4+ 
complex.  
 
Initially, the ββ-[Ru2L
2
2(NO3)4] complex was synthesised as described in chapter 2 
(section 2.3.2). From this structure the bipyridine complex was synthesised via 
replacement of the NO3 ligands with 2, 2-bipyridine. The bipyridine complex synthesised 
has a 4+ charge, unlike the unsaturated chloride/nitrate compounds which are neutral 
molecules. This greatly improves the water solubility and has also been shown to aid 
interaction with biomolecules and cellular uptake.
14
  
 
The 
1
H NMR spectrum, Figure 6. 8, shows that this is indeed the ββ isomer as expected. 
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Figure 6. 8 Representation of structure of ββ-[Ru2L
2
2(bpy)2](NO3)4
i 
with numbering 
scheme and aromatic region of 
1
H NMR spectrum (CD3CN). 
 
It is notable that the spectrum contains six distinct rings: four pyridyl and two phenyl.  
nOe interactions between 3A-3D, 3A-4D and 4A-3D demonstrate that two of the pyridine 
rings are linked: ie. the bipyridine is non-symmetrical, but that only one bipyridine 
environment is present (not two distinct bipyridines). Peaks between 6A-6C and 6A-5/6E 
confirm the A ring of the bipyridine is the one close to the pyridine of the ligand strand and 
                                               
i Structure is shown in 2D not 3D, for ease of visualisation and is the ββ- isomer, not αα- as might be implied 
from this 2D representation. 
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peaks between Pha / Pha‟-6D confirm that the D ring is the one close to the phenyl rings of 
the ligand strand.  
 
The remaining rings (two pyridine and two phenyl) are therefore on the ligand (L
2
) strand. 
Long range nOe coupling between Pha‟ and 3E was used to confirm that phenyl ring Ph‟ is 
attached to pyridine ring E and phenyl ring Ph is attached to pyridine ring C. There are two 
possibilities: that one ligand strand contains C and Ph and the other Ph‟ and E and the two 
strands are non-equivalent: or that C, Ph, Ph‟ and E are the four rings in each strand and 
the two strands are identical. The former would imply two CH2 singlet peaks (or one 
singlet if they overlap exactly). The latter would lead to two distinct coupled protons on the 
CH2 (diastereotopic protons) because of the helical chirality. Examination of the CH2 
reveals that it is two coupled doublets at almost identical chemical shift, confirming the 
second situation, Figure 6. 9. 
Pha CH2
 
Figure 6. 9 Area of ββ-[Ru2L
2
2(bpy)2]
4+ 
NMR spectrum (CD3CN) showing two coupled 
doublets in the CH2 peak. 
 
There are also some Ph-Ph‟ nOe interactions showing possible π-stacking in the structure. 
This would also explain why the Pha peak is at a much lower chemical shift than Pha‟/Phb‟ 
peaks (if it is involved in pi-stacking). 
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The crystal structure of the ββ-[Ru2L
2
2(NO3)4] starting material, Figure 6. 10 shows that 
the two pyridine rings at either end of the ligand L
2
 strand are non-equivalent (one is trans 
to an azo nitrogen and the other is trans to a nitrate). The ββ-[Ru2L
2
2(bpy)2]
4+ 
NMR 
implies the structure is very similar to that of ββ-[Ru2L
2
2(NO3)4] which is only consistent 
with a ββ- configuration. 
 
Figure 6. 10 Crystal structure of ββ-[Ru2L
2
2(NO3)4] showing non-equivalence of 
pyridine rings at each end of ligand L
2
 strand. 
 
The ESI mass spectrum of [Ru2L
2
2(bpy)2]
4+ 
in acetonitrile
 
shows peaks corresponding to 
[Ru2L
2
2(bpy)2]
4+ 
(m/z 318), [Ru2L
2
2(bpy)2]
3+
 (m/z 424) and [Ru2L
2
2(bpy)2]
2+
 (m/z 636) with 
a correct isotopic distribution confirming a dinuclear double stranded conformation is 
retained in solution. Electrochemical reduction can take place during ESI mass 
spectrometry and the ruthenium ion is able to retain its octahedral geometry with a change 
in oxidation state. This explains the retention of structure with a change in charge of the 
mass spectrometry fragments.  
 
6.2.3  DNA Binding Studies of ββ-[Ru2L
2
2(bpy)2]
4+
 
In order to probe DNA binding of this compound, a number of techniques have been used; 
CD, LD, emission and photocleavage studies. A comparison between this compound and 
the related [Fe2L3]
4+
, [Ru2L3]
4+
 and [Ru2L(bpy)4]
4+ 
complexes will be discussed, as it is 
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important to view these results in context in order to gain information about how specific 
structure relates to DNA binding interactions and cytotoxic activity.  
 
6.2.3.1  Circular Dichroism 
Circular dichroism (see section 2.4.2) was used to probe any changes in ct-DNA structure 
as the concentration of ββ-[Ru2L
2
2(bpy)2]
4+ 
was increased. This can give information on 
binding interactions and changes to the ct-DNA conformation. The concentration of ct-
DNA was kept constant throughout the experiment and the resulting spectrum is shown in 
Figure 6. 11. 
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Figure 6. 11 CD spectra of ct-DNA (300 μM) in the presence of varying concentrations 
of  ββ- [Ru2L
2
2(bpy)2]
4+
. Mixing ratios are indicated as DNA bases to complex. 
 
ββ- [Ru2L
2
2(bpy)2]
4+
 shows a strong interaction with ct-DNA, with addition resulting in 
strong induced metal to ligand charge transfer (MLCT) signals in the 300-550 nm region, 
indicating complex-DNA interactions. The characteristic DNA band at 270 nm decreases 
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in intensity while the DNA band at 248 nm increases in intensity (becomes less negative). 
The change in CD value for these bands is due to the contribution to the DNA signal of the 
„in ligand‟ transitions of the cylinder. These small structural DNA modifications are 
expected upon binding of the complex, confirming that ββ-[Ru2L
2
2(bpy)2]
4+
 is indeed 
binding to the DNA. Importantly, the characteristic B-DNA CD signal is retained 
throughout the titration, confirming retention of this form of DNA throughout. 
 
The nature of the DNA binding can be investigated by examining a specific area of the CD 
spectrum and plotting induced CD signal (ICD) versus ββ-[Ru2L
2
2(bpy)2]
4+
 concentration 
at one wavelength, Figure 6. 12.  
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Figure 6. 12 Plot of induced CD signal against ββ-[Ru2L
2
2(bpy)2]
4+ 
concentration (µM).  
 
There is a clear linear correlation, with induced CD signal increasing as the concentration 
of complex increases, suggesting only one binding mode of this cylinder to DNA. This 
linear correlation also exists for the other induced CD bands of this complex and is 
analogous to that of the triple stranded cylinder, [Ru2L3]
4+
 at these concentrations. This 
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shows that ββ- [Ru2L
2
2(bpy)2]
4+
 and [Ru2L3]
4+
 may potentially have the same non-covalent 
binding mode.  
 
6.2.3.2  Linear Dichroism 
Linear dichroism (see section 2.4.3) was used to give information on the orientation of the 
DNA, hence binding, bending and coiling of the DNA upon increase in  ββ- 
[Ru2L
2
2(bpy)2]
4+
 concentration can be seen, Figure 6. 13. 
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Figure 6. 13 LD spectra of ct-DNA (300 μM) in the presence of varying concentrations 
of ββ-[Ru2L
2
2(bpy)2]
4+
. Mixing ratios are indicated as DNA bases to complex. 
 
Upon addition of ββ-[Ru2L
2
2(bpy)2]
4+ 
to DNA, both positive and negative induced LD 
(ILD) signals can be seen in the metal to ligand charge transfer region (300-550 nm). 
Increasing the concentration of the complex leads to an increase of the ILD signal, 
indicating that as more compound is added more becomes oriented with the DNA. 
Furthermore, increasing the concentration of ββ-[Ru2L
2
2(bpy)2]
4+ 
increases the negative 
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DNA LD signal, between 200-300 nm, consistent with loss of DNA orientation due to 
bending or coiling. 
 
A plot of ILD signal at 512 nm against concentration of ββ-[Ru2L
2
2(bpy)2]
4+
, Figure 6. 14, 
shows one linear region.  
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Figure 6. 14 Plot of induced LD signal at 512 nm versus [Ru2L
2
2(bpy)2]
4+
 concentration 
(µM). 
 
This result is in agreement with circular dichroism, showing only one binding mode of ββ-
[Ru2L
2
2(bpy)2]
4+ 
to DNA. 
 
Focusing on the DNA band of the LD spectra, at 258 nm and plotting percentage LD 
against ββ-[Ru2L
2
2(bpy)2]
4+ 
concentration gives information on the loss of DNA 
orientation due to complex interactions. Figure 6. 15.  
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Figure 6. 15 Plot of percentage LD signal at 258 nm against ββ-[Ru2L
2
2(bpy)2]
4+ 
concentration (µM). 
 
The effect of complex-DNA binding is significant, with 8 % of the DNA losing its 
orientation at a DNA base : complex ratio of 100:1, while at a ratio of 5:1  60 % of the 
DNA has lost its orientation. This effect is, however, not as profound as that of [Ru2L3]
4+
 
or [Fe2L3]
4+ 12
, Figure 6. 16. In the case of ββ-[Ru2L
2
2(bpy)2]
4+
, due to the presence of the 
bipyridine moiety on each metal atom, with coordination through two pyridine nitrogen 
atoms rather than one pyridine and one azo nitrogen atom, it is thought that ββ-
[Ru2L
2
2(bpy)2]
4+ 
will be larger in diameter than the triple stranded cylinders. This result is 
therefore in agreement with results found previously where increasing the length of 
cylinders did not affect the DNA binding, but increasing the width significantly reduced 
DNA binding and coiling.
15
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Figure 6. 16 Plot of percentage LD signal at 258 nm against complex concentrations 
(µM) of ββ-[Ru2L
2
2(bpy)2]
4+
, [Ru2L3]
4+
 and [Fe2L3]
4+
.  
 
For [Ru2L3]
4+ 
there is an orientation loss of 74 % at a 5 : 1 DNA base : complex ratio, 
however,  the most severe loss of orientation occurs for [Fe2L3]
4+
, with a loss in DNA 
orientation of ~90 % at a 5:1 ratio.  
 
These results suggest that DNA binding is not only related to specific structure and rigidity 
of complexes but that the choice of metal ion may also play an important role.  
 
6.2.3.3  DNA Emission Studies  
ββ-[Ru2L
2
2(bpy)2]
4+
 is coloured bright red, characteristic of a RuN6 chromophore. The UV-
Visible absorption spectrum (see section 2.4.1) shows two MLCT bands in the visible 
region of the spectrum (380-750 nm) centered at 388 nm and 512 nm. The UV area of the 
spectrum (200-350 nm) shows ligand centered π – π* transitions, Figure 6. 17. 
172 
200 400 600 800
Wavelength (nm)
A
b
s
o
rb
a
n
c
e
/E
m
is
s
io
n
 
(A
rb
it
ra
ry
 u
n
it
s
)
Absorption
Emission
A
b
s
o
rb
a
n
c
e
/E
m
is
s
io
n
 
(A
rb
it
ra
ry
 u
n
it
s
)
 
Figure 6. 17 UV-Visible spectrum of ββ-[Ru2L
2
2(bpy)2]
4+
, with emission after excitation 
at 512 nm. 
 
The complex itself is fluorescent in water, with excitation in the MLCT band at 512 nm 
leading to an emission at 820 nm (see section 2.4.5). This arises from a 
3
MLCT triplet 
excited state. The abrupt decrease in emission is caused by a drop in PMT response at this 
wavelength. ct-DNA titrations were performed with ββ-[Ru2L
2
2(bpy)2]
4+ 
at a constant 
concentration, (19 μM) and emission after excitation at 512 nm was followed, Figure 6. 18. 
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Figure 6. 18 Fluorescence response of ββ-[Ru2L
2
2(bpy)2]
4+
 (19 μM) in the presence of  
increasing concentrations of DNA. Mixing ratios indicated as complex to DNA bases. 
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Successive additions of ct-DNA induced a luminescence enhancement in ββ-
[Ru2L
2
2(bpy)2]
4+
.  The increase in emission can be followed at 820 nm, Figure 6. 19.  
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Figure 6. 19 Plot of emission at 820 nm after excitation at 512 nm of ββ-[Ru2L
2
2(bpy)2]
4+
 
(19 µM) against DNA concentration (µM). 
 
There appears to be a maximum loading of the complex on the DNA, where there is no 
further increase in ββ-[Ru2L
2
2(bpy)2]
4+ 
emission, between a 1:4 to 1:8 complex : DNA base 
ratio. This is similar to the triple stranded [Ru2L3]
4+
 helicate, where a clear maximum 
loading was seen at a 1:4 complex :  DNA base ratio.  The well documented “light switch” 
effect, where emission of a complex is increased upon DNA binding is not as prominent 
with ββ-[Ru2L
2
2(bpy)2]
4+ 
as with many other complexes, notably DNA intercalators.
16
 This 
is due to the fact that ββ-[Ru2L
2
2(bpy)2]
4+ 
is emissive without the presence of DNA. The 
enhancement of emission upon DNA binding is caused by an increase in energy of the 
non-emissive (or in this case slightly emissive) state moving up in energy towards the 
emissive MLCT excited state, allowing energy transfer and thus enhancement of the 
luminescence. It is likely that in the ββ-[Ru2L
2
2(bpy)2]
4+ 
system, fluorescence quenching 
through hydrogen bonding of solvent molecules is prevented upon DNA binding. 
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In parallel with emission experiments, UV-Visible spectra were recorded after each DNA 
titration, Figure 6. 20. As the ββ-[Ru2L
2
2(bpy)2]
4+ 
concentration remains constant, the 
influence of the DNA on its structure can be monitored.  
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Figure 6. 20 UV-Visible spectra showing the influence of increasing DNA concentration 
on ββ-[Ru2L
2
2(bpy)2]
4+ 
structure. Mixing ratios are indicated as complex to DNA bases. 
(Spectra recorded in parallel with emission titration). 
 
Throughout the titration no shift to red or blue (longer/shorter) wavelengths were observed 
for the ruthenium MLCT bands (300-600 nm). This indicates the complex ββ-
[Ru2L
2
2(bpy)2]
4+
 is retained throughout. The observed hypochromicity (decrease) of the 
ligand centred bands at 388 nm and 512 nm is attributed to the interaction between the 
complex and DNA. A decrease in these absorption bands is consistent with a stacking 
interaction involving the ligand.
12  
 
 
The binding constant of ββ-[Ru2L
2
2(bpy)2]
4+ 
to ct-DNA has been estimated using an 
ethidium bromide (EB) displacement assay (see section 2.4.4). ββ-[Ru2L
2
2(bpy)2]
4+
 was 
able to displace EB from ct-DNA, with the distinctive EB-DNA fluorescence signal 
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decreasing in intensity on addition of ββ-[Ru2L
2
2(bpy)2]
4+
. The binding constant of ββ-
[Ru2L
2
2(bpy)2]
4+
 was indicated to be ~ 1.1 x 10
8 
M
-1
 and the binding constant of [Fe2L3]
4+
 
to ct-DNA has previously been estimated to be ~ 0.6 x 10
8 
M
-1
.
 15 
However, an accurate 
binding constant greater than that of EB cannot be calculated using this assay. 
 
6.2.3.4  DNA Photocleavage Studies 
In order to fully investigate the photophysical properties of the ββ-[Ru2L
2
2(bpy)2]
4+
 
ruthenium centre, DNA cleavage in the presence of UVA (320-400 nm) light was 
analysed, Figure 6. 21 (see section 2.4.6). 
Position
In
te
n
s
it
y [Ru2L
2
2(bpy)2]
4+
[Ru2L3]
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Figure 6. 21 Denaturing gel profile showing  guanine residues, DNA cleavage after 
treatment with [Ru2L
2
2(bpy)2]
4+
 and DNA cleavage after treatment with [Ru2L3]
4+
 at a 20 : 
1, DNA base : complex ratio. 
 
The ββ-[Ru2L
2
2(bpy)2]
4+
 gel profile shows DNA cleavage at every base (without post-
treatment with piperidine or aniline). This is markedly different to the triple stranded 
[Ru2L3]
4+
 gel profile which shows cleavage selective to guanine residues. This usually 
implies an oxygen mediated cleavage pathway, due to the higher reactivity of singlet 
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oxygen towards guanine as compared to thymine, adenine or cytosine bases. An oxygen 
mediated pathway cannot, however, be ruled out in the case of ββ-[Ru2L
2
2(bpy)2]
4+
, as 
singlet oxygen is able to diffuse along the DNA helix. This could imply a longer excited 
state lifetime of ββ-[Ru2L
2
2(bpy)2]
4+
 as compared to [Ru2L3]
4+
, in order to sensitise more 
singlet oxygen. However, other explanations for this cleavage pattern exist, so it is not 
certain exactly which pathway is active here. The production of hydroxy radicals
17
 
(although usually associated with hydrogen peroxide treatment) and low energy electrons
18
 
are known to induce cleavage at every base. 
 
6.2.4  Cell Line Testing 
With DNA bending and coiling interactions arising from ββ-[Ru2L
2
2(bpy)2]
4+
 binding, cell 
line tests (see section 2.5.5) were carried out in order to try and correlate any anticancer 
activity with these DNA binding interactions. Results are compared to those previously 
determined for [Ru2L3]
4+ 13
 and [Ru2L(bpy)4]
4+ 19 
in order for a comparison on how specific 
structure is related to cytotoxic activity to be made.  
 
The stability of ββ-[Ru2L
2
2(bpy)2]
4+
 in aqueous medium was recorded over the time period 
of the cell tests (72 hours), at 37 °C in order to check that the compound remains stable in 
solution for this period, Figure 6. 22 (see section 2.4.1).  
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Figure 6. 22 UV- Visible spectra of 17 µM ββ-[Ru2L
2
2(bpy)2]
4+
 over a 72 hr time period 
at 37 °C in water.  
 
It is clear from the spectrum that ββ-[Ru2L
2
2(bpy)2]
4+
 remains stable throughout the 72 hr 
period. 
 
The human ovarian cancer cell line A2780-P was chosen for these cell tests as there also 
exists an engineered cisplatin resistant strain, A2780-R. These cell lines are important to 
study as there is a clinical need for drugs not susceptible to the same resistance 
mechanisms as cisplatin. T47D was chosen as a representative breast cancer cell line, in 
order to investigate the effects of ββ-[Ru2L
2
2(bpy)2]
4+
 on different tumour types, Table 6. 
2. 
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 A2780-P A2780-R T47D 
ββ-[Ru2L
2
2(bpy)2]
4+
 30.7 ± 6.0 > 100
ii
 33.4 ± 7.8 
[Ru2L3]
4+ 13
 72.0 ± 3.3 > 100
ii
 53.0 
Cisplatin 4.4 ± 0.8 19.3 ± 1.8 28.0 ± 1.7 
 
Table 6. 2 IC50 values (µM) in the ovarian cancer cell lines, A2780-P/R and the breast 
cancer cell line T47D of ββ-[Ru2L
2
2(bpy)2]
4+
 and [Ru2L3]
4+
 with cisplatin as control 
following a 72 hour incubation, as assessed using the MTT assay. Data are reported as 
mean IC50 values ± SD from three independent experiments. 
 
ββ-[Ru2L
2
2(bpy)2]
4+
 has comparable activity to cisplatin in the breast cancer cell line, 
T47D. Activity in the ovarian A2780-P line is comparable to that of T47D, however lower 
than that of cisplatin (higher IC50). ββ-[Ru2L
2
2(bpy)2]
4+
 is also inactive, at these 
concentrations, against the cisplatin resistant A2780-R cell line, showing that it may be 
susceptible to the resistance mechanisms present in this cell line.  
 
Interestingly, as the DNA binding of [Ru2L3]
4+
 is clearly distinct to that of ββ-
[Ru2L
2
2(bpy)2]
4+
,  with [Ru2L3]
4+
 having a greater effect on the DNA as shown through CD 
and LD binding studies, it may be expected to have greater cellular toxicity. However, this 
does not appear to be the case and these studies show that DNA binding interactions are 
not the only important factor in determining cellular toxicity and a compromise between 
                                               
ii Due to comparisons being drawn with cisplatin a maximum concentration of 100 µM was tested for all 
compounds. Therefore above this value compounds are classed as inactive, and an accurate IC50 value cannot 
be calculated. 
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rigidity of structure and DNA binding interactions needs to be found in order to find the 
optimum drug candidate.  
 
The single stranded complex, [Ru2L(bpy)4]
4+
 did not display activity in any of the cell lines 
tested.
19
 With the most flexible structure and weakest DNA binding interactions of all the 
complexes discussed this is not an unexpected result, but again highlights the importance 
of finding the correct flexibility in compound structure for optimum cytotoxic activity of 
this range of complexes. 
 
It is also interesting to compare the cytotoxic activity of the ruthenium complexes to that of 
the iron triple stranded parent cylinder, [Fe2L3]
4+
, Figure 6. 23. 
0
10
20
30
40
50
60
70
80
A2780-P T47D
Cell Line
IC
5
0
 (
m
M
)
[Ru2L2(bpy)2]4+
[Ru2L3]4+
[Fe2L3]4+
Cisplatin
0
10
20
30
40
50
60
70
80
A2708-P T47D
Cell Line
IC
5
0
 (
m
M
)
[ (bpy)2]4+
[Ru2L3]4+
[Fe2L3]4+
Cisplatin
[ 2
2
2 2]
4+
[Ru2 3]
[Fe2 3]
4+
is
 
Figure 6. 23 Comparison of IC50 values (µM) of ββ-[Ru2L
2
2(bpy)2]
4+
, [Ru2L3]
4+
 and 
[Fe2L3]
4+
 with cisplatin in the A2780-P and T47D cell lines, following a 72 hour 
incubation, as assessed using the MTT assay. Data are reported as mean IC50 values ± SD 
from three independent experiments. 
 
With [Ru2L3]
4+
  having similar DNA binding activity to [Fe2L3]
4+
, as assessed by CD and 
LD studies, the greater activity of the iron cylinder in the A2780-P cell line would correlate 
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with results previously found where in certain instances the metal centre also plays an 
important role in cytotoxicity. This is not the case in the T47D cell line however, where 
both [Fe2L3]
4+ 
and [Ru2L3]
4+
 display a similar activity, less than that of ββ-
[Ru2L
2
2(bpy)2]
4+
. These results show that the criteria for cytotoxic activity is clearly very 
different in different cell lines, and may indicate that the mechanism of action of this range 
of complexes differs in each cell line. In the cell lines investigated, cisplatin displayed the 
highest activity.  
 
6.3  Conclusions and Further Work 
The novel ruthenium(II) complex,  ββ-[Ru2L
2
2(bpy)2]
4+
 has been synthesised and studied 
using a variety of chemical, biophysical and biological techniques. The results have been 
compared to analogous single and triple stranded ruthenium(II) helicates in order to probe 
DNA binding interactions and the effects specific surface structures have on cytotoxicity. 
It was initially thought that increased DNA binding interactions (bending/coiling) would 
correlate with increased cellular toxicity. However, this was found not to be the case and 
the results discussed herein imply that the specific ligand surface, rigidity of structure and 
the choice of metal centres are incredibly important to consider when designing DNA 
binding drug molecules. The investigation of novel DNA binding agents with anticancer 
activity, as well as other useful properties such as luminescence and a tunable ligand 
surface are important in order to increase understanding in the field of molecular drug 
design. 
 
ββ-[Ru2L
2
2(bpy)2]
4+ 
is helical, and exists as a racemic mixture of enantiomers. Due to the 
chiral nature of DNA it is hypothesised that the two enantiomers of this compound may 
181 
show different DNA binding interactions and potentially distinct anticancer activity. In 
order to understand the nature of these interactions fully, the separation and biological 
studies of the enantiomers would be beneficial to carry out in the future.  
 
Although only ββ-[Ru2L
2
2(bpy)2]
4+ 
has been discussed herein, it is anticipated that due to 
the synthetic route developed for this complex the attachment of ligands such as malonate, 
oxalate, phenanthroline or dppz to each ruthenium(II) centre, in place of the bipyridine 
moieties in ββ-[Ru2L
2
2(bpy)2]
4+ 
will be possible. This will allow the creation of a range of 
compounds with differing ligand surfaces which can be used to study DNA binding 
interactions. The synthesis of ββ-[Ru2L
2
2(ox)2] and ββ- [Ru2L
2
2(mal)2] has been attempted, 
however to date only the oxalate compound has been characterized through ESI mass 
spectrometry, Figure 6. 24, showing retention of a di-ruthenium(II) complex in solution. 
Synthesis of larger quantities needs to be carried out for complete characterisation of these 
complexes. 
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Figure 6. 24 ESI mass spectrum of [(Ru2L
2
2(ox)2) + Na2]
2+ 
Inset shows the main peak 
expanded.
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Chapter 7 
 
 
Conclusions and Future Work 
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In this thesis, biological and DNA binding studies have been carried out on a number of 
supramolecular helicates containing both iron and ruthenium metal centres. Analogous 
single, double and triple stranded helicates have been compared. This work has concluded 
that there are a number of factors affecting the DNA binding of these metal complexes, 
including the metal centre, ligand structure and the specific ligand surface which changes 
flexibility of the overall structure. All these factors must be taken into consideration when 
designing novel metal containing helical drug agents.  
 
This thesis has also advanced knowledge on the biological properties of these complexes 
and their interactions with cancer cell lines through a number of biological assays, a 
number of which have not previously been reported in the literature and which have shown 
very interesting and important results. 
 
Three way junction binding, a novel DNA binding mode, representing the replication fork 
of living cells has been investigated and a possible link has been found between the 
stabilisation of this structure by a the parent iron helicate and its ability to kill cancer cells 
in vitro. This is a link which had not previously been established and is therefore very 
important to help understand existing helical drugs and to design new ones.  
 
Cell line testing of the parent complex showed the influence of parameters not previously 
thought to be important when determining cytotoxicity. Results obtained have shown that 
extra care needs to be taken when assessing cytotoxicity for complexes of this nature with 
an unknown mode of action. This will affect the way cell line testing is carried out in the 
future. Time-lapse microscopy of cells in vitro showed a potential new mode of action of 
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this range of helical complexes not previously considered or investigated, relating to the 
cellular cytoskeleton. 
 
Genotoxicity and mutagenicity studies confirmed that double stranded, unsaturated 
ruthenium complexes do not cause DNA strand breaks or mutations, important results for 
these promising drug agents to progress further towards the clinic. 
 
Finally, a novel supramolecular drug agent with a tunable ligand surface was synthesised 
and investigated. This is important to be able to understand effects of ligand and structure 
flexibility on DNA binding and anticancer activity. 
 
Further work, spanning all chapters of this thesis must be in the elucidation of the exact 
mode of action of this family of complexes. The work herein has identified key areas to 
investigate including interactions of complexes with cell membranes and the cytoskeleton, 
stability of complexes especially those with different metal centres and further DNA 
binding studies.  
 
Further work arising from chapter three needs to be carried out in order to confirm exact 
reasons for differing anticancer activities of parent and methyl substituted iron cylinders. 
Does the inactive methyl substituted cylinder interact with the cell membrane, as images 
would suggest and does this play a more important role than originally thought on lack of 
anticancer activity. Synthesis of the ruthenium analogue of this methyl substituted iron 
cylinder would also be beneficial in order to assess the importance of the metal centre in 
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this complex on cytotoxic activity and also to investigate the role of stability of the various 
helicates on anticancer action.  
 
From chapter four the need arises to elucidate the exact mode of action of the parent 
complex. It appears from results herein that this iron helicate may have a mode of action 
distinct to that of known anticancer agents and that its effect on the cellular cytoskeleton is 
more significant than previously thought. These experiments may take the form of live 
imaging in cells to assess the uptake of the iron helicate and further biological assays to 
assess the full extent of cytoskeleton disruption. Comparison with the analogous ruthenium 
cylinder is also important as these complexes display similar DNA binding but have 
distinct anticancer actions.  
 
Chapter five poses further questions about the ruthenium nitrate substituted helicate, again 
related to interactions with cell membranes. This needs to be investigated further and may 
link the mode of action of the double and triple stranded helicates, important for the 
understanding and design of new agents.  
 
Chapter six discussed one complex in a possible range of many unique supramolecular 
structures and further work should therefore be carried out to synthesise a full range of 
complexes using this design and method of synthesis. Bipyridine moieties should be 
replaced with other ligand surfaces, such as DNA intercalators, to investigate how DNA 
binding and anticancer activities can be modified.  
 
  
